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Summary 
The study shows for the first time that c-Jun stabilizes and activates p73, in turn, p73 
influences c-Jun’s function in cell fate decisions. Genetic evidences consolidated the 
findings, as c-jun-/- cells are defective in p73 stabilization, transcriptional activation, and 
are resistant to cisplatin-induced apoptosis. Introducing c-Jun in c-jun-/- cells restores p73 
stabilization/levels, activation and sensitivity to cisplatin. The half-life of p73 is extended 
by c-Jun resulting in enhanced p73 mediated-transactivation. The ability of p73 to 
transactivate its down stream genes is reduced in p53-/-c-jun-/- cells  compared to p53-/- 
cells. Both the amino and carboxy-termini of c-Jun independently are required for 
increased p73 levels and transcriptional activity. The PY motif is conserved in both p73 
and c-Jun, indicating that they have shared functions in regulating various biological 
processes in the cells. Furthermore, the apoptosis inducing function of p73 is potentiated 
by c-Jun.  
Exposure to UV radiation is shown to induce p73 levels in a variety of cell lines.  
The UV-mediated p73 stabilization occurs at the post-transcriptional level and is not 
compromised in cells lacking c-Abl or c-Jun-amino-terminal kinases, Jnks 1, and 2.  It 
was also shown that when p73 is transiently over expressed, UV stabilizes the transfected 
p73.  However, the consecutive exposure of cells to the γ-irradiation and the UV- 
irradiation enhanced the stabilization of p73 and increased the cell death when compared 
to cells treated with either or UV irradiation alone.  This is exemplified by the absence of 
colony formation in p53-/- cells, indicating that combined signals can induce apoptosis by 
stabilizing p73.  
The ability of TA-p73 to influence c-Jun function was also studied, as both appeared 
                               
 XXI 
to be over expressed and co-exist in tumors.  This study shows for the first time that p73 
increases AP-1 (5XTRE) activity and it synergies with c-Jun to potentiate AP-1 activity.  
The transactivation domain (TAD1) near the NH2-terminus of p73 is necessary for its 
ability to synergize with c-Jun. Furthermore, it appears that p73 potentiated AP-1 
activity, predominantly dependent on the endogenous c-Jun expression.  JNK-mediated c-
Jun phosphorylation is required, but not essential for its ability to co-operate with p73. 
Further, it can increase the expression of AP-1 target genes such as collagenase-1 and 
MSH-2.  P73β shows the best synergistic effects with c-Jun as compared to the other p73 
family members. In addition, the basal level of AP-1 activity was lowered by the 
dominant negative p73 (DD), indicating that p73 is essential for the basal AP-1 activity.  
Both TA and ∆Np73 promoter encodes AP-1 like responsive elements and it indicates the 
possible existence of a regulatory loop between ∆N-p73 and TA-p73/c-Jun.   
This study also show that p73 could transform immortalized fibroblast cell lines 
such as NIH 3T3 in co-operation with c-Jun.  This indicates that p73 could support 
transformation in the presence of excessive oncogenic signals, but not in its absence.  In 
addition, p73-induced MDM2 promoter activity observed in p53-/- fibroblasts is reduced 
in p53-/-c-jun-/- and p53-/-Mdm2-/- fibroblasts. Correspondingly, p73-β, c-Jun, and MDM2 
synergistically increase MDM2 promoter activity. Taken together, these observations 
suggest that p73 function is modulated in cancer cells.  In aggregate, this study has 
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1.1 p53, the tumor suppressor 
The p53 protein is a transcription factor that induces both cell cycle arrest and 
apoptosis, in response to diverse genotoxic and cellular stresses.  The p53 gene is 
frequently mutated in human cancer, being mutated or lost in 55% of all tumors (Oren, 
1999; Hollstein et al., 1991; Sengupta, 2005).  Hence, p53 is thought to play an important 
role in maintaining--commonly referred to as guardian of genome--the integrity of the 
genome (Lane et al., 1992). 
 
1.1.1 p53 structure and targets 
The p53 protein transactivates several sets of genes to execute DNA repair, 
growth arrest and apoptosis (Figure 1.1). It contains an NH2-terminal transactivation 
domain, a central DNA-binding domain (DBD) and a carboxyl-terminal oligomerization 
domain (OD). The DBD-- a mutational hot spot that commonly occurs in various human 
cancers-- facilitates sequence-specific DNA binding to p53 response elements (p53RE) 
present within the regulatory regions of a number of p53-regulated genes (Ko et al 1996; 
El-Diery, 1998). The OD facilitates tetramer formation. Post-translational modifications 
including phosphorylation, acetylation, sumoylation, glycosylation are critical in 
modulating the binding activity of p53 to its responsive elements (Meek et al., 1999; 
Wahl et al., 2001; Brooks et al., 2003).   











Figure 1.1 Activation of p53 can lead to the expression of DNA repair, Cell cycle arrest 
and Apoptotic target genes (Ryan et al., 2001; Chen et al., 1999; Lohrum et al., 2000; Ko 
et al., 1996; Vousden K 2000; El-Diery WS 1998; Sengupta, 2005.) 
 
 
1.1.2 Regulation of p53 function 
Activation of p53 can occur in response to UV, IR, MMS, NO, anti-cancer drugs, 
hypoxia, nucleotide deprivation etc. (Lakin et al., 1999; El-Diery et al., 1998). The 
signals and mechanisms that regulate p53 activity are described in several recent reviews 
(Oren, 1999; 2003 Ko et al., 1996; El-Diery, 1998; Gottlieb et al., 1998; Ryan et al., 
2001; Wahl et al., 2001; Haupt et al., 2004; 2003a; 2003b; 2002; Ashcroft et al., 1999a; 
1999b; May et al., 1999; Sionov et al., 1999). The p53-MDM2 auto regulatory loop is a 
well-established regulatory network:  MDM2 is a target gene of p53 and is a negative 
regulator of p53 protein levels.  In an undamaged cell, p53 is complexed (through the N-






















DNA Repair Growth arrest
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1997).  In response to DNA damage, p53 is phosphorylated at serine-15 and serine-20, 
displacing Mdm2 from the N-terminus, leading to an increase in the protein levels of p53 
(Figure 1.2). Activated p53 is then capable of inducing the transcription of genes that lead 
to cell cycle arrest (p21, TGF-b and Cyclin G), apoptosis (Bax, AIP1, PUMA, Noxa, 
PIG, DR5 etc.)  or enhanced DNA repair (PCDNA, XPE and GADD45) (Oren, 1999; 
























Figure 1.2 The p53-MDM2 auto regulatory loop As with other p53 target genes, 
transcription of MDM2 is increased when p53 is activated and stabilized (Ashcroft, 
1999).  In turn, the MDM2 interacts with p53 and target it for ubiquitin-dependent 
degradation. In response to stress signals, p53 undergoes ser/thr phosphorylation near the 
MDM2 binding site (N-terminus of p53), which blocks MDM2’s ability to target p53 
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1.2 p53 family members 
Given the importance of the p53 gene in human cancers, it is not surprising that a 
considerable effort has been put forth to identify p53 homologues. Only in late 1990s, 
two novel family members were identified and termed p73 and p63 (Kaghad et al., 1997; 
Caput, 1997; Yang et al., 1998).  Though they were structurally similar, research in the 
last 7 years showed surprising diversities. That is, p73 appear to carry out both p53 
related functions and completely novel functions (Irwin et al., 2001). 
1.3 Introduction to p73 
 In a search for new interleukins, a cDNA that was predicted to encode p53 like 
protein, Daniel Caput and co-workers identified p73 in 1997. 
1.3.1 Chromosomal localization of p73 
.  It is located to chromosome 1p36.3, a region that is frequently deleted in variety of 
human cancers or exhibits loss of hetrozygocity (LOCH) in neuroblastoma, lung cancer, 
gastric cancer, HCC, breast cancer, ovarian cancer (Khagad et al., 1997; Barrois et al., 
2001; Blatt et al., 2001; Casciano et al., 2002; Melino et al., 2002; Yang et al., 2001; 
Araki et al., 2002; Nakagawara, 2001; Imyanitov et al., 1999; Ichimiya et al., 1999; 2000; 
2001).  The fact that p73 was located in a long suspected tumor locus, was met with a 
great expectation, as this gene could potentially function as a tumor suppressor.  
However, subsequent searches in many types of cancer have found neither mutations nor 
consistent pattern of loss of hetrozygocity in the remaining allele of p73 gene (Melino et 
al., 2002).  
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1.3.2 Gene architecture of p73  
The structure of the p73 gene is highly complex when compared to that of p53. 
The gene encoding p73 is approximately 65 KB in size. Human p53 gene has a single 
promoter, which directs the production of a single mRNA (Strano et al., 2001; Yang et 
al., 2000). On the contrary, the TP73 gene, contains two independent promoters, P1 and 
P2, which make use of alternative splicing to generate various isoforms (Yang et al., 
2000). The promoter P1 is in the 5’P-UTR, upstream of a non-coding exon 1 and 
produces full-length proteins containing the TA domain (TAp73). The promoter P2 is 
located within the 30 KB spanning, Intron 3. It gives rise to TA-deficient-∆Np73 proteins 
(Melino et al., 2002).  
1.3.3 Structural organization of the p73 promoter 
The upstream promoter region of the human p73 gene has been partially 
characterized (Ding et al., 1999). Unlike the p53 promoter, the p73 promoter contains a 
TATA-like box (Strano et al., 2001). Initial studies show that the region between 
nucleotides –119 to +119 relative to the start of exon 1, contains the region required for 
the basal transcription of p73 (Ding et al., 1999; Seelan et al., 2002). This region contains 
putative SP1, AP-2, and Egr-1, 2,3 sites and several stretches of CpG di-nucleotides 
(Ding et al., 1999; Strano et al., 2001; Davis et al., 2001).  The region located between 
position –119 and –2714 contain additional regulatory sites for: E2F and c-Myb (Levrero 
et al., 1999; Melino et al., 2002; Seelan et al., 2002). Further, a potential p53-binding site 
was identified in the p73 promoter that is responsive to both p53 and p73 and is auto 
regulated (Chen et al., 2001).  Interestingly, ∆N-p73 promoter does not share any sort 
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similarity with its counter part TA-p73 promoter and it appears to be regulated by 
different transcription elements (Melino et al., 2002).   
( Adapted and modified from Melino et al., 2002) 
Figure 1.3 Splice variants of p73, and transcriptional factors regulate p73  The p73 
gene has two promoters, which are divided into two groups. The two groups include 
those containing the TA domain (containing first three exons), directed by the P1 
promoter and the ∆N domain (containing 4-14 exons), directed by the P2 promoter.  The 
use of either alternative splicing or alternative promoters can generate NH2- (due to 
exons 2, 3 and 3’) and COOH-termini isoforms (due to exons 11, 12 and 13). Potential 
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transcription factors/proteins that are active on both TA (red colour) and ∆N-p73 (yellow 
colour) promoters are indicated (Melino et al., 2002). 
 
1.3.4 Structure organization of p73 
The gene encoding p73 contains 14 exons and two alternative promoters.  It is 
subjected to alternative splicing as well.  As a result of the use of alternative promoters 
and splicing, at least five NH2-terminal and six C-terminal isoforms (Melino et al., 2002) 






Figure 1.4 Comparison of the protein structures of p53 and p73.  Percent homology to 
the p53 sequence is indicated above. Potential protein-protein interaction domains, 
include a SAM-like domains found only in p73 (Melino et al., 2003; 2002; Lohrum et al., 
2000). 
 
Transactivation domain (TAD) 
  TAD is subjected to post translational modifications in response to DNA damage.  
MDM2 binds to TAD and modulates protien functions (Michael et al., 2002; Gu et al., 
2000; 2001).  MDM2 can bind to TAD and suppress its transcriptional activity under in 
vitro conditions (Chen et al., 1999; Balint, et al., 1999).  However, MDM2 failed to 
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DNA binding domain (DBD) 
All the ‘hot spot residues”(R175, G245, R249, R273 and R282) in the DBD are 
conserved (Ichimiya et al., 2000; Yang et al., 2000).  The DBD binds to promoter DNA 
for the transactivation of genes, such as p21, MDM2, GADD45, and Bax. 
Oligomerization domain (OD) 
OD mediates homotetramer formation (Ko et al., 1996). Furthermore, a weak 
heterotypic interaction between p63 and p73 proteins was suggested (Kojima et al., 
2001). 
SAM domain and C-terminus (CTD) 
The CTD diverges among the isoforms.  Structural analysis recently elucidated that p73α 
has a molecular feature at the C-terminus representing a sterile alpha motif (SAM)-like 
domain that is not found in p53 (Khagad et al., 1997).  The SAM domain is conserved 
only between p73-α and p63-α and the percentage of homology is 51% (Melino et al., 
2003).  The SAM domain is hypothesized to play a role in protein-protein interaction 
(Davison et al., 1999).  Furthermore, this region could add specificity to the function of 
p73.  
1.3.5 Expression of p73 
1.3.5.1 p73 expression in normal tissues 
Most cells express very low levels of p73.  In human fetal and adult tissues, TA 
(transactivation)-p73 isoforms are most abundant (Ishimoto et al. 2002; Grob et al, 2001), 
while in the mouse neonatal brain and sympathetic ganglia (Pozniak et al., 2000), ∆N-
p73 seems to be the most highly expressed isoform.    
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1.3.5.2    p73 expression in cancerous cells 
In normal cells p73 is present at the low levels, while in tumor cell lines (cancers of the 
breast, lung, esophagus, stomach, colon bladder, ovary, liver, bile ducts, ependymal 
lining, myeloid and neurons) p73 is over expressed (Moll et al., 2001; Chen et al., 2000; 
Codegoni et al., 1999; Dominguez et al., 2001; Zaika et al., 1999; 2002).   
1.3.6 Regulation of p73 
p73 activity is regulated by several of the same molecules as p53, which supports 
the idea that p73 participates in maintaining genome stability.  Recently, it has been 
shown that p73 induces apoptosis by potentiating the expression of scotin, PUMA and 
Bax (Rossi et al, 2005) 
 
1.3.6.1 Regulation in response to DNA damage signals 
Like p53, p73 is induced in response to various DNA damaging agents (Yang et 
al., 2002; Melino et al., 2003; Irwin et al., 2003).   
 
1.3.6.2 Role of Post-translational modifications: Regulation of p73 by c-
Abl, ATM, and MLH-1 network. 
 
  In response to DNA damaging agents such as cisplatin and ionizing radiation (IR) 
p73 is up regulated (Gong et al., 1999; Agami et al., 1999; Yuan et al., 1999).  Although 
the molecular mechanisms by which p73 is activated in response to DNA damage signals 
is not clear yet, the presence of the mismatch repair gene (MLH1) and a functional and 
physical interaction between c-Abl and p73 are important for efficient induction of p73 
(Gong et al., 1999; Agami et al., 1999; Yuan et al., 1999).  As c-ABL (Abelson 
leukaemia) is, itself, phosphorylated and activated by ATM (ataxia telangiectasia 
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mutated), ATM might also be included in this pathway (Yuan et al., 1999).  The 
activation of p73 in response to DNA damage is mainly regulated at the post-translational 
level. However, recent results suggest that p73 is also activated at the transcriptional level 
in response to a DNA damaging drug, Campothesin (Chen et al., 2001).  In addition, 
information is lacking about the interactions of the different splicing isoforms with these 
kinases and acetylases. It seems likely that the response to DNA damage is highly 
dependent on the cellular context, relative abundance, and modification of each of the 
p73 isoforms. 
1.3.6.3 p38 kinase 
It has been shown by Sanchez-Prieto et al., (2002), that the p38 MAP kinase 
phosphorylates p73 on threonine residues adjacent to prolines.  Furthermore, it was 
shown that p38 mediated p73 stability and transcriptional activation is dependent c-Abl.  
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Figure 1.5 Pathway involving p73 in DNA damage  DNA damage that is elicited either 
by cisplatin, or IR-irradiation triggers a p73 pathway-- independent of the p53 status and 
activation-- that is mediated mainly by MLH1, ATM and c-ABL (Gong et al., 1999; 
Yuan et al., 1999; Agami et al., 1999). This p53 pathway requires several complex post-
translational modifications during its activation. Similarly, there is evidence that p73 is 
phosphorylated by c-Abl, p38, HIPK2 and acetylated by p300 (Zeng et al., 2000; Kim et 
al., 2002; Sanchez-Prieto 2002). As with p53, several mechanisms allow p73 to 
differentially regulate distinct classes of promoters such as cell cycle arrest and apoptosis 
(Chen et al., 2000; Stiewe et al., 2001). 
 
1.3.6.4 HIPK2 kinase 
 
Another kinase, home domain interacting protein kinase 2 (HIPK2), has been 
found to bind to p73 and enhance its function (Kim et al., 2002). 
 
1.3.6.5 Acetylases 
The ability of p53 to bind to its cognate DNA sequence and activate p53-
dependent transcriptional activity is regulated by interaction of p53 with the 
transcriptional co-activator p300/CREB binding protein (Lill et al., 1997). Similarly, 
recent studies have demonstrated that the N-terminus (1-156) of p73 directly interacts 
with N-terminal CH1 domain of p300 to activate transcription and to induce p73-
mediated apoptosis (Zeng et al., 2000). More recently, Levrero (2002) and his colleagues 
reported that p73 was acetylated by p300 on carboxyl-terminal lysine residues and this 
specifically potentiates the apoptotic function of p73.  
 
1.3.6.6 Sumoylation 
 p73α, but not p73β has been shown to be covalently modified by the SUMO-1 
(small ubiquitin-like modifier 1)(Minty, 2000). The major SUMO-1-modified residue in 
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p73α is the C-terminal lysine (Lys627).  The SUMO-1 modifed p73 is more rapidly 
degraded by proteasomes than unmodified p73.  In addition, it has recently been shown 
that PIAS-1 binds to p73α and sumoylates it. The PIAS1 mediated sumoylation decreases 
p73 transcriptional activity on several target promoters (Munarriz et al., 2004).   
1.3.6.7 Regulation of p73 by MDM2 
It has been shown that several stress signals activate p53.  Haut et al., (1997) and 
Kubbutat et al (1997; 1999) have reported that MDM2—a target gene of p53—is a key 
player in the regulation of p53 stability (Haut et al., 1997; Kubbutat et al., 1997; 1999).  
Recent studies have suggested that MDM2 itself shows a specific E3 ubiquitin ligase 
activity and it covalently attaches ubiquitin groups to p53 as well as to itself (Linares et 
al., 2003).   
p73 was also shown to induce MDM2 at the transcriptional level. Although 
MDM2 protein binds to N-terminal regions of p73 proteins α and β, it does not degrade 
p73, but neutralizes the ability of p73 to transactivate (Michael et al., 2002). The p73–
MDM2 interaction also affects the sub cellular localization of p73 (Gu et al, 2001), 
potentially contributing to p73 stability.  In fact, MDM2 has been shown to increase the 
stability of the p73 protein (Ongekoko et al, 1999).   
 
1.3.7 ∆ N-p73  
∆N-p73 lacks the transactivation domain and it can be derived either from an 
alternative promoter in intron 3 or an alternative splicing that originates from the first few 
exons namely ∆2Np73 and ∆3Np73.  As shown in the figure (1.4), both ∆2Np73 and 
∆3Np73 are generated from the same promoter as TA-p73 by splicing out exon 2 and 
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exon 3.  ∆N-p73 (P2) promoter has been shown to be transactivated by both TA-p73 and 
p53 (Ishimoto et al., 2002; Fillippovich, et al. 2001; Melino et al., 2002), indicating an 
autoregulatory feed back loop (Grob et al., 2001; Kartasheva et al., 2002). Of note, both 
MDM2 and ∆N-p73 are transcriptional targets of p53.  Deregulation of these regulatory 
loops in cancer cells, resulting in upregulation of either MDM2 or ∆Np73 or both, would 
effectively inhibit the function of p73 (Melino et al., 2002). In developing brain, ∆N-p73 
is highly expressed and appears to play an anti-apoptotic role in-vivo (Yang et al., 2002).  
In human cancers, ∆N-p73 is specifically upregulated (Ishimoto, et al., 2002; Douc-Rasy 
et al., 2002). This study included 35 cancers (cancers of the ovary, endometrium, cervix, 
vulval, vagina, breast, kidney, and colon) (Zaika, et al, 2002). Recently, Casciano et 
al.,(2002) reported that in neuroblastoma patients, expression of the anti-apoptotic ∆N-
variant of p73 is strongly associated with reduced survival and predicts a poor outcome.   
 
1.3.8 Regulation by oncogenes 
It has been shown recently that various oncogenes such as c-Myc and E1A 
upregulate the levels of p73 (Irwin et al., 2000; Zaika et al., 2000).   
1.3.8.1 c-Myc and E1A 
 Zaika et al., (2000) have shown that p73 expression is increased by overexpression of   
c-Myc.  In addition, Watanabe et al. (2002) showed that the interaction between c-MYC 
and p73 results in inhibition of p73’s transcriptional activity.  Flinterman et al., (2004) 
showed that E1A also increases the expression of endogenous TAp73 mRNA and 
protein.  Both E1A and c-Myc appear to increase p73 levels through E2F1. 
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1.3.9 The role of p73 in cancer 
The fact that the regulatory molecules—ATM, ATR, Abl, p38 etc. —that activate 
p73 are similar to those known for p53, suggests a comparable function of tumor 
suppressor genes in human cancers (Stiewe et al., 2002).  However, data obtained from 
knockout mice failed to support its role as a tumor suppressor (Yang et al., 1999). 
Further, several groups reported increased expression levels of total p73 in tumor tissues 
compared to the surrounding normal tissue (Zakia et al., 2002).  However, the role of 
increased expression of p73 in tumors is not clear yet.  Before making a firm conclusion, 
one would need to consider the complexity, different transactivation potential and 
apoptotic activity of p73 isoforms and their ability to interact with each other (Levrero et 
al., 2000).  In the case of hepatocellular carcinomas, overexpression of p73 could be 
correlated with a poor patient survival prognosis (Qin et al., 2000; Herath, et al., 2000).  
Another study determined that ∆N-p73 is a strong adverse prognostic marker in 
neuroblastomas (Casciano et al., 2002).   
1.3.10 p73 mutations, Loss of heterozygosity, Imprinting, and promoter 
silencing 
 
1.3.10.1 p73 mutations and loss of heterozygosity 
 
The human p73 maps to chromosome 1p36.33, which frequently undergoes loss 
of heterozygosity in breast cancer, neuroblastoma and several other human cancers 
(Kaghad et al, 1997).  The mouse p73 maps to the distal part of chromosome 4, which 
undergoes frequent loss of hetrozygosity (LOH) in radiation induced T-cell lymphomas 
(Herranz et al, 1999; Stiewe et al., 2002).  The fact that p73 maps to chromosome 
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1p36.33, which frequently undergoes loss of hetrozygosity, may suggest that p73 could 
be a tumor suppressor gene.  This notion initiated an extensive analysis of the p73 status 
(Zaika et al., 2002; Stiewe et al., 2002).  Unfortunately, loss of function mutations in the 
p73 ORF is quite uncommon (Melino et al., 2002). 
1.3.10.2 Imprinting     
Initial studies indicated that p73 is an imprinted gene (Khagad et al. 1997).  That 
is, only one allele is active and other one is silenced by epigenetic mechanisms.  
However, this appears to be rather infrequent and varies from tissue to tissue (Moll et al., 
2001; Zaika et al, 1999; Kovalev et al, 1998).  A number of studies have demonstrated 
loss of imprinting (LOI), biallelic expression of p73 or allele switching (Stiewe et al., 
2002). In fact, LOI is exemplified in lung, esophageal and renal carcinoma (Mai et al,  
1998 a & b; Cai et al, 2000; Moll et al., 2001).   
1.3.10.3 Promoter silencing 
Loss of p73 expression due to hypermethylation of promoter appears to be 
infrequent in general. It is reported only in certain hematological malignancies such as 
primary acute lymphoblastic leukemia (ALLs) and Burkitt lymphomas (Corn et al, 1999; 
Kawano et al, 1999; Banelli et al., 2000; Stiewe et al., 2002; Puig et al., 2003).  On the 
contrary, increased expression of p73 was reported in chronic myeloid leukemia, acute 
myelogenous leukemia, and B-cell chronic lymphocytic leukemia (B-CLL) (Peters et al, 
1999; Novak et al, 2001; Stiewe et al., 2002).  
1.3.11 p73 alterations in human cancer 
Tumor Mutations Loss of heterozygosity 
Neuroblastoma 2/317(P450R, P425L) 66/307 
Central nervous system 2/142 (N204S, E291K) - 
Melanoma 0/68 3/27 
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Parathyrodi adenoma 0/16 4/16 
Lung cancer 1/114(P450K) 32/107 
Hypopharyngealcarcinomas 0/17 - 
Oesophageal cancer 0/48 25/76 
Gastric cancer 0/82 12/32 
Colorectal cancer 0/125 8/46 
Bladder cancer 0/23 - 
Prostate cancer 0/133 2/38 
Renal cancer 0/27 - 
Cholanglocarcinoma  6/11 
Hepatocellular carcinma 0/48 21/71 
Leukemia &lymphoma 0/91 - 
Breast cancer 1/145 20/194 






(Adapted from Melino et al., 2002) 
 
Figure 1.6 p73 alterations in cancer. 
 p73 mutational analysis presented by Melino et al., (2002) suggests that p73 mutations 
are rare in a variety of tumors. However, there is a significant incidence (40-33%) of 
Loss of heterozygocity especially in gastric, lung, oesophageal and neuroblastoma cancer 
types (Melino et al.,2002). (Neuroblastoma (Douc-Rasy et al., 2002; Kovalev et al., 1998; 
Ichimiya et al., 1999; Ejeskar et al., 1999; Han et al., 1999; Liu et al., 2000; Yang et al. 
2000; Kong et al., 1999); Central nervous system (Chi et al., 1999; Lomas et al., 2001; 
Nozaki et al., 2001 Alonso et al., 2001); Melonoma (Kroiss, et al., 1998; Herbst et al., 
1999; Schittek et al., 1999); Parathyroid adenoma (Shan et al., 2001; Lung cancer (Ikeas 
et al., 1999; Nomoto et al., 1998; Nicholson et al., 2001; Mai et al., 1998; Tokuchi et al., 
1999); Hypopharengeal carcinoma (Faridoni-Laurens et al., 2001); Oesophageal cacner 
(Ryan et al., 2001; Nimura et al., 1998; Cai et al., 2000) ;  Gastric cancer (Han et al., 
1999 ; Kang et al., 2000; Yokozaki et al., 1999); Colorectal cancer (Han et al., 1999; 
Sunahara et al., 1998) Bladder cancer (Yokomizo et al., 1999); Prostate cancer 
(Yokomizo et al., 1999; Takahashi et al., 1998); Renal cancer(Mai et al., 1998); 
Cholangiocarcinoma (Momoi, et al., 2001); Hepatocellular cancer (Mihara et al., 1999; 
Peng et al., 2000; Herath et al., 2000); Leukemia and Lymphoma (Corn, et al., 1999; 
Stirewalt et al, 1999); Breast cancer(Han et al., 1999; Zaika et al., 1999; Shishikura et al., 
1999; Schwartz et al; Dominguez, et al., 2000 ; Ahomadegbe, et al., 2000) ; Ovarian 
cancer (Chen et al., 2000 ; Codegoni, et al., 1999 ; Imyanitov, et al., 1999).  
 
1.3.12 Tumor derived mutants inactivate p73 
A moderate degree of interaction between wild-type p53 and p73 has been shown 
(Kaghad, et al, 1997; De Laurenzi et al, 2000). More than 50% of cancer cells have high 
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levels of mutant p53 and some tumor derived p53 mutants have a significant ability to 
bind and interact with TAp73-α. In co-transfection assays, it has been shown that the 
175, 248 and 281 mutants of p53 interact with p73-α and inhibits its ability to 
transactivate reporter genes and apoptosis (DiComo et al, 1999; Gaiddon, et al, 2001; 
Strano et al, 2001; Melino et al., 2002).  In addition, the association between p53 mutants 
and p73 is regulated by a common polymorphism at codon 72 of p53 that encodes Arg or 
Pro, with Arg leading to a stronger interaction with p73 (Marin et al, 2000; Melino et al., 
2002).  Together, inactivation of p73 by mutant p53 seems to provide a selective 
advantage in promoting tumorigenesis.  
1.3.13 Interaction between p73 and viral proteins  
Several groups showed that DNA tumor viruses (DTV) interact with p53 (Levrero 
et al., 2000; Ko, 1996; Levine 1997; Oren 1999).  The interaction between DTV and p73 
results in inability of p73 to transactivate reporter genes and apoptosis.  For example, 
SV40 T antigen, E1B, HPV proteins bind to p53 and sequester it into an inactive 
complex.  None of these viral proteins interact with p73 (Kaelin, 1999b; Melino et al., 
2002).  However, the Ad E4 and the HTLV1 tax proteins bind to and inactivate p53 and 
p73 (Das et al., 2003; Lemasson et al., 2001; Moll et al., 2001; Melino et al., 2002).  
1.3.14 Phenotypes of p73-/- mice 
Unlike p63-/- mice, TP73–/– mice survive postnatally, despite having multiple 
defects (Yang et al., 2001). Given the similarity of the genes, the TP73 knockout 
phenotype shows no obvious overlap with that of TP53-deficient mice.   p53 deficient 
mice develop thymic lymphoma, fibrosarcoma, other tumors and excencephaly 
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(Donehowver, 1996). In contrast, p73 null mice show no spontaneous tumors (Yang et 
al., 2002).  
TP73–/– mice appear to suffer from the following:  
1.  Somatic growth retardation. 
2.  Malfunctions in fluid control in the central nervous system and respiratory airways. 
3. Middle ear inflammation/infections. 
4.  Defective neurogenesis. 
5. Abnormal reproductive and social behavior (Yang et al., 2000). 
 
1.3.15 p73 participates in DNA repair pathways 
The following facts may suggest that p73 participates in DNA repair pathways:  
1. The ability of p73 to respond to DNA damage signals, just like its counterpart-p53.  
2. MLH-1-/- cells failed to induce p73 in response to cisplatin treatment (Gong et al, 
1999).  
3.  p73 overexpressing clones have increased levels of DNA repair proteins (Vikhanskaya 
et al., 2001). 
1.3.16 p73 participates in differentiation 
The following facts may suggest that p73 participates in differentiation: 
1. The overexpresion of p73β induces morphological and biochemical markers of 
neuroblastoma differentiation (Laurenzi et al., (2000).  
2. Laurenzi et al., (2000) have shown that TA-p73 expression is increased during retionic 
acid-induced and spontaneous differentiation of neurblastoma cells. 
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3. Human skin keratinocytes have been shown to undergo terminal differentiation when 
TAp73-γ and ∆Np73 are overexpressed (Laurenzi et al 2000; Kovalev et al 1998).  
4. Li (2005) showed that p73α suppresses myogenic differentiation on one hand.  On the 
























The proto-oncogene Jun, represents one of the important components of the AP-1 
family of transcription factors (Angel et al., 1991).  
 
2.2 Introduction to c-Jun 
 
The transcription factor, c-jun, is the cellular homologue of v-jun, the 
transforming oncogene of the avian sarcoma virus 17 (Nishimura et al., 1988).  The c-Jun 
appears to regulate both cellular proliferation and apoptosis. 
 
2.3 Gene structure of the c-jun  
 
Hattori et al (1988) and Nishimura (1988) cloned the c-jun gene nearly fifteen 
years ago. Cloning of the c-jun gene revealed that it is a gene without introns (Nishimura 
et al., 1988). The human jun gene is located on chromosome 1 at region p31-32 (Haluska 
et al, 1988).  Murine jun is located on chromosome 4 sub-region C5-C7 (Mattei et al, 
1990; Vogt, 2001).  
2.4 c-jun promoter 
 
 The c-jun promoter region is highly conserved between mouse, rat and human 
(Mechta-Grigoriou et al., 2001). The c-jun promoter contains potential binding sites for 
several transcription factors, including SP1, Jun, CTF (CCAAT Transcription Factor) and 
AP1 (Brach et al., 1992; Angel et al., 1988; Mechta-Grigoriou et al., 2001). 
2.5 Expression pattern of c-Jun 
 
c-Jun has been shown to be mainly expressed in developing cartilage, gut and the 
central nervous system (Mechta-Grigoriou et al., 2001).  However, c-Jun is over 
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expressed in several human tumors or transformed cell lines of different cell origins 
(Zoumpourlis et al., 2000).  c-Jun’s expression level is elevated both in response to 
growth and stress stimuli. Its expression level is regulated both at the transcriptional and 
post-translational level.   
 
2.6 The definition of AP-1 
 
AP-1 is a group of dimeric basic region-leucine zipper (bZIP) proteins that belong 
to the c-Jun, c-fos family and others, which recognize 12-0-tetradecanoylphobol-13-
acetate (TPA) response elements (5’-TGAG/CTCA-3’) (Shualin et al., 2002; Angel et al., 
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2.7 The structural organization of the c-Jun protein 
c-Jun posses a dimerization (280-300), DNA-binding (257-276) and transactivation 
domains (1-100) and these domains can be exchanged with functionally equivalent 
domains within the bZIP family (Vogt, 2001). 
 
 Figure 1.8 Structural domains of c-Jun protein (Morton et al., 2003). 
Transactivation (TA) domain 
The N-terminal half of Jun contains the transactivation domain.  
DNA binding domain (DBD)  
The DBD is located immediately N-terminal to the leucine zipper sequence. 
Residues 252-281 in the c-Jun protein consititues the basic/DNA binding region, which is 
responsible for the sequence specific DNA recognition site or DNA contact surface 
(Krebs 1995).  
Dimerization domain 
This dimerization domain contains five heptad repeats of leucines (Landschulz et 
al., 1988; Alber et al., 1992).  Hence, it is also referred as the leucine zipper (bZIP) 
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domain.  Dimerization is a prerequisite for DNA binding (Halazonetis et al., 1988; Smeal 
et al., 1989) and the dimerization of Jun and Fos enhances their nuclear translocation 
(Chida et al., 1999).   
The c-Jun is known to homodimerize or heterodimerize with the c-fos protein.  
However, c-Jun homodimers are less stable than c-Jun/c-fos heterodimers and they have 
a higher affinity for the DNA target sequence (Allegretto et al., 1990; Halazonetis et al., 
1988; Nakabeppu et al., 1988; Smeal et al., 1989).  Cellular context and extracellular 
signalling molecules decide the composition of the AP-1 family of proteins.  
2.8 Post-translational modifications of c-Jun 
c-Jun mediates transcriptional regulation in response to a variety of stimulants and 







Figure 1.9 Post-translational modifications of c-Jun (Morton et al., 2003; Barilla et al., 
2000; Muller et al., 2000). 
 
2.8.1 Phosphorylation 
Early studies show that c-Jun needs to be phosphorylated at serine 63 and 73 to 
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Smeal et al., 1991, 1992; Davis et al., 2000; Bohmann et al., 1989).  c-Jun is 
phosphorylated at two residues proximal to the major transactivation domain. The 
trasactivation domain is phosphorylated by a family of stress-activated protein kinases 
(SAPKs) (Adler et al., 1992c; Dai et al., 1995; Hibi et al., 1993; Pulverer et al., 1993; 
Davis et al., 2000). The corresponding kinase gene, JNK1(Jun N-terminal kinase), was 
cloned (Derijard et al., 1994).  Cloning JNK2 of a second Jun kinase, followed soon after 
(Kallunki et al., 1994).   
Further, c-Jun was shown to be phosphorylated at sites Thr231, Thr239, Ser 243 
and Ser249, which are located near the DNA binding domain and known to be 
phossphorylated by GSK-3 and Casein Kinase-II (Boyle et al., 1991; Lin et al., 1992). 
Dephosphorylation of these sites in response to growth stimulation augments the binding 
of c-Jun to DNA (Morton et al., 2003). 
2.8.2 Acetylation 
It has been shown recently that c-Jun is acetylated in vivo and the specific 
acetylation of c-Jun enhances its ability to trasactivate downstream genes.  In addition, 
mutational analysis identified that Lys 271 in the c-Jun basic region, is acetylated by 
p300 (Vries et al., 2001).  
2.8.3 Sumoylation 
It has been shown by Muller et al, (2000) that c-Jun is a new substrate for SUMO-
1 both in vitro and in vivo.  SUMO-1 targets a single lysine residue in c-Jun (Lys-229), 
and the SUMO-1 modification decreases transactivation potential on an AP-1-containing 
promoter compared with wild-type c-Jun, suggesting that SUMO-1 negatively regulates 
c-Jun activity. 
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2.9 Biological functions of c-Jun 
c-Jun appears to play a role in proliferation, transformation and apoptosis.  
2.9.1 c-Jun and cell Proliferation 
The following facts support the idea that c-Jun plays a major role in cell proliferation:  
1. Fibroblasts/hepatoblasts lacking c-Jun exhibit a severe proliferation defect. This 
inhibition of cellular proliferation is associated with reduced expression of cyclin 
D1 and D3. Importantly, c-Jun regulates cyclin D1 promoter activity directly 
(Eferl et al., 1999; Hilberg et al., 1993; Johnson et al., 1993; Bakiri et al., 2000; 
Shualin et al., 2000).  
2. Its ability to transform cells either alone or in the presence of a cooperating 
oncogene (Bos et al 1990; 1999; Johnson et al., 1996; Schutte et al., 1989; Leppa 
et al., 1999; Vogt et al., 2001).  
3. Both neutralizing antibodies and anti-sense RNA inhibit the cell’s entry into S 
phase (Kovary and Bravo, 1991; Riabowol et al., 1992; Smith and Prochownik, 
1992; Leppa et al., 1999).   










2.9.3 Constitutive expression of c-Jun alone causes transformation  
It has been shown that both c-Jun and v-Jun could transform primary chicken 
embryo fibroblasts (Cavalieri et al., 1985; Hartl et al., 1995; 1992; Castellazzi et al., 
1990; Wong et al., 1992).  The transformed cells are highly tumorigenic and are capable 
of anchorage-independent growth (Vogt, 2001).  Similarly, in mammalian host systems, 
c- Jun, is able to transform the continuous line of rat fibroblasts known as Rat1a (Schutte 
et al., 1989; Vogt, 2001).  Together, these results support a view that c-Jun plays a 
significant role in tumor pathogenesis.   
2.9.4 c-Jun cooperates with other oncogenes to transform cells 
NIH3T3 cells can be transformed by c-Jun in conjunction with Fra-1 (Mechta et 
al., 1997). In addition, c-Jun can co-operate with mutated ras to transform embryo 
fibroblasts (Schutte et al., 1987).  In the co-transformed cells, ras was shown to act 
upstream of c-Jun, inducing JNK and constitutively phosphorlylating c-Jun (Vogt et al., 
2001; Behrens et al., 1999, 2000).   
2.9.5 c-Jun as a mediator of Apoptosis 
Although c-Jun is known to induce proliferation, it has the capacity to induce 
apoptosis, a property that Jun shares with other oncoproteins like Myc, E1A, or E2F. In 
NIH3T3 cells, over expression of Jun triggers programmed cell death (Bossy-Wetzel et 
al., 1997). c-Jun can trigger either proliferative or anti-proliferative/apoptotic signals 
depending on the dimer composition, context, the cell types or concentration of the DNA 
damaging agents (Leppa et al., 1999).   
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2.9.6 c-Jun and apoptosis 
The following facts support a role for c-Jun in apoptosis: 
1. DNA damaging agents such as UV, H2O2, MMS, TNF-alpha etc. induce c-jun 
expression (Mechta-Grigoriou et al., 2001).  
2. IL-6 depletion causes apoptosis in lymphocytes. During the execution phase of 
apoptosis, both c-jun and c-fos expression is increased. Furthermore, addition of 
c-jun/c-fos antisense oligonucleotides protects these cells from undergoing 
apoptosis (Mechta-Grigoriou et al., 2001; Colotta et al., 1992). 
3. Bossy-Wetzel et al., (1997) showed that increased expression of c-Jun causes 
apoptosis in immortalized NIH3T3 fibroblasts that can be prevented by Bcl-2 or 
inhibitors of ICE/CED-3-type cysteine proteinases.  
4. Over-expression of c-Jun also induces apoptosis in endothelial cells. The process 
is preventable by a dominant negative Jun mutant (Wang et al., 1999). 
All these results provide evidence that c-Jun is a potent inducer of programmed cell 
death in various cell types. 
 
2.10 Knockout studies on c-Jun: c-Jun invivo functions 
c-jun heterozygous mutant mice appear to be normal, but embryos lacking c-Jun exhibit 
impaired hepatogenesis, altered fetal liver erythropoiesis and generalized edema. These 
embryos undergo apoptosis in hepatoblasts and erythroblasts lineage (Hilberg et al, 1993; 
Johnson et al, 1993; Eferl et al, 1999; Mechta-Grigoriou et al., 2001).  In contrast, over 
expression of c-Jun in transgenic mice does not result in any obvious phenotype 
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(Grigoriadis et al., 1993). Further, Jun phosphorylation mutant mice [c-Jun knock-in mice 
carrying c-Jun alleles with JNK phosphorylation site mutations (Jun S63A and S73A)] 
are viable and develop normally, indicating that N-terminal phosphorlylation of c-Jun is 
not requireed for embryonic development and organogenesis (Behrens et al., 2001).   
 
2.11 The Regulation of c-Jun 
2.11.1 Transcriptional mechanisms 
Growth factors (EGF, FGF) and tumor promoting agents (TPA/PMA) induce the 
expression of c-jun at the transcriptional level and they induce it through a TRE- like site 
present in the murine c-jun promoter regulatory sequences (Mechta-Grigoriou et al., 
2001).   
2.11.2 Post-translational mechanisms 
The stimulation of c-Jun expression and post-translation modification seem to be 
regulated sequentially: endogenous basal c-Jun protein is first activated by 
phosphorlyation. Next, phosphorylated c-Jun augments its own expression, which results 
in a positive feed back loop (Angel et al., 1988). The ability of c-Jun to function as a 
transcription factor is enhanced by JNK dependent phosphorylation mechanism. At least 
three classes of JNK kinases (JNK1, JNK2 & JNK3) have been identified (Davis R et al., 
2000). JNK phosphorylates c-Jun and thereby connects Jun to various signals, generated 
by mitogens, stress signals, and genotoxic substances (Adler et al., 1995a,b; Derijard et 
al., 1994; Franklin et al., 1993; Smeal et al., 1991, 1992).  It was suggested that 
phosporylated c-Jun could recruit CBP or histone deacetalase to augment the c-Jun 
dependent transcription (Arias et al, 1994; Mechta-Grigoriou et al., 2001).  The signaling 
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molecules that originates upstream of JNK and their sequential interactions have not been 
fully worked out.  However, it appears that JNK is itself activated by a signal that 
originates in Ras (Adler et al., 1992; Minden et al., 1994; Westwick et al., 1994).   
2.12 The stability of c-Jun protein  
Several studies suggest that multiple proteolytic machineries, including the 
proteasomes, lysosomes, and ubiquitous calpains, may participate in the destruction of c-
Jun. The relative input of each pathway is far from being known.  It has been 
demonstrated that, in certain occurrences, the degradation of c-Jun by the proteasome in 
vivo involves the ubiquitin pathway.  Treier et al (1994) showed that c-Jun, but not v-Jun, 
can be efficiently multiubiquitinated. Consistently, v-Jun has a longer half-life than c-Jun. 
2.13   The relationship between p53 and c-Jun  
c-Jun null  fibroblasts have a proliferation defect. This proliferation defect found in c-Jun 
null cells was attributed to the accumulation of p53.  This data suggests that c-Jun 
negatively regulates p53 in fibroblasts (Shualin et al., 2001) and it was shown to suppress 
the expression of p53 at the promoter level (Schreiber et al., 2000).  In addition, 
fibroblasts lacking c-Jun express very low levels of cyclin D1 leading to slow progression 
from G1 to S phase (Wisdom et al, 1999; Wagner E, 2003).  These observations indicate 
the ability of c-Jun to directly regulate cell cycle and apoptotic machinery. On the one 
hand, it activates cyclin D1 transcription and on the other hand, it inhibits p21 








3.1 Hypothesis: c-Jun plays a role in the regulation of p73 
 
 
3.1.1 c-Abl regulates p73 in response to cisplatin and IR induced DNA damage. 
 
 
c-Abl is activated by certain DNA-damaging agents such as cisplatin and ionizing 
radiation. It contributes to the induction of programmed cell death (apoptosis) by p53-
dependent and p53-independent mechanisms (Shaul et al., 2000).  Cancer cells with 
mutation in p53 gene are resistant to anti-cancer drugs, however, their resistance is 
partial, which indicates that alternative apoptotic pathways exist (Gong et al., 1999). The 
protein p73 is a structural and functional homologue of the p53 tumor-suppressor protein.  
It can induce apoptosis in the absence of p53 (Jost et al., 1997).  The p73 protein level is 
increased in wild-type fibroblasts but not in MLH-/- and Abl-/- fibroblasts.  Also, MLH-/- 
and Abl-/- fibroblasts were more resistant to cisplatin and the half-life of p73 was 
extended by cisplatin (Gong et al., 1999). Further, c-Abl has been shown to bind to p73 
through its SH3 domain with the carboxyl-terminal homo-oligomerization/PxxP domain 
of p73.  c-Abl phosphorylates p73 on a tyrosine residue at position 99 in cells that have 
been exposed to IR (Yuan et al., 1999; Agami et al., 1999).   
 
3.1.2 Cisplatin but not IR stabilizes p73 
 
 Both ionizing radiation and cisplatin induction have been shown to result in 
enhanced c-Abl kinase activity.  However, only ionizing radiation induces tyrosine 
phosphorylation of p73.  Further, only cisplatin treatment results in the stabilization of 
p73, but not ionizing radiation (White and Prives 1999).  These intriguing observations 
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raise the possibility that there could be other molecules involved in cisplatin mediated 
p73 stability.  Ionizing radiation induces double stranded DNA breaks.  This kind of 
DNA damage is more amenable to repair; hence, it induces only cell cycle arrest.  In 
contrast, cisplatin interacts with DNA to form intra- and interstand crosslink adducts 
(Siddik et al., 2003).  The cisplatin-modified DNA is not amenable to DNA repair 
(Jordan et al., 2000).  Thus, it is cytotoxic to cells.  The fact that p73 is not being 
activated in MLH-/- (Mismatch repair deficient) MEFs in response to cisplatin indicates 
that MLH is upstream of p73 and it participates in the DNA repair process.  Transient 
activation of p73 in response to ionizing radiation would result in the activation of repair 
pathways.  This clarifies why p73 is only transiently induced in response to ionizing 
radiation.  While in response to cisplatin, the sustained p73 induction, results in 
stabilization and activation of apoptosis. Hence, it seems clear as to why cisplatin 
stabilizes p73 and not IR.  However, it is essential to identify the molecules that are 




























Figure 1.10 c-Abl regulates p73 in response to cisplatin and IR induced DNA damage 
The resistance of c-abl-/- MEFs to cisplatin treatment was attributed to lack of induction 
of p73 in these cells. c-Abl has also been shown to interact and phosphorylate p73 in 
response to IR. Both c-Abl and p73 seem to cooperate with each other in inducing 
apoptosis in response to cisplatin treatment. 
 









Figure 1.11 cisplatin stabilizes p73 but not IR Both IR and cisplatin induce c-Abl 
activity, however, only cisplatin stabilizes p73 but not IR.  This fact raises the question of 
how cisplatin stabilizes p73.  
 
3.1.3 Does c-Jun play a role in cisplatin mediated p73 stability? 
It has been shown earlier that c-Jun act as a convergence point of many signaling 
pathways (Karin et al., 1997).  Its activity is regulated at the transcriptional and post-
transcriptional levels. Serine/threonine phosphorylation at Ser63/73 (Phosphorylated by 
JNKs) and Thr91/93 (Phosphorylated by MAP kinases) sites induces an increase in the 
DNA-binding and transactivation potential of the protein, as well as an increase in the 
stability of c-Jun (Treisman, 1996; Karin et al., 1997).  It has been shown that increased 
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c-Jun levels increase the activity of c-abl, in turn, c-abl kinase phosphorylates Jun on 
tyrosine 170 (Barila et al., 2000; Raitano et al., 1995; Renshaw et al., 1996). This positive 
feedback loop enhances the ability of Jun to activate Abl further.  However, whether c-
Abl enhances JNK activity or c-Jun enhances c-Abl activation in response to stress 
signals is not clear.  For example, UV and IR do not induce c-Abl activity and c-Jun 
expression respectively (Liu et al., 1996; Shualin et al., 2000) 
Cisplatin induces the expression and activity of c-Abl, JNK and c-Jun, while IR is 
known to induce only c-Abl, raising a possibility that c-Jun could play a role in cisplatin 
mediated p73 stability.  Furthermore, c-Jun might influence the ability of c-Abl to 
activate p73. However, the study led by Superti-Furga (2000) failed to indicate the 
significance of tyrosine phosphorylation of c-Jun by c-Abl and its importance in 
genotoxic signaling.  
3.1.4 The Role of c-Jun in cisplatin resistance and p73 activation. 
 
Most of the anti-cancer drugs exert their action by inducing apoptosis. Cisplatin, a 
well-known anti-cancer drug, is used to treat a wide variety of cancers, although its 
efficacy is often limited by its inherently poor activity against many tumor types and by 
the development of resistance (Young, et al., 1989; Siddik et al., 2003). The mechanism 
through which cisplatin exerts its toxicity in cancer cells is not clear yet, but it is 
generally accepted that it acts through the formation of DNA adducts (Zamble, et al., 
1995; Jordan et al., 2000).  Thus, it is important to understand the mechanism of action of 
cisplatin and molecules involved in the signaling pathway in order to increase the 
efficacy of the anti-cancer treatment.  
Cisplatin has been shown to activate both p53-dependent apoptosis and p53-
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independent apoptosis in cancer cells (Hawkins, 1996.  The p53 is not a determinant of 
cisplatin cytototoxity in ovarian cancer cells (De Feudis, et al., 1997), testicular tumor 
cell lines (Burger, et al., 1997), breast cancer, and human foreskin fibroblast cell lines 
(Fan, et al., 1994; Hawkins, 1996).  
Furthermore, cisplatin has been shown to activate c-Abl, p38 MAP kinase and 
JNK. However, the components involved in the cisplatin-mediated p53-independent 
apoptotic program are not clear yet.   
Together, the facts described so far, support the hypothesis that if cisplatin 
mediated p73 stability/activation requires c-Jun then c-jun-/- cells will be resistant to 
cisplatin mediated apoptosis and this can be attributed to the lack of stabilization of p73 
in these cells. 
 
                               
 37 
Figure 1.12 C-Jun could play a role in cisplatin mediated p73 stability.  A schematic 
diagram illustrating the difference in p73 stability in response to cisplatin and IR 
mediated signaling. Although both ionizing radiation and cisplatin induction results in 
enhanced c-Abl kinase activity, only cisplatin treatment, but not ionizing radiation results 
in stabilization of p73. This indicates that other molecules play a role in p73 stability. 
cisplatin has been shown to induce both c-Abl and c-Jun, while IR induces only c-Abl 











* Are c-Jun null cells resistant to Cisplatin- mediated apoptosis?
* Is c-Jun required for cisplatin-mediated activation/apoptosis?
 








Figure 1.13 A & B, A role for c-Jun in regulating cisplatin mediated p73 stability and 
apoptosis.  Integration of facts derived from various cellular network indicates a 
possibility that c-Jun could play a role in cisplatin resistance and stabilization of p73.  
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4.1 Aims and scope of the thesis 
 
The tumor suppressor, p53 is mutated in at least 55% of cancers, suggesting its 
pivotal role in the prevention of tumor development.  It can promote growth arrest and 
apoptosis in response to various anti-cancer drugs.  The p53-related gene, p73 also 
induces growth arrest and apoptosis when overexpressed or induced by certain DNA 
damaging agents like -irradiation and cisplatin treatment. Unlike p53, p73 is not 
susceptible to mutations.  The p73-mediated apoptosis can occur in a p53-independent 
manner, suggesting that p73 activation can be exploited for the elimination of various 
cancers with p53 mutations.  Hence, identifying molecules that activate or potentiate p73 
in tumor cells would have therapeutic benefits.  In addition, it would pave the way for 
better treatment of cancers, specifically those harboring p53 mutations, as these tumors 
are often resistant to p53-mediated drug induced apoptosis. 
The mechanism of p73 stabilization is not clear yet.  Besides c-Abl, a non-receptor 
tyrosine kinase, no other physiological molecular determinant of p73 activation has been 
identified.  Earlier, it was shown that irradiation and cisplatin, a DNA damaging agent 
and anti-cancer drug could activate p73 in c-Abl dependent manner. c-Abl has been 
shown to be induced by both cisplatin and  irradiation. However, only cisplatin treatment 
results in p73 stability.  This suggests that other molecules are involved in cisplatin 
mediated p73 stability.  
 Understanding of the MLH1–ATM-c-Abl–p73 pathway is potentially of great 
clinical relevance, as it might explain the response to chemotherapy in the majority of 
cancers that have mutated or functionally inactivated p53.  Interestingly, it has been 
shown that c-Abl phosphorylates c-Jun, which in turn enhances the ability of c-Abl to 
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enter into the nucleus (Barila et al., 2000).  In addition, only cisplatin has been shown to 
induce c-Jun, but not IR, which raises the possiblity that c-Jun could play a role in 
cisplatin mediated p73 stability. c-Jun, a well-known player in cell proliferation, can 
induce apoptosis in certain cellular settings. However, targets for c-Jun mediated 
apoptosis have not been described so far.  
 
The following goals were set  as objectives for my Ph.D thesis: 
1. Identifying the molecular component(s) responsible for cisplatin mediated p73 
stability. 
2. Clarifying whether c-Jun null cells are resistant to cisplatin-mediated apoptosis. 
Then, identifying molecular component(s) responsible for it.  
3. To find out whether c-Jun stabilizes p73. 
4. To find out whether c-Jun interacts with p73.  If so, identifying domains 
responsible for the interaction.  
5. To find out the physiological significance of c-Jun mediated p73 stabilization. 
6. Clarifying how c-Jun influences p73’s ability to transactivate its downstream 
genes (p53 RE promoters).    
7. To test whether p73 is stabilized in response to UV irradiation. 
8. To test how p73 influences c-Jun’s function (on AP-1RE promoters). 
9. To test whether phosphorylated c-Jun is required for its ability to cooperate with 
p73 (on AP-1RE promoters). 














“To engage in experiments on heat was always one of my most agreeable 
employments”.   Benjamin Thompson (Count Rumford) (1753-1814) Physicist and 
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2.1 Cell lines used in this study 
NIH-3T3, COS7, HI299, SAOS2, 293 HK, Jun-/-, abl-/-, p53-/-, p53-/-MDM2-/-, p53-
/-Jun-/- Jnk1-/- Jnk2-/-, p53-/- cells and a number of 3T3 immortalized fibroblasts. Schreiber 
et al., (1999) generated p53-/-jun-/- cells by crossing p53+/+jun+/- and p53-/- jun-/- 
mice.  
2.2 Cell maintenance 
Indicated cell lines were cultured in DMEM supplemented with 10% (v/v) fetal 
calf serum (FCS), antibiotics, pyruvate and glutamate. 
2.3 Transient transfection of Cos 7 cells (Calcium phosphate method) 
Cells were transfected by a calcium phosphate co precipitation method according 
to standard Manniatis (book) protocol.   
2.4 Transient transfection using Lipofectamine plus reagent (COS7, NIH-3T3, 
HI299, SAOS2, 293 HK, jun-/-, abl-/-, p53-/-, p53-/-MDM2-/-, p53-/-Jun-/- Jnk1-/- Jnk2-/-, 
p53-/-)  
 
In this study, Lipofectamine reagent was mainly used for most of the transient and 
stable transfections (according to standard LifeTechnologies prescribed protocol). 
 2.5 Establishment of stable cell lines 
NIH3T3/MCF7 cells were transfected in a 10cm tissue culture plate with 2 mg of 
purified DNA following the lipofectamine protocol.  24 hours after transfection cells 
were reefed with 10ml of fresh medium for overnight. The following day transfected cells 
were trypsinized and seeded at 1:5 ratio.  Once cells adhere to the plates, 1 mg of 
G418/ml was added. Every 72 hours later, the G418 was resupplied with 10 ml fresh cell 
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culture medium. Drug resistant clones carrying the expression vector was pooled after 3 
weeks and grown as cell lines.  
2.6 Cell survival assays 
For the analysis of cell survival 0.5x106 cells in a total volume of 1 ml were 
dispensed into a 6/10 cm tissue culture plate. After 48 hours, the live cell numbers were 
determined by trypan blue exclusion method. 
2.7 Colony formation assays 
NIH3T3/MCF7/Cos7 cells were transfected in 10cm tissue culture plate with 2µg 
of purified DNA (2µg each-PCDNA-p73α/β or PCDNA-p73α/β with PCDNA-c-Jun/c-
Jun mutants) following the lipofectamine protocol.  6 hours after transfection, 5ml of 
complete medium was added.  24 hours after transfection, cells were washed with PBS 
and reefed with 10ml of fresh medium for overnight. The following day transfected cells 
were trypsinized and seeded at 1:5 ratio.  1µg of G418/ml was added. Every 72 hours 
later, the G418 was resupplied with 10 ml fresh cell culture medium. After 2 weeks, 
colonies were fixed and visualized by staining with crystal violet.  Colony numbers were 
counted in the respective plates. 
 
2.8 Retroviral infection 
 
 
High titer retroviral stocks were produced by transfecting retroviral construct pBabe-c-
Jun (2µg) into a packaging cell line by the lipofectamine method (Schreiber et al., 1999). 
Virus containing culture supernatants were collected 72 hours post-transfection, at 24 
hours intervals, and pooled together.  Frozen low passage Jun-/- MEF’s were thawed and 
plated at a density of 2x105/10cm dish.  After fourteen-hours, cells were infected with 
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filtered supernatants in the presence of polybrene (5µg/ml; sigma).  Fresh supernatants 
were added three times, at 4h intervals. Forty-eight hours post-infection, cells were 
trypsinized and replated; twenty-four hours later, fresh medium containing 10% FCS was 
added to the cells.  Cells were selected in puromycin 1.5 µg/ml of the medium for about 3 
weeks.   
2.9 TRYPAN blue dye exclusion assay 
This assay is used to measure the cell viability. Trypan blue dye is impermeable 
to viable (white) cells, but it is permeable to dead (blue) cells. A cell suspension was 
mixed with 0.4% trypan blue in PBS to assess the cell viability in haemocytometer. 
Placed the haemocytometer on microscope and counted the number of blue and white 
cells.  
2.10 Annexin-V binding assay 
During the early stages of apoptosis, Phosphatidylserine is translocated from the 
inner to the outer surface of the plasma membrane (Emoto et al., 1997). AnnexinV 
protein binds to Phosphatidylserine with high affinity. Therefore, increased AnnexinV 
staining is used to detect cells in early stages of apoptosis (Martin et al., 1995). The cells 
were pelleted and washed with PBS, and re-suspendend in 200µL of 1X annexiin binding 
buffer.  To the cell suspension, 5µL of annexin V-FITC (final concentration was 0.5 
µg/ml) was added and incubated at room temperature for 15 min in the dark before 
subjecting it to flow cytometric analysis.  
2.11 Preparation of single cell suspension for cell cycle 
The cells were washed twice with sample buffer and resuspended in sample 
buffer. The cells were centrifuged, and the supernatant was removed.  For fixing, 1ml ice-
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cold 70% ethanol was added to the cell pellet drop by drop while vortexing the cells.  The 
cells were fixed in the ethanol overnight at 4C. 
 
2.12 Propidium iodide (PI) staining and flow cytometry 
The fixed cell sample was vortexed and centrifuged to remove the 70% ethanol. 
Cells were gently resuspended in residual ethanol and 0.5ml PI staining solution added 
(25µL PI stock (1mg/ml). 50 Kunitz units RNAase A in 0.5 ml sample buffer was added 
to each sample. Samples were incubated in the dark at room temperature for at least 30 
minutes before flow cytometric analysis (Bossy-wetzel et al., 1997).  
2.13 Sub-cloning: Restriction enzyme digestion 
 
All the restriction enzymes were purchased from New England Biolabs or 
Promega.   All digestions were carried out at 37oC or 30oC overnight, with proper 
restriction buffer in a total volume of 20 to 100µL.  
2.14 Ligation of DNA fragments 
 
DNA fragments from digestion were ligated to linearized vectors. pBabe-c-Jun 
and pcDNA plasmids were restriction digested with EcoRI and BamH1 enzymes. 
Restriction digested plasmids were run on a gel and purified the c-JuncDNA fragment 
(insert) and linearized pcDNA vector (vector). DNA ligation reaction (1:10 molar ratio of 
(pcDNA) vector: insert (c-JuncDNA) was carried out typically in 20µL of volume at 4oC 
for 16 hours.   
2.15 Isolation of RNA from cells 
Trizol RNA isolation procedure was used to isolate RNA.  
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2.16 Running RNA samples on denaturing gels 
The integrity of RNA was checked in a denaturing formaldehyde-agarose RNA 
gel before subjecting it for RT-PCR analysis.  
2.17 Reverese transcriptase (RT) reaction- PCR 
The QIAGEN OneStep RT-PCR Kit (210210) was used to check the expression 
of p73 and its downstream targets. After checking the integrity of the RNA isolated, 
cDNAs [e.g. with reverse transcriptase from Moloney murine leukemia virus (M-MuLV) 
or avian myeloblastosis virus (AMV)] were amplified and quantified carefully with 
housekeeping primers such as β-tubulin and GAPDH as controls.  The following p73 
primers were used for RT reaction and PCR analysis (Laurenzi et al., 1998).   
5'-TTCTGCAGGTGACTCAGGCTG-3' for RT p73 
5'-ACTTTGAGATCCTGATGAAG-3'(sense primer) and  
5'-CAGATGGTCATGCGGTACTG-3' (anti sense primer)  
2.18 Gene Sequencing 
 
c-Jun, N-c-Jun, C-c-Jun, p73α and β etc. were sequenced and verified using specific 
primers. The purified DNA was sequenced using a Taq Dye Deoxy TM Terminator cycle 
sequencing kit (Perkin Elmer, CA) based on he chemical dideoxy-termination method.  
Sequencing results were analyzed using Biosystems. 
2.19 Bio-Rad protein assay 
Coomassie Brilliant Blue G-250 dye (Promega) was used to measure the protein 
concentration. Equal volumes of cell lysate was added to the dye and mixed well.  
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Known quantities of standard albumin (Sigma) were used as a standard.  The absorption 
at wavelength 595 was measured versus dye.  
2.20 SDS PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) and 
Transfer/ Immunobotting/Western blotting.  
 
Whole cell extracts were prepared in lysis buffer (Sabapathy et al., 1999), and protein 
content was measured. 30-300µg of protein was run on 10-12% SDS-polyacrylamide gels 
and transferred the proteins by electroblotting to nitrocellulose membrane for 2 hours (for 
large gels). Ponceau S fixative dye solution was used to check if transfer has taken place, 
Transferred filters were incubated with blocking buffer (5% non-fat dry milk/5% BSA in 
TBST) for 1 hr at room temperature or overnight at 40C on a shaker.  Antibodies were 
diluted in washing buffer containing 3% non-specific milk and 0.05% tween-20. After 2-
3 hours incubation at room temperature or overnight incubation at 40C, membranes were 
washed three times with TBST, each time for 10-15 min. Diluted (1:1000) the 
appropriate peroxidase-conjugated secondary antibody in TBST, added to the membrane, 
incubated at room temperature for 60 min and washed three times in TBST (Bossy-
wetzel et al., 1997). Finally, the specific protein of interest was identified using 
chemiluminescence reaction (ECL-system): incubated the membrane in a 1:1 mix of ECL 
solutions 1 and 2 or super signal for 1-5 minutes (Pierce). 
 
2.21 Antibodies used in the immunoblot analysis 
 
p73 antibodies  
 
1.mAb ER-15(Santa Crutz). 
 
Immunogen: N-terminus of p73 
 
Specificity: Recognizes p73 α and β . 
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2. mAbGC-15 (Oncogene science):  
 
Monoclonal GC15 (AB-3 from Oncogene Science; recognizes amino acids 380–499 of 
human p73 b); WB: 2 micrograms/ml; IP: 5-6 micrograms/tube. 
 
Immunogen: GST fusion-protein corresponding to residues 380-499 of p73β . Clone 
GC15. 
 
Specificity: Recognizes p73β  (MW~70kDa). This antibody does not effectively blot 
p73β, but will immunoprecipitate p73-β under non-denaturing conditions. 
 
Imgenex antibodies:  
 
3. IMG-246 - recognizes N-terminal epitope; human and mouse.  
 
4. IMG-260 - recognizes C-terminal epitope; human only. 
 
5. IMG-259 - recognizes all protein isoforms; human and mouse 
 
c-Jun antibodies:  c-jun (H79) rabbit polyclonal antibody was from Santa Cruz  
 
Biotechnologie. 
p53 antibodies: CM5 (Abcam, ab 2433) Rabbit polyclonal to human p53. 
 
GFP: Rabbit polyclonal (clone tech) 
 
Actin: Rabbit polychlorure(Santa crutz) 
 
2.22 Immunoblot stripping 
 
Primary and secondary antibodies were removed from the membrane using stripping 
buffer. The membrane was incubated in stripping buffer for 30 min at 500C. The 








For immunoprecipitation of cellular proteins, protein G/A sepharose was used.  Cell 
Lysates were first precleared with the proteinG/A sepharose.  Then 20 to 50µg Sepharose 
was incubated with 3-5µg of antibody, 300-500µg precleared lysate and the volume made 
up to 1 ml in an Eppendorf tube using lysis buffer. Samples were incubated on an 
incubator for at least 4 to 12 hours at 4oC and then washed with appropriate wash buffers, 
depending on the stringency required. The immunoprecipitated proteins were boiled in 
Laemmli buffer and subjected to SDS PAGE and Western blotting. 
 
2.24 Metabolic labeling & Immunoprecipitation  
 
Radiolabelling consists of two steps:  
1. Pulse - Short period of incubation with 35S-methionine or cysteine.  
2. Chase- Incubation with excess concentration of unlabeled Met+Cys. 
Metabolic labeling   
 
Cos7 or jun-/- and jun-/- +Jun cells were transfected with 2µg of p73/c-Jun pcDNA/ plate. 
After 7-9h incubation with DNA: lipofectamine mix rinsed once and replaced with fresh 
medium (10ml/plate). 24h after changed medium, rinsed cells with Labeling Medium 
(5ml/plate). Added 250µCi of [35S] methionine/cysteine/10cm plate and cultured for 
another 2 hours at 37°C (pulse).  Then added 5ml/well chase medium and cultured for 
another 4 hours (chase). Harvested metabolically labeled cells at the regular intervals. IP 
was carried out as described previously. The immunoprecipitated proteins were boiled in 
Laemmli buffer and subjected to SDS PAGE. Soaked gels into enhancer solution for one 
hour and then dried completely.  p73 expression was detected by autoradiography using 
intensifying screen. 
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2.25 Luciferase reporter gene assay 
 
p73, c-Jun, c-Jun mutants expression vectors and 0.5µg of plasmid containing PG13 
/MDM2/GADD45/p21/Bax/p53AIP1/5XTRE/Collagenase-I promoters hooked to  
luciferase reporter gene were transfected either alone or in combination into H1299/ 
SaOs2; p53-/-; p53-/-jun-/-; Jnk1-/-2-/- cell lines at the indicated ratios in the respective 
experiments using Lipofectamine transfection method. The PG13 luciferase reporter gene 
contains 13 tandem repeats of a p53 binding sequence, Bax, MDM2, GADD45, p21 
promoters encode p53 binding sequences and 5XTRE contains 5 tandem repeats of TPA 
responsive elements upstream of the luciferase reporter gene. The transfected cells were 
harvested and lysed in 100µl of lysis buffer and incubated on ice for 30 min. The crude 
cell lysates were precleared by centrifugation at maximum speed for 30 min. 50 µl of 
precleared cell extract was added to Luciferase Assay Buffer. The activity was measured 
after injection of 50µl of D-luciferin solution on a luminometer. The luciferase activities 
were normalized against the ß-galactosidase activity of co-transfected 0.5µg gal vector in 
the ß - galactosidase assay. Results are presented as luciferase units normalized to beta-
gal units. Each experiment is performed in duplicates or triplicates. The mean and 
standard deviations of two independent experiments are shown in the figures. 
2.26 β-galactosidase assay 
The ß-galactosidase assay was performed according to a standard protocol 
(Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989: Molecular cloning: A laboratory 
Manual 2nd Ed., Cold Spring Harbor Laboratory Press, New York). Precleared cell lysate 
was added to ß-gal Assay Buffer and ONPG-solution and incubated for 1 hour.  The ß-gal 
activity was measured on a luminometer.  




“I do not know what I may appear to the world; but to myself I seem to have been only 
like a boy playing on the seashore, and diverting myself in now and then finding of a 
smoother pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all 
undiscovered before me”   
 













SECTION I: C-JUN IS REQUIRED FOR 









“Theory guides.  Experiment decides.”   
“An old saying in science, seen attributed to many different persons.” 




3.1.1 Role of c Jun in cisplatin resistance and p73 activation 
 
3.1.1.1 c-Jun null 3T3 fibroblsts are resistant to cisplatin-mediated apoptosis 
 
 
The feasibility of the hypothesis proposed in Chapter I was examined by treating 
wild type and jun null mouse fibroblasts with cisplatin. In agreement with the hypothesis 
proposed, 3T3 cells lacking c-jun were more resistant (37%) to cisplatin than wild type 
fibroblasts.  This data suggests that c-Jun is required for cisplatin-mediated apoptosis.  
The c-Jun expression is increased in response to cisplatin (Sanchez-Periz et al., 1998) and 
its activity is sufficient to trigger apoptotic cell death in NIH 3T3 fibroblasts (Bossy-
Wetzel E, 1997), in human vascular endothelial cells (Wang et al., 1999), and in neuronal 
cells (Ham et al., 2000).  However, how c-Jun regulates apoptosis is far from clear.  
 


























Figure 3.1.1.1 The absence of c-Jun confers resistance to apoptosis after treatment 
with cisplatin. (TRYPAN  blue dye exclusion assay)  
 
Wild type and jun-/- fibroblasts were treated with 25µM of cisplatin for 24 hours.  Cell 
viability was estimated as previously described (Chapter 2, 2.9).  Each time point is the 
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3.1.1.2  p53-/- cells are more sensitive to cisplatin-mediated apoptosis than p53-/-Jun-/- 
fibroblasts 
 
Several studies suggest that treatment of cells with cisplatin results in increased levels of 
p53 in the nucleus and concomitantly increased apoptosis.  However, further studies 
suggest that cisplatin induces both p53-dependent and p53-independent apoptosis.  To 
eliminate the contribution of p53 in cisplatin mediated cell death and evaluate the 
cisplatin-mediated p53-independent cell death, p53-/- and p53-/-jun-/- cells were checked 
for cisplatin resistance.  Furthermore, to rule out the possibility that the reduced rate of 
proliferation of jun-/- cells--rescued by deletion of p53 gene--is responsible for the 
reduced rate of apoptosis (Shaulian, 2002). As shown in figure 3.1.1.2, p53-/- cells were 
found to be more sensitive to cisplatin compared to the p53-/- jun-/- cells, indicating that c-


























Figure 3.1.1.2   p53-/- cells are more sensitive to cisplatin than p53-/-jun-/- cells 
(TRYPAN  blue dye exclusion assay) 
 
Wild type or jun-/- fibroblasts were treated with indicated concentrations of cisplatin for 
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3.1.1.3 jun-/- cells are resistant to cisplatin mediated apoptosis  
In a detailed analysis, to confirm the earlier results obtained by an independent 
assay, we measured staining of phosphatidylserine exposed on the outer cell membrane 
by flow cytometry.  In agreement with the data obtained by Tryphan blue dye exclusion 
assay, annexin V staining showed that only wild type and not mutant cells exhibited a 
higher percentage of apoptosis.  c-jun-/-, c-jun-/-+ Jun, and abl-/- cells were treated with 
4µM and 20µM of cisplatin and collected after 24 hours treatment. As shown previously 
in figure 3.1.1.3  and Table 2,  jun-/- mouse 3T3 fibroblasts were found to be more 
resistant to cisplatin compared to c-jun-/- + c-Jun cells (figure 3.1.3) . c-abl-/- fibroblasts 





















































Figure 3.1.1.3 c-Jun is required for cisplatin-induced p73-mediated apoptosis (flow 
cytometry) 
 
Wild type and c-jun-/- 3T3 fibroblasts transduced with the retroviruses directing the 
expression of c-Jun or the puromycin resistance gene only. These cells were selected with 
puromycin for two weeks and treated with the indicated concentrations of cisplatin for 24 
hours. The extent of apoptosis was determined by staining cells with annexin-V FITC and 
subsequent flow cytometric analysis. Each time point is the average of few experiments 
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3.1.1.4 p53-/- cells are more sensitive to cisplatin-mediated apoptosis than p53-/-Jun-/- 
cells (Flow cytometry) 
 
 
In a similar annexin-V FITC staining and subsequent FACS analysis, we 
determined the sensitivity of   p53+/-c-jun+/-,  p53-/-c-jun-/- and p53-/- cells to cisplatin. The 
difference in the number of dead cells between p53-/- and p53-/- jun-/- is ~17% (figure 
3.1.1.4).  On the other hand, the difference in the number of dead cells between jun-/- and 
jun-/- with c-Jun or wild type cells is ~35%(figure 3.1.1.1), which means, the contribution 
of p53 in cisplatin-mediated apoptosis is 18% (35%-17%).  Therefore, it appears that the 
contribution of cisplatin-mediated-p53–independent and c-Jun dependent apoptosis is 
17%.  Together, the data presented here confirm that c-Jun is required for cisplatin-

































































Figure 3.1.1.4 p53-/- cells are more sensitive to cisplatin-mediated apoptosis than p53-/-
Jun-/- cells  
 
p53+/-cjun+/-, p53-/- and p53-/-c-jun-/- fibroblasts were treated with indicated 
concentrations of cisplatin for 24 hours, and the fraction of viable cells was estimated by 
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3.1.1.5 c-Jun is required for increased p73 levels in response to cisplatin 
In the earlier experiment c-jun null cells were compared against wild type 
fibroblasts to see whether p73 is induced in response to cisplatin treatment. In order to 
avoid any clonal specific effect in the c-jun null background, jun-/- cells were transduced 
with recombinant retroviruses directing the expression of wild-type c-Jun or puromycin 
resistance gene only (as described in chapter 2). As shown in figure (3.1.1.5), cisplatin 
induced expression of p73 in c-jun-/- + c-Jun cells but not in cells lacking c-Jun.  This 

































Figure 3.1.1.5 c-Jun is required for p73 induction (GC15) 
jun-/- and jun-/- + c-Jun cells were treated with cisplatin at different concentrations as  
indicated above.  At 24 hours after cisplatin treatment, cell extracts were prepared and 
400µg of proteins per sample was loaded and subjected to Western analysis. The blot was 
probed with the following:  1. anti-p73-β specific (GC15) mAb (1:1000) 2. anti-actin 
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3.1.2 c-Jun stabilizes p73 
 
Our preliminary analysis suggests that c-Jun is required for increased p73 levels 
in response to cisplatin treatment.  However, it is not clear whether c-Jun is required for 
p73 induction or stabilization. Thus, experiments were designed to address the question 







































3.1.2.1 c-Jun is required for increased p73 levels in 3T3 mouse fibroblasts 
 
To check whether transiently transfected c-Jun increases p73 levels, p73 was 
either transfected alone or in the presence of c-Jun in jun-/- and jun-/- + Jun fibroblasts. 
Cell extracts were collected 48 hours post-transfection and subjected to Western analysis.  
As shown in figure 3.1.2.1, p73 protein expression is weak in jun-/- fibroblasts (panel 2, 
lane 3). While in jun-/- + Jun fibroblasts, p73 expression is seen, indicating that c-Jun 
augments p73 levels (panel 2, lane 5). On the other hand, p73 expression is seen in jun-/-
+Jun cells (panel 2, lane 3), indicating that c-Jun contributes to the increased levels of 
p73 (panel 2, lane 5). It is also important to note that jun-/-+Jun cells express c-Jun at the 



















































Figure 3.1.2.1 c-Jun is required for increased p73 levels in 3T3 mouse fibroblasts 
 
jun-/- and jun-/-+Jun cells were transfected with the indicated expression vectors. EGFP 
expression vector was cotransfected to assess the transfection efficiency.  The levels of 
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To test whether co-transfection of p73 and c-Jun in an epithelial cell line, 
increases p73 levels, COS7 cells were transfected with p73, c-Jun, or in combination..  
EGFP expression vector was also cotransfected to normalize the transfection efficiency. 
As shown in figure 3.1.2.2, co-expression of c-Jun and p73β in H1299 cells increases p73 
levels compared to expression of p73 alone (compare lanes 2 to 4). In contrast, 























































Figure 3.1.2.2 c-Jun increases p73 protein levels in Cos 7 (Monkey kidney cell line) 
cells 
This blot is a representative of three experiments carried out. Cos7 cells were transfected 
with vectors encoding empty vector (pcDNA), pcDNA-c-Jun, pcDNA-p73β, or in 
combination as indicated above. Transfected cells were collected 48 hours post-
transfection.  Antibodies specific for p73-β ((GC15) mAb (1:1000)), c-Jun (H-79) 
(1:1000), EGFP (1:1000) and actin (1:400) were used for western analysis.              
1 2 3 4
 





3.1.2.3 Expression of c-Jun results in increased p73 levels in Human non-small cells 
lung carcinoma cell line (H1299) 
 
 
To check the universal nature of the observation and to analyze if the earlier 
observation can be reproduced in a human cell line, H1299 [(p53 null) human epithelial 
cell line] cells were transfected with the indicated expression plasmids (3.1.2.3).  As 
shown in figure 3.1.2.3, co-expression of c-Jun and p73β in H1299 cells resulted in a 
dramatic increase in the levels of p73β compared to expression of p73β alone (compare 
lanes 2 to 4).  Thus, this data confirmed our earlier observations in various cell lines of 


































Figure 3.1.2.3 c-Jun increases p73 protein levels in Human non-small cells lung 
carcinoma (H1299) cells 
This blot is a representative of three experiments carried out. H1299 cells were 
transfected with vectors encoding pcDNA, pcDNA-c-Jun, pcDNA-p73β, or in 
combination as indicated above.  The level of p73, c-Jun and actin proteins were assessed 
by western analysis using antibodies directed against their protein products. 




3.1.2.4 Increasing concentration of c-Jun increases the p73 protein levels 
 
To validate the earlier observations in a more rigorous way, increasing amount of 
c-Jun (100ng and 300 ng) was co-transfected with constant amount of p73(100ng) in 
COS7 cell line.  As shown in figure 3.1.2.4, transfecting increasing amount of c-Jun 
increases the levels of p73 compared to the expression of p73 alone (panel 1, lane 2-3).  
This data clearly confirmed our previous findings that, indeed, c-Jun plays a causative 














































Figure 3.1.2.4 Increasing concentration of c-Jun increases the protein level of p73-β 
Cos7 cells were transfected with empty vector pcDNA, increasing concentration of 
pcDNA-c-Jun and constant amount of p73 as indicated above.  Antibodies specific for 
p73-β ((GC15) mAb (1:1000)), anti-c-Jun (H-79) (1:1000) and anti-EGFP (1:500) were 










3.1.2.5 c-Jun increases the half-life of p73β 
 
 
To check whether c-Jun regulates p73β stability, we followed the half-life of over-
expressed p73β in COS7 cells. Transfected COS7 cells were pulse labeled with 35S 
Met/Cys followed by a four-hour chase (Figure 3.1.2.5). Transiently expressed p73β had 
a half-life of about 1.5 hours (Figure 3.1.2.5: p73). When c-Jun was co-transfected with 
p73β, its half-life increased to 4 hours (Figure 3.1.2.5: p73 + c-Jun).  Furthermore, 
coexpression of c-Jun and p73 led to the highest levels of p73 expression, thus 





















































Figure 3.1.2.5 c-Jun enhances the half-life of p73β 
Cos 7 cells were transfected with expression vectors as indicated above.  Transfected 
cells were 35S labelled and chased over time as indicated above. 300 µg cell lysate/sample 
of transfected protein was pre-cleared using mouse Ig-Agarose conjugated. Pre-cleared 
samples were immunoprecipitated using p73 (5µg/sample) specific mixture of antibodies 
(p73β specific GC15 and mouse mono clonal antibodies).  p73 immunoprecipitates were 
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3.1.2.6 c-Jun does not induce p73 mRNA in response to cisplatin treatment 
 
To check whether c-Jun induces or stabilizes p73 mRNA, Cos7 cells were transfected 
with vector or p73 alone or in the presence of c-Jun. 48 hrs after transfection, RNA was 
extracted and then reverse transcribed using MMLV Reverse transcriptase. cDNAs were 
calibrated carefully house keeping primers such as GAPDH and tubulin primers.  As 
shown in figure 3.1.2.6, in response to cisplatin treatment c-Jun does not alter p73 mRNA 
levels.  However, the fact that jun-/- cells have decreased level of p73 protein in response 
to cisplatin treatment clearly indicates that c-Jun increases p73 protein either at the 
translational or post-translational level. 
 
























Figure 3.1.2.6   c-Jun does not induce p73 mRNA in response to cisplatin treatment 
Cos7 cells were transfected with 2µg of human p73-β expression plasmid, either alone 
(lane 2) or together with 2µg of c-Jun expression plasmid (lane 3) treated with cisplatin 
(25 µM). As a negative control parallel cultures were transfected with pCDNA3 empty 
vector. Total RNA was isolated and from each culture 48 hours after transfection, and 
1µg RNA was subjected to RT-PCR analysis with gene specific primers.  cDNAs were 
amplified and quantified carefully with house keeping primers such as β-tubulin and 
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3.1.2.7 The effect of c-Jun mutants on p73 stability 
 
To determine the domain(s) involved in c-Jun’s ability to stabilize p73, Cos 7 cells were 
transfected with p73, c-Jun and its deletion mutants such as N-c-Jun (∆194-334) and C-c-
Jun (∆1-194) either alone or together with p73-β. As shown in figure 3.1.2.7, The N-
terminus of c-Jun (transactivation and delta domains) is essential for c-Jun’s ability to 
stabilize p73, indicating a possibility that transcription and delta domains could 
contribute to the increased p73 protein levels.  On the other hand, C-terminus of c-Jun 
(DNA binding and dimerization domains) mutant weakly stabilizes p73 compared to wild 
type c-Jun (lane 6).  Together, these findings suggest that transactivation, DNA binding 




























Figure 3.1.2.7 The effect of c-Jun mutants on p73 stability  
 
Cos 7 cells were transfected with indicated combination of vectors encoding empty 
vector pcDNA, p73β, c-Jun, N-terminus-c-Jun and C-terminus-c-Jun either alone or in 
combination as indicated above. Transfected cells were collected after 48 hours.  Cell 
lysates were prepared and protein concentration measured.  Transferred membranes were 
sequentially probed with the following antibodies:  
1. anti- p73β specific (GC15) mouse monoclonal antibody (1:1000). 
2. A mixture of anti-c-Jun antibodies (c-Jun (H-79) mouse polyclonal antibody (1:1000) 
and c-terminus specific c-Jun antibody)  
3. Anti- EGFP specific antibody (1:1000).  
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3.1.3 Expression of c-Jun modulates transactivation function of p73 
It has been shown that the enhanced stability of transcriptional factors can lead to 
increased transcriptional activity towards its downstream genes. Thus, it was decided to 
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3.1.3.1 C-Jun enhances the induction of MDM2 promoter by p73 
 
The effect of c-Jun over expression on the ability of p73 to stimulate transcription 
from the p53-responsive promoter was tested.  H1299 cells were transfected with c-Jun 
and p73-β or c-Jun alone in addition to a plasmid containing p73-responsive MDM2 
promoter, which in turn drives the luciferase reporter gene.  As shown in figure 3.1.3.1, 
while p73 stimulated MDM2 promoter activity (1 fold), over the control vector, the 























































Figure 3.1.3.1 c-Jun enhances the induction of MDM2 promoter by p73 
 
H1299 cells were transiently transfected with the indicated combinations of plasmids (in 
duplicates) encoding pcDNA (empty vector), p73β, c-Jun, MDM2-luc and beta-gal 
plasmids. The total amount of plasmid DNA used for transfection kept constant by 
adding an empty PCDNA3. Luciferase activity measured (in duplicates) 48 hours post-
transfection and normalized for transfection efficiency with beta-gal activity. Standard 
































3.1.3.2 c-Jun enhances the induction of GADD45 promoter by p73 
 
To check the consistency of this observation H1299 cells were transiently 
transfected with a luciferase reporter gene driven by the p53-responsive GADD45 
(Growth arrest and DNA damage-inducible gene number 45) promoter. Even though 
GADD45 has been identified as a downstream target of p53, it is induced in response to 
several stresses such as MMS, UV and IR, in a p53-independent manner (Takekawa and 
Saito, 1998).  As shown in figure 3.1.3.2, co-transfection of c-Jun and p73 enhance the 





























































Figure 3.1.3.2   C-Jun enhances the induction of GADD45 promoter by p73 
 
H1299 cells were transiently transfected with the indicated combinations of plasmids (in 
duplicates) encoding pcDNA, p73β, c-Jun, GADD45-luc and beta-gal plasmids.  Cell 
extracts were prepared 48 hours post-transfection and subjected to the determination of 
luciferase and beta-gal activity. Results are represented as fold induction of ratio between 








































3.1.3.3 c-Jun has minor effect on the induction of p21 promoter by p73 
 
 
The p53 target gene, p21 protein, is a well known inhibitor of cyclin dependent 
kinases(cdk’s) and it is known to be induced in p53-dependent and p53-independent 
manner. The p53 dependent p21 expression promotes G1 arrest (Dulic et al., 1994).   
However, cells that lack p53 fail to activate the G1 checkpoint in response to DNA 
damage (Shaulian, 2002). To check the consistency of this observation H1299 cells were 
transiently transfected with a luciferase reporter gene driven by the p53-responsive p21 
promoter.  As shown in figure 3.1.3.3, cotransfection of p73 and c-Jun resulted in less 
than two fold induction of p21 promoter, relative to the vector (PCDNA) control.  
However, in comparison to other p53 responsive promoters such as GADD45 and 







































Figure 3.1.3.3 c-Jun has minor effect on the induction of p21 promoter by p73 
 
H1299 cells were transiently transfected with the indicated combinations of plasmids 
encoding pcDNA, p73β, c-Jun, p21-luc and beta-gal plasmids. The total amount of 
plasmid DNA used for transfection was kept constant by adding pCDNA3 (3.1λg).  











































3.1.3.4 c-Jun is required for p73 transcriptional activity 
 
 
To get an insight into how c-Jun enhances p73 transcriptional activity, p53-/- jun-/- 
cells were chosen for study, as it is important to confirm the enhanced transcriptional 
activity of p73, which operates not only on H1299 cell line, but also on an authentic and 
genetically defined (p53-/- jun-/- Vs p53-/-) cell line.  In p53-/-jun-/- cells, the ability of p73 
to transactivate p53 responsive gene promoter (MDM2-luc, which has an authentic p53 
responsive elements) is reduced, while in the p53-/- cell line the p73 transcriptional 
activity enhanced by six folds.  This data is consistent with levels of p73 and AP-1 
activity seen in these cell lines, as p53-/-jun-/- cells have lower levels of p73 and AP-1 
activity compared to p53-/- cells (data not shown). Together, the data suggests that an 
endogenous c-Jun protein is utilized by p73 to execute transcription in cells, and lack of 














































Figure 3.1.3.4    c-Jun is essential for enhanced p73 transcriptional activity 
p53-/-jun-/- and p53-/- fibroblasts were transiently transfected with p73-β or pCDNA, 
p53RE-luc and β-gal plasmids. 100ng of p73 was transfected in p53-/-Jun-/- and in p53-/- 
cell lines (which has an intact c-Jun gene). Total amount of transfected DNA was kept 
constant by the addition of pCDNA. Cell extracts were prepared 48 hours post-











3.1.3.5 c-Jun potentiates p73’s ability to induce p53 downstream genes 
 
 
The various Luc-reporter assays (figure 3.1.3.1 to 3.1.3.4) shown earlier suggest that the 
enhanced stability of p73 can lead to enhanced transcription of its downstream genes. In 
order to confirm that whether the c-Jun enhances p73’s ability to trasactivate its 
downstream genes such as GADD45, MDM2, p21 RNAs, p73 was transfected either 
alone or in the presence of c-Jun into Cos7 cells.  Total RNA was collected from each 
cell pellet and checked for the quality of the RNA before submitting it for reverse 
transcriptase reaction.  As shown in figure 3.1.3.5, co-transfection of c-Jun and p73 lead 
to enhanced RNA levels of MDM2, GADD45 and p21 in Cos7 cells. This data confirms 




















































Figure 3.1.3.5 c-Jun potentiates p73’s ability to transactivate its downstream genes 
 
Expression of p53/p73 target genes was analysed by RT-PCR analysis. Cos 7 cells were 
transfected with indicated combinations of expression vectors and then total RNA was 
isolated.  Integrity of the RNA was verified before subjecting it to the reverse 
transcriptase reaction.  cDNAs amplified were quantified carefully with house keeping 
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3.1.3.6 c-Jun enhances the induction of MDM2 proteins by p73 
 
 
To determine whether c-Jun enhances p73 mediated transcriptional activity, not 
only on artificial promoter constructs but also on endogenous p73-responsive 
chromosomal genes, MDM2 (a p53/p73 target gene) protein was analysed in Cos7 cells. 
Cos7 cells were transiently transfected with p73β alone or together with a plasmid 
encoding c-Jun.  As shown in figure 3.1.3.6, in the presence of co-transfected c-Jun 
steady state levels of MDM2 protein increased compared to p73β alone.  Thus, this data 






































Figure 3.1.3.6   C-Jun enhances the induction of MDM2 protein by p73β 
Cos7 cells were transiently transfected with plasmids encoding p73β (2µg/10-cm dish) or 
c-Jun (2µg/10-cm dish) and EGFP (500ng/10cm)/ dish. Antibodies specific for p73-β 
((GC15) mAb (1:1000)), Jun (H-79) (1:1000), MDM2 (1:1000) and EGFP (1:500) were 














3.1.4 The PY motif conserved in both p73 and c-Jun 
 
 
PY motif functions as a transcription activation domain in a subset of 
transcription factors.  It utilizes a WW domain— two signature tryptophan residues—
containing protein as a co-activator for the efficient stimulation of transcription (Sudol et 
al., 2001).   
The p73α and β contain a PY motif in their C-terminal regions, but not p53.  It has 
been shown that PY motifs present in p73 are required to function as an efficient 
transcription factor (Strano et al., 2001).  The fact that c-Jun stimulates p73 function 
prompted us to look for conserved sequences in the amino acid sequence of c-Jun and 
p73. This analysis has identified the PY domain as a conserved motif in both human and 
mouse c-Jun (figure 3.1.4.1). The conservation of PY motif in both c-Jun and p73 
indicate that they have similar/shared functions in regulating various biological processes 
in cells. In addition, it indicates that common regulators carrying WW domain containing 
proteins can regulate both c-Jun and p73.  For example, any WW domain containing 
protein, which binds to both p73 and c-Jun through PY domains, could convert a 
relatively weak transactivator to a strong one (Kristie and Sharp, 1990; Stern and Herr, 
1991).   Since there are many WW domain-containing proteins with different functions in 
the cell (Rotin, 1998), it is possible that a WW domain-containing protein(s) associates 





































Figure 3.1.4.1   The PY motif conserved in both p73 and c-Jun 
 
A comparison between p73 (α, β and γ) and c-Jun amino acid sequences identified 
conserved PY domain.  
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3.1.5 The Role of Phosphorlylation: c-Jun stabilizes and activates p73 
 
 
3.1.5.1 The effect of c-Jun phosphorlylation mutants on p73 
trasncrptional activity  
   
To determine the domain(s) involved in the c-Jun’s ability to co-operate with 
p73β in mediating the transcriptional activation of the p53RE gene promoter, p73, c-Jun 
and its deletion/point mutants such as N-c-Jun (∆1-194), C-c-Jun (∆194-334), Jun 
S63/73A (JNK phosphorlylation mutants), Jun S91/93A (phosphorylation mutants), 
5XASP (five serine residues are replaced with aspartate residues, to mimic the 
phosphorylation state) and c-Jun delta domain (30-57) and Jun delta NLS (232-334) were 
transfeted into human lung carcinoma H1299, either alone or together with p73-β.  As 
shown in figure 3.1.5.1, c-Jun cooperates with p73 to transactivate p53RE reporter 
activity compared to p73β alone. Interestingly, c-Jun point mutants also co-operate with 
p73, which indicates that the phosphorlyated c-Jun is not an absolute requirement for its 
ability to co-operate with p73.  On the other hand, both N and C-termini of c-Jun mutants 
included in the assay failed to co-operate with p73.  Together, this data indicates that 










Figure 3.1.5.1 The effect of c-Jun phosphorlylation mutants on p73 transcriptional 
activity 
H1299 cells were transiently transfected with indicated combinations of plasmids 
encoding pcDNA, p73β, c-Jun, c-Jun phosphorlylation mutants, c-Jun delta domain 
mutant, 5XASP, MDM2-luc and beta-gal. The total amount of transfected DNA in each 
dish was kept constant by the addition of empty vector wherever necessary.  Cell extracts 
were prepared 48 hours post-transfection and subjected to the determination of luciferase 
and beta-gal activity. Results are represented as fold induction of ratio between luciferase   
and beta-gal activity. 
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3.1.5.2 p73 is stabilized in Jnk1-/-2-/- fibroblasts 
 
To check whether p73 levels can be increased in the absence of JNK1 and 2, Jnk1-
/-2-/- cells were transfected with p73 or c-Jun or in combination. As shown in figure 
3.1.5.2, c-Jun increases p73 levels even in the absence of both Jnk1 and Jnk2. This data 
indicates that JNKs are not essential for c-Jun mediated p73 stability. Of note, c-Jun is 
normally expressed and phosphorylated in jnk1/2 double knockout embryos, presumably 
by JNK3 (Hochedlinger et al., 2002). Similarly, in response to UV irradiation or cisplatin 
treatment, c-Jun is induced in Jnk1-/-2-/- cells, indicating that c-Jun can be activated 





































Figure 3.1.5.2   JNK 1 and 2 are not required for c-Jun mediated p73 stability       
Jnk1-/-2-/- cells were transfected with indicated combination of vectors encoding pcDNA, 
p73β and c-Jun. 48h later, lysates were subjected to SDS-PAGE.   Western blots were 








3.1.5.3 p73 transcriptional activity is not compromised in Jnk1-/-2-/- cells. 
 
To determine whether phosporylated c-Jun is essential for its ability to stimulate 
p73 function, Jnk1-/-2-/- cell lines were chosen for study.   p73 was transfected in Jnk1-/-2-    
and wild type fibroblast cell lines and its ability to function as a transcription factor was 
tested in these cell lines. As shown in figure 3.1.5.3, the ability of p73 to transactivate 
p53 responsive gene promoter MDM2-luc (which has an authentic p53 responsive 





















Figure 3.1.5.3 JNKs 1 and 2 are not required for p73 transcriptional activity 
 Wild type and JNK1-/-2-/- cells were transiently transfected with the indicated 
combinations of plasmids encoding pcDNA, p73β, MDM2-luc and beta-gal. The total 
amount of transfected DNA in each dish was kept constant by the addition of pcDNA 
wherever necessary.  Cell extracts were prepared 48 hours post-transfection and subjected 
to the determination of luciferase and beta-gal activity. Results are represented as fold 
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3.1.6 c-Jun potentiates p73’s ability to induce apoptosis in response to Stress 
 
 As stated in the introductory sections, there is ample evidence exist that links the 
c-Jun to the control of cell death.  In a few set of experiments, whether p73 and c-Jun 






























3.1.6.1 c-Jun potentiates the ability of p73 to induce apoptosis: AIP1 
 
Our earlier findings presented in this thesis indicate a causal link between c-Jun 
and p73 in cisplatin-mediated apoptosis. Further, both c-Jun and p73 are induced in 
response to cisplatin treatment, and p73 is stabilized in c-Jun dependent manner that 
results in increased activity of p73 towards its downstream genes. Interestingly, it has 
been shown recently that p300 acetylates p73 in response to DNA damage and thereby 
potentiates the apoptotic function of p73 by enhancing the ability of p73 to selectively 
potentiate the transcription of p53AIP in comparison to p21 (Costanzo et al., 2002). 
These findings indicate that acetylation guides p73 towards apoptotic pathway. Thus, it 
was decided to determine whether c-Jun mediated p73 stability results in enhanced 
activity of p73’s apoptotic target genes such as p53AIP1. This possibility was checked by 
co-transfecting p73 and c-Jun in H1299 cells with p53AIP-luc reporter.  As shown in 
figure 3.1.6.1, in the presence of c-Jun, p73 displays enhanced activity towards p53AIP1 
promoter, indicating that c-Jun potentiates the ability of p73 to transactivate its apoptotic 

























Figure 3.1.6.1   C-Jun enhances the induction of p53AIP promoter by p73  
H1299 cells were transiently transfected with the indicated combinations of plasmids 
encoding pcDNA (empty vector) p73β, c-Jun, AIP-luc and beta-gal.  The total amount of 
transfected DNA was kept constant by the addition of empty vector wherever necessary.  
Cell extracts were prepared 48 hours post-transfection and subjected to the determination 
of luciferase and beta-gal activity. Results are represented as fold induction of ratio 
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3.1.6.2 p73 co-operates with c-Jun in transactivating Bax promoter 
 
 
Recent findings suggest that early induction of apoptosis is associated with 
mitochondrial changes.  Bax, a p53 target gene, has been known to alter mitochondrial 
events and promote apoptosis by facilitating the release of apoptosis-inducing factor 
(AIF) and cytochrome C from the mitochondria, which in turn triggers a cascade of 
caspase activation (Narita et al., 1998; Susin et al., 1999).  Bax appears to be essential for 
p53-mediated cell death in brain tumours (Yin et al., 1997) and fibroblasts (McCurrach et 
al., 1997) but not thymocytes (Brady et al., 1996).  Hence, it was of interest to determine 
whether c-Jun potentiates the ability of p73 to transactivate, Bax promoter, an apoptotic 
target.   H1299 cells were transfected with p73, c-Jun either alone or in combination.  As 
shown in figure 3.1.6.2, when c-Jun was co-transfected with p73 about 2 fold increase 

















Figure 3.1.6.2   C-Jun enhances the induction of Bax promoter by p73 
The indicated plasmids were transfected in H1299 cells with a reporter plasmid 
containing bax promoter, which drives the luciferase gene, and a plasmid encoding 
beta-galactosidase gene for evaluating the transfection efficiency. Cell extracts were 
analyzed 48 hours post transfection for beta-galactosidase and luciferase activity. Results 































3.1.6.3 c-Jun potentiates the ability of p73 to induce apoptosis 
 
 
Since c-Jun appears to potentiate the apoptotic function of p73 by enhancing its 
ability to transactivate its apoptotic target genes such as Bax and p53AIP-1.  It was 
decided to determine whether the co-operation between c-Jun and p73 result in increased 
apoptosis. Cos7 cells were transfected with p73, c-abl, and c-Jun either alone or in the 
presence of each other as indicated in figure 3.1.6.3.  Transfected cells were analysed by 
tryphan blue exclusion method and both dead and live cells were counted in duplicates. 
Number of live cells was plotted against the plasmid combination transfected. As shown 
in figure 3.1.6.3, co-trasfection of p73 α or β and c-Jun resulted in reduction of number 
of viable cells by approximately 15%.  It has been shown earlier that c-Abl potentiates 
p73’s ability to induce apoptosis (Agami et al., 1999). Thus, c-Abl and p73 were co-
transfected to see the reduction of number of viable cells. These results indicate that both 
c-Jun and p73 collaborate to induce apoptosis.  
Further more, p73-β was transfected in c-jun-/-+ jun mouse fibroblasts or those 
lacking either c-Jun or c-Abl, and followed the fate of transfected cells by including the 
EGFP expression plasmid in the transfections. Analysis of cells under fluorescence 
microscopy indicated that unlike c-jun-/-+ c-Jun fibroblasts and similar to c-abl null cells, 
c-Jun deficient cells were relatively resistant to p73-β-mediated cell death, ascertained by 


































Figure 3.1.6.3     c-Jun potentates the ability of p73 to induce apoptosis  
Quantitative representation of c-Jun-induced cell death in Cos7 cells after transient 
trasfection of indicated expression vectors.  48 hours post transfection, cell viability was 
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3.2.1 Background and Hypothesis 
        
UV can induce p73 
 
Several lines of evidence indicate that UV and Ionizing radiation cause different kinds of 
DNA lesions and trigger different repair pathways. While UV radiation activates nuclear 
excision repair, IR radiation results in the activation of the base excision repair 
machinery. It seems that UV and ionizing irradiation increase p53 levels through 
different mechanisms (Zeng et al., 2000).  Activated p53 can turn on its downstream 
target genes.  It seems that p53 is required for IR, but not UV, mediated G1 arrest.  For 
example, UV, but not ionizing radiation, induced p21, and G1 arrest in p53 deficient 
fibroblasts from Li-Fraumeni syndrome patients (Loignon et al., 1997) and G1 
accumulation was observed in UV-irradiated p53-/- T lymphoma cells expressing Bcl-2 
(Strasser et al., 1994).  Furthermore, several studies suggest that p53 null fibroblasts 
(both primary and immortalized) are sensitive to UV radiation mediated apoptosis (Al, 
Mohanna et al., 2001, Lackinger et al., 2001, Lackinger and Kaina, 2000; Mckay and 
Ljungman, 1999; Wani., 1999), indicating the presence of p53-independent apoptotic 
program. Thus, the requirement of p53 in UV-dependent G1 arrest and apoptosis is less 
clear.  
UV increases the expression of c-Jun and it is not yet clear whether UV-induced 
c-Jun participates in DNA repair or apoptosis.  Nevertheless, it has been shown that jun-/- 
cells are less responsive to UV-mediated apoptosis.  This data suggests that c-Jun could 
participate in apoptotic response (Shualin et al., 2001).  The data presented in chapter I 
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suggests that c-Jun is required for increased p73 levels. Hence, we propose that UV can 








3.2.2.1 p53-independent pG13-luc transcriptional activity  
 
It has been shown that UV-irradiation induces apoptosis in p53-/- cell lines (Al, 
Mohanna et al., 2001, Lackinger et al., 2001, Lackinger and Kaina, 2000; Mckay and 
Ljungman, 1999; Wani et al., 1999). Recently identified p53 homologues, such as p73 
and p63 are shown to be capable of transactivating p53 responsive element containing 
promoters( Yang et al., 2001).  To check whether p53 independent p53RE- activity can 
be observed in p53-/- cells, a panel of p53-/- cell lines such as SAOS2 (Osteosarcoma cell 
line), H1299 (non-small cell lung carcinoma) and p53-/-(fibroblasts) were chosen and 
transfected with plasmids containing p53 responsive elements, which in turn drive the 
luciferase gene reporter. As shown in figure 3.2.2.1, p53-independent p53RE-reporter 
activity was observed in p53-/- cell lines. Thus, this result suggests that p53 related 




















Figure 3.2.2.1 p53-independent pG13-luc transcriptional activity  
p53-/-, H1299 and SAOS2 cells were transfected with reporter plasmids expressing the 
luciferase gene under the control of p53RE (pG13) promoter and a plasmid encoding the 
beta-gal promoter for evaluating the transfection efficiency. Transfected cells were 
analysed after 48 hours (post-transfection) for both luciferase and beta-gal activity.  
 




3.2.2.2 UV induces p53 reporter activity in p53-/- cell lines 
 
 Our earlier observation suggests that the p53 reporter activity is present in p53-/- 
cell lines.  To check whether UV light can stimulate the p53RE reporter activity further, 
the same panel of p53-/- cell lines used in the earlier study was transfected with pG13-luc 
reporter.  Subsequently, these cells were UV irradiated.  As shown in figure 3.2.2.2, in 
UV-irradiated p53-/- cell lines, the p53 reporter activity is augmented. Hence, this 
















Figure 3.2.2.2   UV induces p53 reporter activity in p53-/- cell lines   
p53-/-, H1299 and SAOS2 cells were transfected with reporter plasmids expressing the 
luciferase gene under the control of p53RE (pG13) promoters and a plasmid encoding the 
beta-gal promoter for evaluating the transfection efficiency. Transfected cells were 
analyzed 48 hours post-transfection for both luciferase and beta-gal activity. 
 




3.2.2.3 Dominant negative p73 inhibits endogenous pG13 luciferase activity in p53-/- 
cells 
 
In order to clarify whether p53 reporter activity present in p53-/- cell line is 
contributed by p73,  p73DD (∆315-636 a.a), a dominant negative of p73, p53 binding 
sites driving a luciferase reporter gene, beta-gal plasmids were transfected in H1299 (p53 
null) cell line.  As shown in figure 3.2.2.3, the p53 reporter activity observed in the p53 
null background was brought down by the p73 DD (Irwin et al., 2000).  Furthermore, p73 
transcriptional activity is efficiently brought down by p73 DD. This data suggests that 







































Figure 3.2.2.3 Dominant negative p73 inhibits endogeneous pG13 transcriptional 
activity in p53-/- cells  
H1299 cells were transfected with pcDNA, p73-β,  p73DD separately and in combination 
with p73-β,  reporter plasmids expressing the luciferase gene under the control of p53RE 
(pG13) and the beta-gal promoters for evaluating transfection efficiency. The total 
amount of DNA was kept constant by using the PCDNA. Transfected cells were collected 
after 48 hours. Both luciferase and beta-gal activity were measured as described in 


























3.2.3 UV increases p73 levels 
3.2.3.1 UV increases transfected p73 levels in cos7 cells 
The following facts may suggest that UV-light can stabilize p73 levels:  
1. UV is a potent inducer of c-Jun. 
2. c-Jun stabilizes p73.  
3. UV- can induce p53 reporter activity in p53-/- cell lines.  
Cos7 cells were transiently transfected with p73β.  After 24 hours, cells were irradiated 
with UV light (50J/m2).  As shown in figure 3.2.3.1, in contrast to the earlier suggestion 
that UV-light may not induce p73, UV radiation could stabilize p73 further when it was 
















Figure 3.2.3.1 UV increases p73 levels in Cos 7 cells 
Western blot analysis of p73 and actin protein levels after transfection into Cos 7 cells. 
Transfected cells were UV irradiated (50J/m2) for about 12 hours and collected 48 hours 
post-transfection.   
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3.2.3.2   UV-induced endogenous p73 is p53 independent 
 
To check whether UV induces endogenous p73 irrespective of the p53 status, 
p53+/+ and p53-/- 3T3 fibroblasts were UV irradiated (50J/m2) for two hours. As shown in 
figure 3.2.3.2, p53 null cells expressed detectable levels of basal p73, which was further 
induced by UV-irradiation (Figure 3.2.3.2), indicating that UV-mediated p73 induction 
occurs independent of p53.  This data suggests that p53-independent UV-mediated cell 
death observed in p53-/- cell lines could be attributed to the increased p73 levels. In 
support of this notion, it has been shown that p73 is capable of inducing apoptosis when 

























Figure 3.2.3.2 UV-induces endogenous p73 levels independent of p53  
 p53-/- cells and 3T3 wild-type fibroblasts were UV irradiated (50J/m2) for two hours.  
After 48 hours, cell lysates were prepared and subjected to Western analysis. Transferred 
membranes were sequentially probed with antibodies raised against p73-β ((GC15) 





                               
 116 
 
3.2.3.3 UV but not IR increases p73 levels  
 
It has been shown that UV can induce c-Jun expression but not IR (Shualin and Karin, 
2001). The data presented in this thesis suggests that c-Jun stabilizes p73. Keeping these 
facts in mind, we proposed that UV irradiation should augment p73 levels but not IR. To 
test this, H1299 (null for p53 expression) and COS7 (p53 is inactivated by large T 
antigen) cells were transfected with pCDNA or p73β. These cells were irradiated with 
UV (50J/m2) or IR (20γ).  As shown in figure (3.2.3.3), only UV irradiation stabilizes p73 
but not IR. 





Figure 3.2.3.3   UV increases p73 levels but not IR   
Cos7 cells were transfected with pCDNA-3 or p73-β (2λg). 24 hours after transfection, 
trasfected cells were either UV (50J/m2) or IR (20λ) irradiated for about 12 hours.  The 
level of p73 and actin proteins were assessed by Western analysis using antibodies 
directed against their protein products.  
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3.2.3.4   Cisplatin but not IR induces c-Jun  
 
 
It has been shown that only cisplatin stabilizes p73 but not ionising radiation (IR) 
(White and Prives, 1999). Further, it has been shown that cisplatin treatment alone 
induces c-Jun but not IR irradiation (Shualin et al., 2001).   Keeping these facts in mind, 
3T3 cells were either irradiated (20γ) or cisplatin (25λM) treated as indicated in figure 
3.2.3.4.   γ-irradiation did not induce c-Jun, whereas cisplatin treatment resulted in c-Jun 
induction.  The same blot was probed with actin antibody to check the equal loading of 
proteins in each lane. In line with the earlier observations, this data confirms that c-Jun is 



















Figure 3.2.3.4    cisplatin but not IR induces c-Jun 
3T3 fibroblasts were exposed to cisplatin or IR irradiated (20 γ) as indicated above.  Cell 
lysates were prepared and protein concentration measured.  The level of p73-beta and 
actin proteins were assessed by western analysis using antibodies directed against their 
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3.2.3.5 c-Jun over expressing cells increase p73 levels in response to IR 
 
The lack of c-Jun induction in response to IR irradiation could be the cause for 
lack of p73 stability in response to IR. In order to probe into this issue, human colon 
carcinoma cells (H1299) stably over expressing c-Jun or the vector were generated and 
subjected to -irradiations (20 γ).  As shown in figure 3.2.3.5, p73 basal level is increased 
in c-Jun over expressing cell line, which indicates that c-Jun contributes to the increased 
levels of p73. Further, p73 was induced after 1 hour as expected but the levels had 
declined by 24 hours post-irradiation in vector expressing H1299 cells. On the other 
hand, p73 was detected at similar levels at both 1 and 24 hours post-irradiation in c-Jun 
over expressing cells. This result confirmed that the presence of c-Jun is sufficient to 






























Figure 3.2.3.5   IR stabilizes p73 in c-Jun overexpressing cells 
HI1299 cells were exposed to ionising radiation.  Cells were harvested at 1 hour and 24 
hours after irradiation for western analysis. 300µg of total lysates were used for WB 
analysis. Transferred membranes were sequentially probed with anti-p73-beta specific 
(GC15) mouse monoclonal antibody (1:1000), anti-c-Jun (H-79) specific (1: 1000) 
antibody and an actin (1:400) mouse monoclonal antibody. 
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3.2.3.6 UV mediated p73 stability is increased in the presence of c-Jun 
 
 
To determine further whether c-Jun is required for UV mediated p73 induction, 
jun-/- and jun-/- + Jun cells were transfected with PcDNA3 and p73.  Transfected cells 
were subjected to UV-irradiation or γ-irradiation. UV, but not γ-irradiation, enhanced 
both p73 and c-Jun levels in c-jun-/-+ c-Jun cells (compare lanes 7 with 9 and 12 with 
respect to actin in figure 3.2.3.6).  On the other hand, UV did not effectively increase p73 
in jun-/- cells (compare lanes 1, 3 and 5), indicating that UV-mediated p73 stability is 
increased in the presence of c-Jun.  Together this data suggests that c-Jun is required, but 






























Figure 3.2.3.6 UV enhanced p73 levels is further increased in the presence of c-Jun  
 
The c-Jun null cells and Jun null cells reconstituted with c-Jun were transfected with 
pCDNA-3(V) or p73-β.  24 hours after transfection, cells were irradiated with either UV 
(50J/m2) or IR (20λ) for 12 hours.  Antibodies specific for p73-β ((GC15) (1:1000)), c-
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3.2.4   Factors influencing UV-induced p73 levels 
 
3.2.4.1 UV increases p73 levels mainly at the post-transcriptional level in MCF7- 
p73-β clones 
 
To test whether it is due to the increased transcription, MCF-7-p73β cells were 
treated with Actinomycin D, a transcription inhibitor.  As shown in figure 3.2.4.1, UV 
mediated p73 increase did not decrease in the presence of transcription inhibitor.  This 
































Figure 3.2.4.1 UV increases p73 levels at the post-transcriptional level in stable clones 
The MCF7-p73-β stable clones were either untreated, treated with actinomycin D 
(25ng/ml) for about 15 minutes. Drug treated and untreated plates were UV (50J/m2) 
irradiated for about 12 hour. Cell lysates prepared and protein concentration measured 
using Bradford method. Antibodies specific for p73-beta (GC15 (1:1000) and actin 
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3.2.4.2 UV increased p73 levels do not depend on JNK 1 and 2 and Abl 
 
It was shown earlier that Jnks are not required for c-Jun mediated p73 stability. 
To test whether UV mediated p73 induction and stability require JNK 1 and 2 and Abl, 
jnk1-/-2-/- fibroblasts and abl-/- cells were transfected with pCDNA or p73.  48 hours later, 
cells were UV (50J/m2) irradiated for about 16 hours and subjected to Western analysis.  
As shown in figure 3.2.4.2, p73 is stabilized by UV irradiation in both jnk1-/-2-/- and abl-/- 
cells This data suggests that both Jnks and abl are not required for UV induced p73 
stability.  It is not surprising to find p73 stability in the absence of c-Abl, as only ionizing 









































Figure 3.2.4.2   Jnks and abl are not essential for UV increased   p73 levels   
Jnk1-/-2-/-; abl-/-; jun-/- and jun-/-+Jun cells were transfected with pCDNA-3 or p73-β.  
These cells were either untreated or UV irradiated (50J/m2) for 6 hours and subjected to 
Western analysis using antibodies specific for the p73-β. (GC15) (1:1000). Transferred 
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3.2.4.3 Generation of p73-β expressing MCF-7 stable clones: UV increases p73-β 
levels in MCF-7-p73 stable clones 
 
To test the ability of UV to induce p73, p73-β expressing stable cell line was 
generated.  For this purpose, MCF7 (human breast carcinoma cell lines) cells were 
transfected with pcDNA and pcDNA-p73-β.  48 hours after transfection, 250µg G418/ml 
was added to the transfected cells.  After two weeks in drug selection medium, very few 
surviving clones were selected and developed as cell lines. This is the first demonstration 
that p73-β expressing stable cell line can be developed. MCF-7-p73-β stable clones were 
either untreated or UV irradiated (50J/m2). As shown in figure 3.2.4.3, UV increased the 














































Figure 3.2.4.3 UV increases p73-β levels in MCF-7-p73-β  stable clones  
 
The MCF-7-p73-β/vector (V) cells were UV (50J/m2) irradiated as indicated at 
the top of each lane. 48 hours later, cell lysates were prepared and subjected to SDS-
PAGE.  Western blot analysis was performed using anti- p73-β specific (GC15) (1:1000), 
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3.2.4.4 UV induces both p73 and p53 levels in MCF-7-p73-β expressing stable clones 
 
Earlier we have shown that MCF-7 cells stably expressing p73β was further 
stabilized after UV irradiation.  In this experiment, we have decided to compare p73β 
expression with its counter-part, endogenous p53 expression. MCF-7 cells were UV 
irradiated for the indicated periods and cell lysates were subjected to western analysis.  
















































Figure 3.2.4.4 UV increases both p73 and p53 levels in MCF-7-p73 stable clones 
The MCF-7 cells stably expressing p73-β were UV (50J/m2) irradiated for the indicated 
periods.  Transferred membranes were sequentially probed with the following: 
1. anti-p73-β specific (GC15) mouse monoclonal antibody (1:1000) 
2. anti-p53 specific polyclonal antibody (rabbit) (1:500)  







Time(h) :   0      2     4     6    24
UV50J/m2
MCF-p73 stable
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3.2.5.1 Synergistic signals (UV+IR) stabilize p73 
 
We proposed that exposure of the cells to inductive/activation signal (Ionizing 
Radiation-IR) followed by stabilization signal (Ultraviolet radiation-UV) would further 
enhance the stabilization of p73. To verify this possibility, COS7 cells were either or UV 
irradiated alone or in combination. γ-irradiation resulted in induction of p73 levels after 
one hour, but reduced by 4 hours (Figure 3.2.5.1).  However, treatment of -irradiated cells 
one hour later with UV-irradiation rescued the decrease in p73 levels and p73 was 
detected at 4 hours post -irradiation. In contrast, UV irradiation (l0J/m2) alone did not 






































Figure 3.2.5.1   Synergistic signals (UV+IR) stabilize p73 
Cos 7 cells were either UV (10J/m2) or IR (10γ) irradiated or both as above. Western blot 
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3.2.5.2 Synergistic signals (UV+IR) induce apoptosis 
 
IR promotes transient cell-cycle arrest in most of the cell types except 
thymocytes. It has been shown that IR induces apoptosis in only thymosites but not in 
fibroblasts (Levrero et al., 2001).  To check the possibility of long-term effect of and UV 
treatment on replicative cell death in cells lacking p53, colony-forming assay was 
performed. As shown in figure 3.2.5.2, colony number was reduced under either UV or   
irradiation treatments in comparison to untreated cells; Cells treated with both and UV 
irradiation did not form any colonies (see figure, untreated: >100; 34; UV: 25; + UV: 0). 
It is possible that UV irradiation could have further stabilized p73 that is induced by 
irradiation, which led to   p53-independent cell death. 
 




Figure 3.2.5.2 Synergistic signals (UV+IR) led to reduced colony numbers in p53-/- 
fibroblasts  
 p53-/- (5X104 cells per 10 cm) cells were washed, fixed as described in Materials and 
methods. Colony formation assay was carried out after UV (10J/m2) or IR (20γ) 
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3.3.1 Background and hypothesis:  p73 could positively influence AP-1 
transactivation. 
 
A structural comparison between p53 and its homologue p73 suggests that DNA 
binding regions (DBD) of p73 possess a high level of conservation with DBD of p53 
(63%)  (Levrero et al., 2000).  p73 regulates the genes that are regulated by p53 (Yang et 
al., 2002). However, the striking differences between p53 and p73 knockout mice suggest 
that invivo p73 may regulate different genes.  While p53 null mice develop spontaneous 
tumors,  p73-deficient mice have neurological, pheromonal and inflammatory defects and 
lack spontaneous tumors (Yang et al., 2000), suggesting that invivo p73 may regulate 
different genes. In aggrement with this notion, microarray data from several laboratories 
suggest that the genes regulated by p53 and p73 are considerably different (Fontemaggi 
et al., 2002).  Further, it seems that p73 may regulate both p53-responsive elements 
containing genes and other responsive elements containing genes either directly or 
indirectly.  It has been shown that AP-1 activity is highly pronounced in several tumor 
cell lines. Similarly, it has been recently established that several primary tumor cells and 
tumor cell lines overexpress wild-type p73 including cancers of the breast, lung, 
esophagus, stomach, colon, bladder, ovary, liver, bile ducts, ependymal lining, 
myelogenous leukemia and neuroblastoma (Moll et al., 2001).   
The fact that both p73 expression and AP-1 activity are highly pronounced in 
most of the human tumors indicates a possibility that both p73 and c-Jun could co-exist in 
human tumors.  It appears that most of the tumors have lower levels of p53RE-promoter  
activity (at least 50% tumors have mutation in p53 gene) but higher levels AP1 activity. 
This data prompted us to propose that p73 could positively influence the function of c- 
Jun/AP-1 transcriptional activity. 
























Figure 3.3.1.1 a & b Hypothesis: p73 could augment AP-1 activity   
Facts supporting the hypothesis
AP-1 activity is high; p53 activity is low
C-Jun transactivates AP responsive element containing promoters
P73 transactivates p53 responsive element containing promoters
Both c-Jun and p73  co-exist(over expressed) in tumors
Does p73 increase AP-1 activity?
Cancer cell
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The diagram depicted above indicates the expression status of p73 and c-Jun transcription 
factors in cancer cells.  Although both p73 and c-Jun are upregulated and co-exit in many 
tumors, only AP-1 transcriptional activity is high, but not p53RE activity.  Hence, it was 
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3.3.2 p73 potentiates AP-1 activity. 
3.3.2.1 p73-β increases AP-1 activity. 
 To check whether p73 influences AP-1 activity, p73 and c-Jun were transfected 
separately in HI299 cells (a human osteosarcoma cell line, p53 null producer), along with  
5XTRE-luc [5X 12-0-tetradecanoyl-13-acetate(TPA)-responsive elements-TRE (5XTRE, 
five tandem AP-1-binding sites) ] and ß-gal promoters. As shown in figure 3.3.2.1, p73 
potentiated 5XTRE luciferase activity. c-Jun was used as a positive control for its ability 
to transactivate AP-1 responsive elements.  It was observed that p73 activity is as good as 
c-Jun mediated AP-1 transcriptional activity.   On the other hand, the expression of p53 
did not have any effect on 5XTRE elements.  Hence, the ability of p73 to stimulate AP-1 























Figure 3.3.2.1 p73β potentiates AP-1 responsive element (5XTRE) promoter activity 
 
H1299 cells were transfected with plasmids encoding 5XTRE-luc (0.5µg), ß-gal 
(0.5µg), PCDNA3, p73(100ng), p53(100ng) and c-Jun(2µg). The total amount of plasmid 
DNA used for transfecteion was adjusted to 3.1µg by adding PCDNA3.  Luciferase 
activity was measured 48h after trasfection and normalized for transfection efficiency 
with ß-gal activity. Results of at least three independent experiments performed in 
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3.3.2.2 p73β potentiates  Collagenase-1 promoter activity. 
To generalize the fact that p73 can increase the activity of AP-1 responsive 
elements containing promoters activity, collagenase-1 promoter was considered as it 
contains 1X AP-1 responsive elements.  p73β was  in the presence of collagenase-1 
promoter along with  ß-gal plasmid in H1299 cells.  As shown in figure 3.3.2.2, p73β 
potentiated collagenase-I promoter in comparison to vector control.  This finding strongly 
































Figure  3.3.2.2 p73β potentiates collagenase-1 promoter activity 
 
H1299 cells were transfected with plasmids encoading collagenase I-pro-luc 
(0.5µg), ß-gal plasmid (0.5µg), PCDNA3, p73β (100ng), p53 (100ng), and c-Jun (2µg).   
The total amount of plasmid DNA used for transfection was adjusted to 3.1µg by adding 
PCDNA3.  Luciferase activity was measured 48h after trasfection and normalized for 
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3.3.3 The Dose effects of p73β on the reporter expression from 5XTRE promoter: 
p73β synergizes with c-Jun in potentiating AP-1 activity 
 
To check whether increasing amount of c-Jun increases the ability of p73 to increase AP1 
activity, HI299 cells were transfected with an AP-1-driven luciferase reporter gene in the 
presence of increasing amount of c-Jun (100ng; 2µg) and constant amount of p73β (100 
ng).  All luciferase activity was normalized using a co-transfected ß-gal expression 
vector. Over expression of c-Jun caused an increase in the relative activation levels of the 










































Figure  3.3.3.1  Synegistic effect of p73β and Jun on AP-1 promoter activity 
 
H1299 cells were transfected with 0.5µg of 5XTRE--luc, 0.5µg ß-gal plasmid and 100ng 
of p73β, 100ng and 2µg of c-Jun.   The total amount of plasmid DNA used for 
transfecteion was adjusted to 3.1µg by adding an empty PCDNA3.  Luciferase activity 
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3.3.3.2 p73β synergizes with c-Jun in potentiating the AP-1 activity 
 
Previously, we showed that c-Jun stabilizes p73.  The fact that c-Jun homodimers 
and c-Jun-c-fos heterodimers increases AP1 activity, through their ability to interact with 
each other,. prompted us to ask whether p73 synergies with c-Jun in increasing 5xTRE-
luc activity.  Both p73 and c-Jun were transfected in the presence of the reporter 5XTRE-
luc in H1299 cell line.  Remarkably, luciferase activity was much enhanced (5 to 6 folds) 
than expected in their combination (2 folds), indicating that p73 and c-Jun synergistically 
increase AP-1 activity and not p53/Jun.  These results imply that p73 could be a partner 
in AP-1 dimers.  The importance of AP-1 composition in transcriptional activation is 
beginning to emerge.  c-Jun containing dimers showed distinct promoter specificity in 
transient-transfection experiments, depending on the partner. It is possible that choice of 
dimerization partner defines the role of c-Jun in gene activation and cell cycle regulation 
(Kaminska et al., 2000). It would be interesting to delineate the functions of p73 and c-
Jun dimers within a cell.  Together, this data suggests that p73 not only synergizes with c-



















Figure 3.3.3.2 p73 co-operates with c-Jun in potentiating AP1 activity 
H1299 (75% confluence in 35mm plates) cells were transfected with 100ng p73β, 
alone or with 2µg c-Jun, 500ng of the luciferase reporter plasmid driven by the 5XTRE 
motif and 500ng ß-gal plasmid (as an internal control). The total amount of plasmid DNA 
used for transfecteion was adjusted to 3.1µg by adding an empty pCDNA3. Transfected 
cells were collected 48 hours after transfection. Luciferse activity was measured and 
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3.3.3.3    p73-β efficiently synergies with c-Jun but not with other family members 
The structure of p73 gene is highly complex when compared to that of p53.  The 
p73-α contains the SAM domain near the C-terminus but not p73-β. To find out whether 
there is any difference in the ability of p73 isoforms to increase AP1 activity, H1299 cells 
were transfected with indicated combinations of plasmids in addition to 5XTRE-luc and 
ß-gal plasmids.  As shown in figure 3.3.3.3, the co-transfection of both p73-β and c-Jun 
reproducibly resulted in a moderate increase of the AP1 activity, as measured by 
luciferase and ß-gal assays.  In contrast, none of the other p73 family members increase 
AP1 activity as much as p73-ß does.  Furthermore, p73-α did not co-operate efficiently 
with c-Jun to increase AP1 activity. Of note, SAM domain may not be essential for p73’s 



































































Figure 3.3.3.3   p73-ß synergies with c-Jun better than p73-α and other p73 family 
members 
 
H1299 (75% confluence in 35mm plates) cells were transfected with p73α 
(100ng), p73β (100ng) alone or with c-Jun (100ng) and the luciferase reporter plasmid 
(100ng) driven by the 5XTRE motif and 500ng ß-gal plasmid (as an internal control). 
The total amount of plasmid DNA used for transfection was adjusted to 3.1µg by adding 
an empty pCDNA3. Transfected cells were collected after 48 hours and luciferse activity 
was measured.  Luciferase activity was normalized with β-galactocidase activity. 
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3.3.4 Structural requirements of c-Jun and p73 in potentiating AP-1 
activity 
3.3.4.1   The effect of c-Jun mutants on the abilty of p73-β to stimulate AP1 activity 
 To identify which domain of c-Jun is important for its ability to cooperate with p73-β, 
p73 and a series of c-Jun mutants (Jun N (∆ 1-194); JunC (∆ 194-334); TAM (∆ 142-
334); c-Jun-d-domain (∆30-57); c-Jund-NLS (∆1-232)) were co-transfected into H1299 
cells. As shown in figure 3.3.4.1, although c-Jun mutants synergized with p73-β to 
potentiate 5XTRE-luc activity, they were not as good as wild-type c-Jun.  Interestingly, 
c-Jun mutant lacking δ domain, which is similar to v-Jun, synergized with p73-β much 
better than wild-type c-Jun.  This could be because c-Jun-δ-domain mutant is 















































































Figure 3.3.4.1   The effect of c-Jun mutants on the abilty of p73-β to stimulate AP1 
activity.  
 
H1299 cells were transfected with PCDNA, vector control, p73-β, and c-Jun, N-c-
Jun (1-194), C-c-Jun (194-334), TAM (142-334); c-Jun-d-domain (30-57); c-Jun-NLS (1-
232) separately, or in combination.  In addition, reporter plasmids expressing the 
luciferase under the control of 5XTRE promoters and a plasmid encoding the ß-gal 
promoter were co-transfected.  The total amount of plasmid DNA used for transfection 
was adjusted to 3.2µg by adding PCDNA3.  Transfected cells were collected 48h after 
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3.3.4.2 TAD1 domain of p73 is essential to cooperate with c-Jun 
N-terminus of p73 contains transactivation domain, which shares 34% sequence 
identity with p53 though it is not the only transactiavtion domain proposed.  It seems that 
p73 has an additional glutamine rich transactivation domain near the c-terminus.  In an 
effort to understand whether N-terminus of p73 is important for its ability to transactivate 
AP-1 responsive element containing promoters, indicated vectors (figure 3.3.4.2) were 
transfected either alone or in combination. Although DeltaN-p73 increases 5XTRE 
activity, it was not as efficient as p73-ß, indicating that N-terminus of p73 is not essential 
for its ability to transactivate 5XTRE elements.   However, delta N-p73 failed to co-
operate with c-jun in transactivating 5XTRE elements, indicating a possibility that c-Jun 





















Figure 3.3.4.2   N-terminus of p73 is not essential for its ability to transactivate AP-1 
responsive element but for its ability to co-operate with c-Jun 
 
H1299 cells were transfected with vectors encoading PCDNA3, p73-ß, c-Jun, 
delta N-p73, p53 separately, or in combination with either delta N-p73 or p53 and a 
plasmid expressing the luciferase gene under the control of 5XTRE promoters and a 
plasmid encoding the ß-gal promoter for evaluating the transfection efficiency.   The total 
amount of plasmid DNA used for transfection was adjusted to 3.2µg by adding PCDNA3.  
Transfected cells were collected 48h after transfection and both luciferase activity and ß-
gal activity in cell extracts were measured.  This reporter assay was part of the earlier 
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3.3.5 The role of Post translational modifications 
 
3.3.5.1 JNK phosporylation is (63/73a.a) required, but dispensable for c-Jun’s 
ability to co-operate with p73 
To check whether JNK-mediated c-Jun phosphorylation is required for its ability 
to co-operate with p73 to transactivate AP-1 (5X TRE) response elements, p73, c-Jun and 
its phosporylation mutants (Jun63A/73A and 5XASP, serine residues are replaced with 
aspartate residues) were transfected separately or in combination in HI299 cells, which 
do not produce p53 protein. As shown in figure 3.3.5.1, though c-Jun 63/73 co-operated 
with p73 in transactivating 5XTRE elements, it was not as much as wild-type c-Jun.  On 
the other hand, phosporylation-mimicking (5XASP) c-Jun co-operated with p73 in 
comparison to wild-type c-Jun, indicating that phosporylation is important for its ability 
to transactivate 5XTRE elements.  
 
 













Figure 3.3.5.1 Phosphorlylation of c-Jun is required for its ability to co-operate with 
p73 
H1299 cells were transfected with reporter plasmids 0.5µg 5XTE-luc, 0.5µg ß-gal 
(for evaluating the transfection efficiency) and expression vectors encoding p73β 
(100ng), c-Jun (2µg), Jun 5XASP (2µg), Jun S63/73A (2µg), and PCDNA3.  The total 
amount of plasmid DNA used for transfection was adjusted to 3.1µgm by adding 
PCDNA3.  Luciferase activity was measured 48h after transfection and normalized for 
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3.3.5.2 c-Abl negatively regulates c-Jun’s ability to co-operate with p73 in increasing 
AP-1 activity 
c-Abl has been shown to increase the ability of p73 to induce apoptosis by 
directly phosphorylating it (Yuan et al., 1999; Agami et al., 1999; Gong et al., 1999).  c-
Abl is also known to phosporlylate c-Jun at tyrosine 170.  The tyrosine phosporlyated c-
Jun, promotes a positive feedback loop by enabling c-Abl to enter into the nucleus (Barila 
et al., 2000).  In order to find out whether c-Abl influences c-Jun to co-operate with p73 
to increase AP1 activity, H1299 cells were transfected with the indicated vectors (figure 
3.3.5.2).  c-Jun co-operated with p73 better than tyrosine phosphorlyation mutant of c-Jun 
(Y170F170).  This data suggests that c-Abl down regulates the ability of p73-β to 























Figure 3.3.5.2 C-Abl negatively regulates the ability of p73 to increase AP1 activity  
 
 H1299 cells were transfected with reporter plasmids 5XTRE-luc, beta-gal, expression 
vectors PcDNA3, PcDNA3-p73-ß, PcDNA3-c-Jun, PcDNA3-Jun170F separately and in 
combination with either c-Jun or c-Jun 170F.  Transfection efficiency was controlled by 
cotransfection of a ß-gal construct.  The total amount of plasmid DNA used for 
transfection was adjusted to 3.2µg by adding PCDNA3.  Transfected cells were collected 
48 hours after transfection for luciferase and ß-gal assays. Luciferase activity was 
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3.3.6 Dominant negative p73 (p73 DD) inhibits AP-1 transcriptional 
activity. 
3.3.6.1 Dominant negative p73 (p73 DD) inhibits AP-1 transcriptional activity. 
The p73-DD encodes (315a.a-636 a.a) carboxyl terminus of p73, which retains the 
oligomerization domain.  It has the capacity to oligomerize with wild-type p73 to 
inactivate its transcriptional activity towards p53 responsive elements (Jost et al., 1997). 
To clarify whether p73 activity is essential for the AP-1 activity, we checked if the 
endogenous AP-1 activity was brought down by the p73 DD in H1299 (p53-/-) cell line. 
Remarkably, 5X-TRE-luc activity was lowered by the dominant negative p73, indicating 
that p73 contributes to the AP-1 transcriptional activity (Figure. 3.3.6.1).  Intriguingly, 
the basal AP-1(5XTRE) activity seen with PCDNA3 is diminished in the presence of 
p73DD. Thus, this data suggests that p73 contributes to the basal AP-1 activity.













Figure 3.3.6.1 Dominant negative p73 inhibits AP-1 transcrptional activity 
 
H1299 cells were transfected with PcDNA3, p73-ß, c-Jun, p73 DD separately and in 
combination with either c-Jun or p73DD and reporter plasmids expressing the luciferase 
gene under the control of 5XTRE promoters and a plasmid encoding the ß-gal promoter 
for evaluating the transfection efficiency. The total amount of plasmid DNA used for 
transfection was adjusted to 3.2µgm by adding an empty PCDNA3.  Transfected cells 
were collected 48 h after transfection and both luciferase activity and ß-gal activity in cell 
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3.3.6.2 p73’s ability to stimulate AP-1 transcription in  p53-/- jun-/-  null cells 
To check whether p73 induces the AP-1 transcriptional activity through c-Jun, 
increasing concentration of p73 was transfected in p53-/-c-Jun-/- null fibroblasts.  As 
shown in figure 3.3.6.2, increasing concentration of p73β mildly increases luciferase/ß-
gal ratio. This data may suggest that the ability of p73 to stimulate AP-1 activity is not 
completely compromised in the absence of c-Jun.  However, it is important to note only 






















Figure 3.3.6.2 Dose effect of p73β on the reporter expression from 5XTRE in p53-/-
Jun-/- fibroblasts 
p53-/-Jun-/- cells were transfected with  reporter plasmid 0.5µg 5XTE-luc, 0.5µg ß-gal 
plasmids and increasing amount of  p73 and p73DD.  The total amount of plasmid DNA 
used for transfecteion was adjusted to 3.1µg by adding PCDNA3.  Luciferase activity was 
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3.3.6.3 p73 synergizes with c-Jun in potentiating hMSH2 promoter (p53RE and AP-
1) activity.  
The following facts support the idea that p73/c-Jun could regulate the expression of 
hMSH2 promoter: 
1. Treatment of cells with tetradecanoylphorbol- 13-acetate (TPA) specifically increases 
the amount of p73 mRNA (Fontemaggi et al., 2001). 
2. p73 increases the AP1 activity.  
3.  TPA is known to induce AP-1/c-Jun activity. 
4.  hMSH2 contains AP-1 responsive elements.  
As shown in figure 3.3.6.3, the synergism between p73 and c-Jun when they were co-
transfected can be explained on   the basis of the presence of binding sites for both p53 
and AP-1 in the hMSH2 promoter sequence.  However, the hMSH2 transcription is 









































Figure 3.3.6.3 p73 cooperates with c-Jun in potentiating MSH2 promoter (p53RE and 
AP-1) activity 
Saos2 cells were transfected with reporter plasmid hMSH2 promoter-luc(5µg), ß-gal 
plasmids(0.5µg) and increasing amount of  p73(10ng to 100ng),  and p53.  The total 
amount of plasmid DNA used for transfection was kept constant by adding PCDNA3.  
Luciferase activity was measured 48h after trasfection and normalized for transfection 
efficiency with ß-gal activity. Transfected cells were collected 48 hours after transfection 
and both luciferase activity and ß-gal activity in cell extracts was measured. 
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3.3.6.4 p73 promoter contains AP-1 like responsive elements  
Fontemaggi et al., (2001) have shown that TPA, a potent inducer of c-Jun/AP-1 
activity (Lamph, 1988), increases TAp73 mRNA levels, which indicates a possibility that 
AP-1/c-Jun could also regulate TAp73 at the transcriptional level. These observations 
prompted us to analyze TAp73 promoter for any AP-1 like responsive elements. As 
shown below, promoter analysis ranging from 2713/+1 revealed the presence of a 
consensus binding site for the transcription factor AP-1. The exact localization of this 
sequence (5'-TGA C/G TCA-3') is circled in figure 3.3.6.4.  Promoter analysis of the 
human TA-p73 promoter revealed seven putative AP-1-like binding sites.  The 
identification of AP-1 like sequences in the p73 promoter indicates a possibility that c-
Jun/AP-1 family of proteins can regulate p73 levels—in a context dependent manner— at 























p73 promoter sequence accession number:.  E51345. 
AP1 sites:  (5’-TGA G/C TCA-3’). 
                                             
No. AP-1 like sites Positions 
1 tga a tac 127-134 
2 tga g cac 414-420 
3* tga ga tca 830-838 
4 tgg a  tcg 890-897 
6 tga g cca 1411-1417 






























       1 gcggccgccc ccggccctgc ccgccgggga cgctggcacc gaggatgtcc tgcccgtggc 
       61 ccaggtcccc gccgctcacc aggtacttgc cgtccgggga gaacttgcag agtaagctgg 
      121 agagct tga a tac ctcggag aagttcatgg ccgccgcctg ccgcgggcgc caccctgcgc 
      181 ccgaaaaccc gcgggacccc tgggcgcgca gcaggctgca acagccgacg ccggcctccg 
      241 aggccggaag tcagaaggcg gaagtgaact gcagcctatc agcgccgccg acttccgcgc 
      301 ggcattgtgg ggcttgtagt tcttgtgccg cagggcttta aaggaaacgc ccacgtttct 
      361 tccgaccagg gatttccgac ccgagaacct tacctcaaag gccgggaggc ctt tgagcac 
      421 ctccagctag ggctgctgat aaaaatgtag aaagcacagt aaaatt tgaatttca gattc 
      481 acaacaaatc tagttataag tatgttccca aatattgcac gggacatgct aatacggaaa 
      541 aattactcgc tagtctgaaa ttcaaattta attgagcgac ctgtgtgtct gcgtgtgtgt 
      601 acacatgcat a tata tata t ttatatttata tgtaaatgt atgtttacat gtaaatatat 
      661 gtttacctac aaatatatct ttaataagta atacggtgtc tgtcgcacat atattatatc 
      721 gtgtatgtaa tgtataagta tttatttcgt ttgcttgggg ttttgtttgc ttttgctgag 
      781 tccgacccct ctacctgccg cctggccctt gcctcacgct ccagtgccac tgaga tca ag 
      841 gagagaacga atttgccgct gactgggcag agcgagcgcg tggatcgcgg ccaccgcccg 
      901 ttcatcaccc gcgcgcatct gggctggcac cgggcgaaga atcgtgcggg tctgggacct 
      961 gggggcccag agggagcgag ctcctgcgcg ggcgctcggt ccgcaggttt cgcaggctca 
     1021 ggggcgtgcc tcgttctcac ccccactccg gaccccggtc ctcttcccta gacagcggcc 
     1081 ccctccaccc ctggctcccg caggccgcta gtagtccgcg ccaggccccg ccggcgcctc 
     1141 tagggccccc cagatcgcgc agaccctgac atccccgcct ggccctgggt tctgggagct 
     1201 gagagccggc cagggtcctg ctcgtacctc cgggcgccca gcctcgggtc tgctccccgc 
      

































Figure 3.3.6.4 p73 promoter possesses AP-1 like responsive elements  
 
The promoter analysis of TA p73 promoter (TAp73 promoter sequence accession 
number-E51345) has identified at least seven AP-1 sequences (highlighted in blue).  
 
     1261 ggacgcccca acctccccgg ccgaatggat ggtggtgcgc gcgcgtccta ctccggcggt 
     1321 gccggccttt tctgttgcca aaactagacc caaacctctg catgggattc gtctttgggt 
     1381 ccccaccccg tgcgcccagc aaacagtggg tgagcca tga agatg tg cgagtca gccgga 
     1441 ccctccccgt caggcgcgga cccgctgcgg ccagagaacc cagtctgcgc cagcccggct 
     1501 cgctcgcgaa gccacgggct tcactgacgc gactttccaa gacgtggggg tcaccatggg 
     1561 cagaggacat cggttcggag ccagatcacg ggccccataa gcatcagacc ataagcagcg 
     1621 ccgccactga gagccgctcg gaactcgccc agcatgtcgg gtcccctagc cagggcctgg 
     1681 tgtacgtggt cgagggccct ggaagccccg atggcctagg aggagcaggc gggcggggcg 
     1741 gcgggtgtcg ctggccggta gagagcttcg gcctgaccta gcgcaggtct ggtgcgcgca 
     1801 gagaacaact ccaagcgcac cgacgcccgc gagctccttc caaacaccga acgggatcca 
      1861 gagcccgagc ccacaggcgg cggccggggg agggagcagg gtgctggccg ccgcccggga 
     1921 gtgttcgcgt cctgggtgac ccctggaagg acgtggggcc caaactccgg ctggggttgg 
     1981 gagagcagcc cccagaggct ctccgcggga tcctctgccg ggcgggaccg tggctccaca 
     2041 ggagaagtgg gtggcaagcc ctgcttggcg gaaagcagcc gttcccctcc tcctgggcct 
     2101 ggggcggcgc ccctcacccc tgttccccgc ccctcacccc tgttccccgc cggccacatc 
     2161 ccctgcccct tggattccaa gcgccccgcg cgccgaggag cccagcgcta gtggcggcgg 
     2221 ccaggagaga cccgggtgtc aggaaagatg ggccgtctgg gggacagcag ggagtccggg 
     2281 ggaaacgcag gcgtcgggca cagagtcggc accggcgtcc ccagctctgc cgaagatcgc 
     2341 ggtcgggtct ggcccgcggg aggggccctg gcgccggacc tgcttcggcc ctgcgtgggc 
     2401 ggcctcgccg ggctctgcag gagcgacgcg cgccaaaagg cggcgggaag gaggcggggc 
     2461 agagcgcgcc cgggaccccg acttggacgc ggccagctgg agaggcggag cgccgggagg 
     2521 agaccttggc cccgccgcga ctcggtggcc cgcgctgcct tcccgcgcgc cgggctaaaa 
     2581 aggcgctaac gcccgcggcc gcctactccc cgcggcgcct cccctccccg cgcccatata 
     2641 acccgcctag gggccgggca gcccgccctg cctccccgcc cgcgcacccg cccggaggct 
     2701 cgcgcgcccg cga 
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3.3.6.5 ∆Np73 promoter contains AP-1 like responsive elements  
Costanzo et al have suggested in abstract presented in the ESDR meeting (2002) 
that deltaNp73 promoter can be regulated by both c-Jun and p53.  However, whether 
deltaN p73 promoter has AP-1 elements is less clear from this study.  Interestingly, 
deltaN p73 promoter could be analogous to MSH-1 promoter, as it has been shown to 
encode both p53 and AP-1 RE at the proximal sites and regulated by both c-Jun and p53.  
Similarly, MDM2 promoter contains both AP1 and p53RE in its promoter and is 
subjected to the regulation both by AP-1/c-Jun and p53 (Ries et al., 2000).  Therefore, 
deltaNp73 promoter was analyzed carefully for any AP-1 like responsive elements.  
Interestingly, as shown below, deltaNp73 promoter analysis ranging from - 2940/+1 
revealed the presence of a consensus binding site for the transcription factor AP-1.  The 
exact localization of this sequence (5'-TGA C/G TCA-3') is circled in figure 3.3.6.5.  This 
promoter analysis revealed seven putative AP-1-like binding sites.  The identification of 
AP-1 like elements in deltaNp73 promoter analysis suggests that human deltaNp73 
promoter can be synergistically potentiated by p73 and c-Jun/AP-1 transcription factors. 
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DeltaNp73 promoter sequence accession number: intron 3, which includes the DeltaNp73 
promoter. 
 
No. AP-1 like sites Positions 
1 tca gc tca  60-67 
2 tga c aca 235-242 
3* tga g tca 454-460 
4 tag c tca 662-668 
5 tgc a tca 883-889 
6 tga aa tac 1841-1847 
7 tga a tac 2547-2553 
 



























       1 ccagggagga tctgtagctg gaggaagggt ggggtcatgc gtgggagcag ggagggggct 
       61 cagctcacca cggtcagctc tgagactcca gcccacccgt taccccctcc cagagagccc 
      121 ccactcagcc tttcctttgg tgggctttcg tgacaaagca ctttggggct gcacagaagt 
      181 gaaccccacc cagcacccag gtctcagagc cttgcagctt ctgcggcctc ttccatgcgg 
      241 tgggatgaag ccagctgccc agcagggacc ctgtgccatg agtttggcct tgaactgaca 
      301 ca tcactggc accaggaaac gaagtccccc tgtctgttct ggcacataac ccctcccact 
      361 aactggttcc tgaagagtgc cgtggcctgc ggcagcgtcg ttcccccctg tcctgcggcc 
      421 cagggtcctgcggaaagtca ggcggaatcc ccgg tgag tca gaagcagaa tgaaagcaga 
      481atggaggacccagcagggag ggaacctgga ggaggcgcta agggccacgc caagggggtg 
      541 tggccccaga tcccctgtcc ctgtcctctg caaggctggg ccttgggaac gtttgcagaa 
      601 agctgggtgc cgctctgggg cagaggccag tggttttggg tgcttttgag ttggaaacgt 
      661gtagctcagc cgcactggga tccccgcagc ctggcccaga tgctaagggt ggagagatgc 
      721 ggggtctcag gcacggtgcc ctgggcatgg gtggggctcg tgctgaaggc agcctggctg 
      781 tcttccttcc tcacgtcctt ccacttggcg ctctcctttt ggctatttat aaaaccatca 
      841 ggccggccctgtgcatggga  ctcgcctgagtctccttttc aa tgc a tca t tccctttggc 
      901 aggagaggac accgcctaca gaggctgagg atgtgccctg tgggggtcgg gagcggaacc 
      961 caggccccgc ctcggccctg ctctgagggt ctgtccatcc ctggggagcc cgcccccaac 
 







































     1021 ccaagagggg tcccaggctc agaagcagaa ggcaccctca tccccagggc atccccgatc 
     1081 ccagcaggag tctcctagtg ctcgccctgg gctctcctgc aaggaggctg ctgctttccc 
     1141 cagaacatcc agtctgggcc ccagccgacc ccctgcaggg ggcttcccag agacgccctt 
     1201 cctgaacctg atctaccaga caaaactgtc tttttctcag tcgtctcctc ctgagtgctg 
     1261 ctgcccttcc tgttgggggc tgagatcctc tgccacagga agagacgggc gtccaggact 
     1321 cacctgctgc ctcccggccc tagggccctg agctgggctc tccaggcccc agccccttgg 
     1381 ggcacaacac ctggaatcgt cctttcgtcc tcagcccggc ctgctggtgg ggcagggcgg 
     1441 gtccccaggg ctcctcaggc agctgcagtc caaacctccc ctgccctcac ccagctctgc 
     1501 ccgctctccc gggggtgggg gtggggagcg atgaggcccc tgccggctct cggtggggac 
     1561 gacagggagg aaggaagctg gggagatgga gacaagagaa agcaggcagg tggtttggga 
     1621 tttggcagga aaaggttgga aggaaagggg aaagggtctc cgcatggatt tctca gctcc 
     1681 ccatggattt ctca gccctc gtgagagcca cggcgccctg gggactggaa gtgtgggtcc 
     1741 gcaggcccca gtccccaggt ttgtctgagc atagatgccc tgcctgcttc cagggggact 
     1801 cgggcccctc tgccagggtc aactttgtac ccaagacggc tga aa tacaa tggaaattca 
     1861 gacggcccaa cagggag tgg cag tca cctc aaaggcccca ctagacgggt gcggggcacc 
     1921 actgcagagc ccctccctgg ctgtgccaag gccgtccacg cctgcagggg gccccactgc 
     1981 cgggctgttc tttggcaaca gtggcttgtc cctgtttcct gggggcttgg ccagtgccag 
     2041 ggtgggctcc aaacgcacgg ctctgggctc ttggactcac ccctgctttg ggcaggcagt 
     2101 ggaaggcagg ccccacaaga gctgctcact cccgtcacct gtctccctcg ggggtctagg 
     2161 gtcgaacctc ctgtgagccc ctcctctcca tgcagccctt ggactagtcc tggcggacca 
     2221 ccgagttccc cgcgcagggg gcaggtgcgc cccacctggg tgccaaggga ggcgacacca 
     2281 tctctccccc ttggggtggc ccagccttgc ctaccatgat ctccagggcc ggggctcagc 
     2341 cctcatgcct gggaacagag gctgctttac ggggtgaggg cctggggccc cccgagcctt 
     2401 ccccaggcag gcagcatctc ggaaggagcc ctggtgggtt taattatgga gccggcgctg 
     2461 accggcgtcc ccgccctccc cacgcagcct ccttggtgcg gtccaacaca tcaccgggca 
     2521 agctgaggcctgccccggac ttgga tga a tac tca tgagg aataaagggg tgggccgcgg 
     2581 gttttgttgt tggattcagc cagttgacag aactaaggga gatgggaaaa gcgaaaatgc 
     2641 caacaaacgg cccgcatgtt ccccagcatc ctcggctcct gcctcactag ctgcggagcc 
     2701 tctcccgctc ggtccacgct gccgggcggc cacgaccgtg acccttcccc tcgggccgcc 
     2761 cagatccatg cctcgtccca cgggacacca gttccctggc gtgtgcagac cccccggcgc 
     2821 ctaccatgct gtacgtcggt gaccccgcac ggcacctcgc cacggtaggt gtgacgcgcc 





Figure 3.3.6.5 DN p73 promoter encoades AP-1 like responsive elements  
 
The promoter analysis of DN p73 promoter (DeltaNp73 promoter sequence accession 
number ACCESSION AB055067) has identified at least seven AP-1 sequences 
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3.4.1.1 p73 is over expressed in various human cancers 
 
Whether p73 is a tumor suppressor or a proliferation associated gene is still under 
immense scrutiny.  However, it is certain that p73 is not a classical tumor suppressor 
gene that would follow Knudson’s two hit hypothesis (Melino et al., 2002).  Despite the 
search in 900 human tumors for mutation in p73 gene, the results were unfruitful for 
cancer biologists (Zaika et al., 2002; Stiewe et al., 2002).   
Current studies strongly suggest that p73 appears to be over expressed in a variety 
of tumors including neuroblastomas, ependymomas, hepatocellular, gastric, breast, 
bladder, ovarian, and esophageal cancers compared with their normal tissue counterparts 
(Moll et al., 2001). Importantly, p73 over expression appears to be positively correlated 
with prognostically relevant parameters (Petrenko et al., 2003; Sun, 2002).  The 
correlations between high-level expression of p73 and various prognostic factors indicate 
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3.4.1.2 Role of c-Jun/JNK in supporting transformation events in tumor cells 
It has been shown earlier that both c-Jun and JNK play an important role in tumor cells. 
The following evidence suggests a role for both c-Jun and JNK in transformation and 
tumor cell survival: 
1. The AP-1 activity is required for tumor promotion (Young, et al., 2002). 
2. Ras induced transformation requires c-Jun (Johnson et al., 1996) 
3. Ras induces c-Jun phosphorlyation on sites that are phosphorlyated by JNK 
(Pulvrer et al., 1991; Smeal et al., 1991). 
4. Knock-in studies demonstrated that mutation of the JNK phosphorlyation sites on 
c-Jun prevented Ras-induced tumorigeneicity (Behrens et al., 2000) 
5. In addition, it has been shown that JNK is constitutively activated in several 
tumor cell lines and that the transforming actions of several oncogenes (for eg., 
BCR ABL) have been reported to be JNK dependent (Ip and Davis, 1998).  
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3.4.1.3 Hypothesis: p73 and c-Jun can cooperate in transformation 
 
The p73 (wild-type) is over expressed in variety of tumor cells.  However, it is 
unclear why TA-p73 did not prevent tumorigenesis, especially when it is expressed in the 
wild-type form. Why would tumors need to retain factors or express factors that would 
make them more sensitive to apoptotic stimuli?  Further, it is intriguing to note that p73-/- 
cells slowly exit from S-phase in response to UV irradiation, indicating that it could play 
a role for p73 in G1-S phase transition/proliferation (Costanzo et al., 2002). Alternatively, 
it may suggest that p73 does not act as a UV checkpoint but rather counteracting 
checkpoint function.  Indeed, p73 expression is itself modulated during the cell cycle and 
TAp73 proteins accumulate in S phase. In addition, the function of p73 proteins is also 
regulated by post-translational modifications and protein-protein interactions in different 
cellular and pathophysiological contexts (Fulco et al., 2003). Furthermore, it has been 
shown that cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-
dependent manner and negatively regulate p73 function. All p73 proteins have a Cyclin 
Recognition Motif located within the N-terminal portion of the DNA binding domain 
(KKL; 149) (Gaiddon et al., 2003).  Alternatively, over expressed dominant negative p73 
or interacting oncogenes could modulate TA-p73 function in tumor cells. Intriguingly, 
p73 is regulated by oncoproteins such as c-Myc, MMI, c-Jun, MDM2, and mutant p53 
etc.  All these proteins could effectively bind to p73 in tumors and suppress its p53 
related functions. Similarly, during the tumor development Jun/JNK-dependent stress 
induced apoptosis must be suppressed or adopt mechanisms to suppress Jun/JNK-
dependent apoptosis. It is also possible that tumor cells may activate survival pathways 
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that function dominantly with respect to the JNK/Jun pro-apoptotic pathway.  JNK/Jun 
could even function differently in tumors and normal cells.  Evidently, it has been 
demonstrated that JNK is required for stress-induced apoptosis of primary cells (Garay et 
al, 2000; Ho et al., 2002).  In contrast, induction of apoptosis and inhibition of growth of 
tumor cells were noted when tumor cells were transfected with anti-sense JNK 
nucleotides (Bost et al., 1999; Patopova et al., 2000).  These results imply that JNK 
supports transformation in tumor cells.   
Together, all these critical facts and questions raise the possibility that the 
function of p73 is modulated in tumor microenvironment and p73’s “p53 related 
functions” are compromised in cancer cells.  Primarily, p73 and other oncogenes such as   
c-myc and c-Jun have the capacity to induce apoptosis when they are over expressed.  
However, it does not happen efficiently in tumors, otherwise tumorigenesis would be 
prevented.  Alternatively, the majority of tumor cells would have undergone apoptosis 
and a few surviving cells could have learnt to modulate the functions of these proteins 
through protein-protein interactions and developed as clones.  This onco-suppressor 
protein function is tuned or modulated according to the needs of the cancer cells to 
sustain proliferation and this could one of the reasons why p73 is over expressed in 
tumors. 
   Keeping all these facts in mind, it was hypothesized that both p73 and c-Jun can 









Figure 3.4.1.1 Hypothesis: p73 and c-Jun can cooperate in transformation 
 
It appears that AP-1 activity is required for tumor promotion (Young, et al., 2002) in the 
mouse model.  c-Jun is specifically activated in several tumor cell lines and AP-1 activity 
is highly pronounced in tumors (Shualin et al., 2002). Furthermore, both p73 and c-Jun 
synergistically increase AP1 activity. These findings may support the hypothesis that p73 
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3.4.2 p73 transforms fibroblasts in conjuction with c-Jun. 
 
3.4.2.1 p73 α/β inhibits colony formation.  
 
NIH 3T3 cells were transfected with pCDNA, p73 alpha and p73-beta and 
selected in G418 for about two weeks. As shown in figure (3.4.2.1), transfection of either 
p73α or p73β did not give rise to any macroscopic colonies. The suppression of colony 
formation could be due to apoptosis. In contrast, many drug resistant colonies were 
formed following transfection with the empty vector (pCDNA3).   This confirms the 





















Figure   3.4.2.1 p73α/β inhibit colony formation 
 
NIH 3T3 cells were transfected with a pcDNA that conferred G418 /neomycin resistance 
and pcDNA plasmids expressing p73α and -β (2 micrograms each). For colony formation 
assay 5X104 cells per 10 cm plate were transfected with a neomycin plasmid and were 
grown for 48 h before 750 µgm/ml of neomycin was added.  After 2 weeks, colonies 
were fixed and visualized by staining with crystal violet.  Note that the inhibition of 
colony formation by p73α is much better than p73β. 
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3.4.2.2 p73 and c-Jun co-operate in transformation  
TA-p73 (wild-type) is over expressed in many human tumors (Moll et al., 2002). 
However, it fails to induce apoptosis to prevent tumor formation.  In addition, its putative 
target genes (p53 responsive element encoding genes such p21, Bax, p53AIP1) seem to 
be not upregulated in tumors. One could argue that delta N-p73, which has the ability to 
inactivate both p73 and p53 are also over expressed in tumors. Thus, it was hypothesized 
that wild-type transcriptionally active p73 (TA-p73) alpha and beta cannot prevent 
proliferation in the presence of oncogenic signals provided by c-Jun.  This hypothesis 
was tested by transfecting wild-type pCDNA-p73 alpha/beta together with pCDNA-c-Jun 
in immortalized fibroblast cell lines such as NIH 3T3 cells and selected in 
G418/Neomycin 750-1000(microgram/ml). As shown in the figure 3.4.2.2, p73 increased 
the number of colony formation in the presence of c-Jun, in comparison to vector 
(pcDNA) and c-Jun. This result indicates that c-Jun modulates the function of p73 in such 
a way that it supports the transformation process, as Jun has been shown to support 


















Figure 3.4.2.2   p73α/β transform fibroblasts in co-operation with c-Jun 
 NIH 3T3 cells were transfected with a pcDNA that conferred G418 /Neomycin 
resistance and pcDNA plasmids expressing p73α and p73-β (2µg each). For colony 
formation assay 5X104 cells per 10 cm plate were transfected with a Neomycin plasmid 
and allowed to grow for 48 h before 750 µg/ml of Neomycin was added.  After another 2 
weeks, colonies were fixed and visualized by staining with crystal violet.  Note that 
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3.4.3   c-Jun mutants ability to modulate p73 function 
3.4.3.1   c-Jun mutants cooperate with p73 in transformation: Either N or C-termini 
of c-Jun co-operates with p73 in transformation 
  
In the earlier chapter (chapter 2) it was shown that both N and C-termini of c-Jun 
(1-194 and 194-334, respectively) cooperate with p73 in inducing AP1 activity.  To 
check how the binding of N and C-termini of c-Jun influences p73 in promoting 
transformation, NIH 3T3 cells were transfected with indicated vectors. As shown in 
figure, p73 increased the number of colony formation even in the presence of either N or 
C- termini of c-Jun independently (Figure 3.4.3.1).  Interestingly, both N and C-termini 
of c-Jun by itself reduces the colony number compared to full-length c-Jun, but in the 















Figure 3.4.3.1   p73 transform fibroblasts in co-operation with both N and C-termini of 
c-Jun 
 NIH 3T3 cells were transfected with pcDNA that conferred G418 /Neomycin resistance 
and pcDNA plasmids expressing p73α and -β, c-Jun, N-c-Jun(1-194), C-c-Jun(194-334) 
(2µg each) separately and together as shown in the figure.  For colony formation assay, 
transfected NIH3T3 cells were allowed to grow for 48h before 750 µg/ml of Neomycin 
was added.  After 2 weeks, colonies were fixed and visualized by staining with crystal 
violet.  Note that C-terminus of c-Jun is much better than N-terminus of c-Jun to co-
operate with p73-β in transformation. In the presence c-Jun, both p73 α and β increased 
the colony number. 
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3.4.4 Factors contributing to c-Jun- p73 mediated transformation 
 
 
3.4.4.1 Both c-Jun and MDM2 are required for enhanced MDM2 promoter activity 
 
 
In an effort to look at other cellular changes that would have favored the ability of 
p73 and c-Jun to co-operate in transformation, it was decided to look at changes in the   
p53 level, as the presence of p53 has already been shown to hinder transformation 
process.  p73 has also been shown to  transactivate MDM2 promoter. Unlike p53, MDM2 
does not promote degradation of p73, but it has been shown to inhibit transactivation at 
the highest concentration. Interestingly, MDM2 has been shown to stabilize p73 
(Ongkeko et al., 1999) at the protein level. However, the mechanism of action is not yet 
clear. To clarify this point, the ability of p73 to augment MDM2 promoter activity was 
checked in genetically defined p53-/-; p53-/-jun-/-; p53-/-Mdm2-/- cell lines.  Equal amount 
of p73 and MDM2-luc plasmid and beta-gal plasmids were tranfected and luciferase 
assays were performed to find out the MDM2 promoter activity in the knockout cell lines 
chosen.   Interestingly, MDM2 activity was high in p53-/- cell line, in comparison to both 
p53-/-jun-/- and p53-/-Mdm2-/- cell lines, indicating that both c-Jun and MDM2 




































Figure 3.4.4.1 Both c-Jun and MDM2 are required for enhanced MDM2 promoter 
activity  
 p53-/-; p53-/-Jun-/-; p53-/-MDM2-/- cells were transfected with pcDNA,Vector control,  
p73-beta and reporter plasmids expressing the luciferase gene under the control of 
MDM2 promoter and a plasmid encoding the beta-gal promoter for evaluating the 
transfection efficiency.   The total amount of plasmid DNA used for transfecteion was 
adjusted to 1.2µg by adding an empty PCDNA3.  Transfected cells were collected 48 































3.4.4.2 Immunoprecipitation analysis to find out the interaction between c-Jun, p73 
and MDM2: Immunoprecipitation(IP) with c-Jun Ab 
Our earlier observations suggest that c-Jun and p73 interact with each other 
through both N and C-termini of c-Jun.  It has already been shown that p73 interacts with 
MDM2. Unlike p53, MDM2 does not promote the degradation of p73. Further more, 
when a large amount of MDM2 was over expressed p73 transcriptional activity towards 
p53 responsive elements was lost. Considering these observations, it was decided to 
check whether a complex containing these proteins exist in invivo.  To determine whether 
c-Jun, p73 and MDM2 interact with each other, cos7 cells were transfected with vector 
carrying no insert (pCDNA), p73-ß, c-Jun, MDM2 and in combination as shown in figure 
3.4.4.2. 48h after transfection, cell extracts were prepared and immunoprecipitated with 
agarose conjugated c-Jun Ab and c-Jun immunoprecipitates were analyzed by western 
blotting. The membrane was sequentially probed with, p73, c-Jun and MDM2, indicating 
a possibility that in invivo such a complex could exist.  C-Jun antibody efficiently 
immunoprecipitated p73 when either p73 alone or both c-Jun and p73 were transfected 
together, indicating that endogenous c-Jun interacts with over expressed p73. When 
p73.MDM2 or p73.c-Jun.MDM2 was transfected together, again c-Jun antibody 
efficiently immunoprecipitated p73. Next, the membrane was stripped and re-probed with 
a mixture of MDM2 antibodies (SAM10 and a mouse monoclonal antibody). When p73/ 
MDM2 or p73/c-Jun/MDM2 were transfected together c-Jun efficiently pulled down  
MDM2.  Interestingly, when p73 was transfected alone, more MDM2 was brought down 
by c-Jun, indicating that p73 induces MDM2 expression and is being brought down by 
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the endogenous c-Jun. In addition, when MDM2/c-Jun was tranfected it did not bring 
down either MDM2 or c-Jun indicating that this plate was not transfected efficiently.  
Finally, the membrane was stripped again and re-probed with c-Jun antibody to check 
whether the agarose conjugated c-Jun antibody is efficiently pulling down 
overexpressed/endogeneous c-Jun.  As can be seen from the figure, c-Jun antibody pulls 
down c-Jun. Together, this experiment failed to imply c-Jun physically bind MDM2, but 








Figure 3.4.4.2 A c-Jun, MDM2 and p73 interact with each other: IP using c-Jun 
antibody 
 COS7 cells were transfected with expression vectors as indicated above. Transfected 
cells were collected 48 h after transfection and cell extracts were prepared and protein 
concentration measured.  Equal amounts of protein lysates (300µg/sample) were first pre-
cleared with glutathione agarose beads and then immunoprecipatated with Agarose 
conjugated polyclonal-c-Jun (H-79) antibody.  Immunoprecipitates were analyzed by 
immunoblotting with p73 (mouse monoclonal antibody), c-Jun (poly clonal antibody-



























                               
 187 
3.4.5 The co-operative effect of c-Jun, MDM2 and p73: a potential 
mechanism to degrade p53 
3.4.5.1 The co-operative effect of c-Jun, MDM2 and p73 on MDM2 promoter 
  Since these proteins interact with each other and there is a possibility that they 
may coexist in human tumors, we checked their ability to transactivate MDM2 promoter 
in human lung carcinoma cell line (H1299). H1299 cells were transfected with the 
indicated vectors and cells were collected 48h post-transfection. Extracts were analyzed 
for luciferase and beta-galactisidase activity.  As shown in figure (3.4.5.1), when MDM2 
was co-transfected with p53, it brings down the activity, while it did not inhibit the 
transcriptional activity of p73.  MDM2 promoter activity was maximal and induced by 
six folds when p73 and c-Jun were co-transfected together. In addition, when p73, c-Jun 
and MDM2 expression vectors were transfected together, it augmented the MDM2 
promoter activity by fourteen folds, indicating a possibility that coexistence of these 



















Figure 3.4.5.1   The co-operative effect of c-Jun, p73 and MDM2 on MDM2 promoter   
H1299 cells were transfected with the indicated expression vectors.  In addition 
reporter plasmids expressing the luciferase gene under the control of MDM2 (full length) 
promoter and a plasmid encoding the beta-gal promoter were transfected.   The total 
amount of plasmid DNA used for transfecteion was adjusted to 6µg by adding an empty 
PCDNA3.  Transfected cells were collected 48h after transfection, both luciferase activity 































































































“Science does not know its debt to imagination” Ralph Waldo Emerson. 
                               
 190 
 
Section I:  c-Jun is required for p73 activation and stabilization 
1. jun-/- and p53-/-jun-/- cells are resistant to cisplatin 
 
The resistance of jun-/- cells to cisplatin suggests that c-Jun is required for cisplatin-
mediated apoptosis.  Further, the resistance of p53-/-Jun-/- cells to cisplatin indicates the 
importance of c-Jun in cisplatin-mediated p53-independent apoptosis. A number of 
studies suggest that c-Jun participates in stress responses. It is induced by various stress 
stimuli such as UV radiation, MMS and anti-cancer drugs etc. Furthermore, it has been 
shown that over-expression of c-Jun induces apoptosis in 3T3 fibroblasts (Bossy-Wetzel 
et al., 1997), in human vascular endothelial cells (Wang et al., 1999), and in neuronal 
cells (Behrens et al., 2001).  Studies using sympathetic neurons and PC12 cells have 
shown that inhibition of c-Jun activity either by microinjection or expression of dominant 
negative mutant forms of c-Jun protects the cells from Nerve Growth Factor (NGF) and 
withdrawal-induced apoptosis (Estas et al., 1994; Ham et al., 1995; Xia et al., 1995). c-
Jun has also been shown to inhibit oncogene-mediated transformation in primary rat cells 
(Ginsberg et al., 1991). However, neither the mechanism of c-Jun-mediated apoptosis nor 
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2. c-jun null cells have low levels of p73, and re-expression of c-Jun 
restores p73 levels and sensitivity to cisplatin 
 
 If cisplatin mediated p73 stability occurs through c-Jun then c-jun-/- cells would be 
resistant to cisplatin-mediated apoptosis and p73 stabilization and function will be altered 
in these cells. Further, a number of studies suggest that ras can augment c-Jun expression. 
Fokstuen et al.(1997) showed that ras farnesylation inhibitor BZA-5B increases 
resistance to cisplatin in a human melanoma cell line. Of note, ras also regulates p73 
levels (Melino, 2001). Moreover, transfection of a dominant negative c-Jun mutant ∆169 
resulted in cisplatin resistance (Sanchez-Perz and Perona, 1999). Thus, these studies 
indicate a logical relationship between loss of c-Jun and p73 expressions and cisplatin 
resistance. In line with these studies, low expression of p73 was found in c-jun-/- cells in 
response to cisplatin treatment. In addition, re-expression of c-Jun in c-jun null cells 
restored p73 levels in response to cisplatin treatment, indicating that c-Jun is required for 
increased p73 levels and cisplatin-mediated apoptosis. It has been shown that p73 can 
activate p53-responsive genes and it can induce apoptosis in several cell lines (Khagad et 
al., 1997; Jost, 1997). Thus, it is possible that c-Jun may stabilize/increase p73 levels and 
thereby controls cellular fate.  Further, Flores et al., (2002) suggested that p53 is 
upstream of p73 and p63.  In the absence of p73, mouse embryonic fibroblasts failed to 
undergo apoptosis in response to various chemotherapeutic drugs such as cisplatin in 
comparison to wild-type cells (Flores et al., 2002). Interestingly, c-jun null cells have 
higher levels of wild-type p53 but are still resistant to cisplatin-mediated apoptosis. This 
can be explained by considering the fact that in the absence of c-Jun, p73 levels are low 
and p73 expression may be required for effective induction of cisplatin-mediated 
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apoptosis (Flores et al., 2002). Thus, these data suggest that the presence of c-Jun is 
necessary for induction of p73. Further, these studies indicate a possibility that in the 
absence of p53 protein chemotherapeutic drugs can induce p73 protein to execute 
apoptosis. The following facts highlight the role of p73 in chemotherapeutic drugs 
induced apoptosis in various cancers: 
1. The ability of p73 to induce p53-independent apoptosis explains the sensitivity of 
human cancers (in spite of p53 mutations) to chemotherapeutic drugs (Kaelin et al., 2000; 
2003).  
2. Das et al., (2005) have shown that Ad-p73 is more potent than Ad-p53 in enhancing 
the chemosensitivity of mutant p53 expressing cancer cells.   
2.  p73, but not p53, expression differs between the cisplatin-resistant cell line and its 
isogonics cell line, emphasizing the importance of p73 in cisplatin mediated apoptosis 
(Ono et al., 2001).  
3. p73, but not p53, expression differs in cells defective in mismatch repair, such as those 
derived from the hereditary cancer syndrome human non-polyposis colon carcinoma 
(Zheng et al., 1999).  
4. SK-N-AS (a human neuroblastoma cell line-p73 negative) cells are more resistant to 
cisplatin than SK-N-SH (p73-positive) cells (Zheng et al., 1999).  
 
Thus, understanding p73 mediated p53-independent apoptotic pathway is of paramount 
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3. c-Jun stabilizes p73 in response to cisplatin treatment: Possible and 
potential mechanisms 
 
Cisplatin has been shown to stabilize both p53 and p73 at the post-transcriptional levels 
(Gong et al., 1999).  The data presented here suggest that both exogenously transfected c-
Jun and endogenous c-Jun increase p73 levels.  c-Jun does not alter p73 RNA in response 
to cisplatin treatment, but it stabilizes p73 at the protein level. This conclusion is drawn 
from various experiments (Co-transfection, Western, Pulse chase, RT-PCR etc.) 
presented in Chapter III.  In line with this, Gong et al., (1999) showed that cisplatin does 
not increase p73 at the RNA level.  
The stability of key proteins involved in cell fate decisions is regulated by several 
degradation mechanisms. Regulatory proteins are often ubiquitinated, depending on their 
association with auxiliary proteins that serve as adapters of the ubiquitination machinery. 
Both c-Jun and p73 are degraded by proteasome dependent and independent mechanisms 
(Muller et al., 2000; Lee et al., 1999; Bernassola et al., 2004). c-Jun is targeted for 
ubiquitination by its association with inactive JNK (at the basal level). On the other hand, 
c-Jun is protected from ubiquitination by its association with active JNK (in response to 
various external and internal stimuli) (Fuchs, et al., 1997).  It has recently been shown 
that Itch, a Hect ubiquitin-protein ligase, binds to p73 and target it to proteasome 
dependent degradation (Rossi et al., 2005).  Furthermore, RanBPM has been shown to 
bind to p73alpha and stabilzes p73 by inhibiting proteasome mediated degradation 
(Kramer et al., 2005). Asher et al (2005) have shown that p73 stabilization is regulated by 
NQO1 as well.  It appears that NQO1 interacts with p73 in an NADH-dependent manner 
and guards them from proteasomal degradation (Asher et al., 2005).  However, p73 
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degradation and/or stabilization mechanisms are not very clear yet.  c-Jun has been 
shown to interact with Ubc9 (E2 ubiquitin-conjugating enzyme) (Gottlicher et al., 1996). 
Likewise, p73 has been shown to interact with several ubiquitin related proteins such as 
Ubc-9, SUMO1 (Minty et al., 1999). This data suggests that c-Jun by competing with p73 
for binding Ubc9, it could prevent the interaction between p73 and Ubc9. By preventing 
the interaction between p73 and Ubc9, c-Jun could protect p73 from being degraded. It 
has been shown that serum is a potent inducer of c-Jun expression (Lamp et al., 1988).  
Serum also stabilizes p73 with no significant change in p73 mRNA levels (Weiss et al., 
2001). These data suggest that serum could stabilize p73 by activating the expression of 
c-Jun. Alternatively, c-Jun can increase p73 levels by negatively regulating repressors of 
p73.  
 Recently, Zaika et al., (2002) and Slade et al., (2004) showed that DN-p73 
increases p73 protein levels, but it decreases its functional activity. Intriguingly, deltaN-
p73 promoter encoades AP1 responsive elements. In agreement with this data, c-Jun has 
been shown to increase the deltaNp73 at the promoter level (Costanzo, et al., 2002). 
Thus, it is also possible that in response to growth stimuli c-Jun can stimulate deltaN-p73 
expression, which in turn enhances p73 protein levels.   
 Further, N-terminus of c-Jun ((∆194-334) mutant does not stabilize p73. This 
data suggests that transactivation and delta domains are essential for c-Jun mediated p73 
stability. On the other hand, C-terminus ((∆1-194)) of c-Jun mutant weakly stabilizes p73 
compared to wild type c-Jun, indicating that DNA binding and dimerization (leucine 
zipper) domains are important as well. Thus, both N- and C-termini of c-Jun (containing 
transactivation, dimerization and DNA binding domains) are required for its ability to 
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stabilize p73. In support of this finding, it has been shown that c-Jun mediated apoptosis 
require both bZIP and transactivation domains, suggesting that apoptosis depends on 
transcriptional regulation (Bossy-Wetzel et al., 1997).    
Next, the likelihood of interaction of p73 with c-Jun was revealed in the 
immunoprecipitation experiments carried out in cells over expressing c-Jun or p73 (data 
not shown).  However, immunopreciptation of endogenous c-Jun with p73 antibody was 
unsuccessful, indicating that higher levels of p73/c-Jun expression is required for 
interaction invivo.  
The central part of c-Jun protein contains PPXY(Tyr170) domain. This PPXY 
domain is also conserved in p73 (near the carboxy termini). The domain could bring 
about PPXY motif-WW domain interaction, which constitutes a part of a complex 
network of multiple signal transduction pathways.  If this indeed the case, then c-Jun may 
be part of complex in which p73 is constituent or c-Jun and p73 can interact indirectly 
through WW domain containing proteins. This explains the difficulties in 
coimmunoprecipitating the endogenous p73/c-Jun protein. Further efforts to identify the 
binding partners of the PY motif of p73 and c-Jun should contribute to our understanding 
of the overall network of cellular signaling involved.  Evidently, it has been shown that c-
abl interacts with the PPXY domain of c-Jun (Barila et al., 2000). 
Further, it appears that both the N (∆1-194) and C-termini of c-Jun (∆ 194-334) 
bind to p73 independently under over expressed conditions (data not shown).  This data 
implies a possibility that c-Jun interacts with p73 through multiple regions, one near the 
N-terminus of c-Jun and the other near the C-terminus (possibly through the DNA 
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binding and leucine zipper domains), but both may be required for efficient interaction 
and stabilization.  
c-Abl has been shown to stabilize p53 by direct protein-protein interaction. .  
Though c-Abl has been shown to interact with p53, it does not phosphorlyate p53. 
Therefore, it appears that c-Abl through direct interaction with p53 masks the export and 
ubiquitination signals, which results in retention and stabilization of p53 in the nucleus     
( Shaul, 2000; Sionov et al., 2001; 1999). Both c-Jun and Abl haave been shown to 
interact with each other. The intramolecular interactions between c-Abl, c-Jun and p73 
will certainly affect their stability, though the extent may depend on the cellular context. 
Our data suggests that p73 and MDM2 interact with each other.  Also, both Abl and c-Jun 
have been shown to interact with each other (Agami et al., 1999; Barla et al., 2000) Thus, 
the intermolecular interactions between c-Abl, MDM2, c-Jun and p73 will have an effect 
on their stability and function, though the extent may depend on the cellular context. 
4. Expression of c-Jun modulates p73-mediated transactivation 
 
The data presented here suggest that c-Jun, by increasing p73 protein levels, 
augments its ability to transactivate p53 responsive genes such as p21, GADD45 and 
MDM2 in the reporter and RT-PCR analysis.  Further, it also augments p73’s ability to 
increase MDM2 at the protein level. Correspondingly, the ability of p73 to transactivate 
its downstream genes is markedly reduced in p53-/- cells compared to p53-/-Jun-/- cells, 
indicating that c-Jun is required for increased p73-dependent transcriptional activity.       
c-Jun could protect against proteasome dependent degradation by binding to the shared 
component of proteasome machinery and thereby increase stability and transcriptional 
activity of p73.   It has been shown that Abl by directly binding to p53, potentiates p53’s 
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ability to transactivate its downstream genes.  It has been established that CBP/p300, 
which binds both p73 and c-Jun independently, functions as a co-activator for both. 
Hence, it is possible that p300 could bring p73 and c-Jun closer to the proximity of the 
p53 responsive element containing promoters and thereby it could augment the capacity 
of p73 to transcribe its target genes. On the other hand, c-Jun neither binds to p53 nor 
stimulates its function (our observation; Shualin et al., 2001). Infact, it has been shown 
that c-Jun suppresses the expression of p53 and its target gene, p21 at the promoter level 
(Shualin et al., 2000; Schreiber et al., 1999).    
A recent study by Faniello et al., proposes an alternative model of H-ferritin 
promoter transactivation by p300.  p300 can recruit c-Jun to promoters that do not 
contain AP-1 binding sequences. c-Jun, when over expressed, is able to potentiate the 
transcription of promoters without binding directly to the DNA. All these observations 
are consistent with the hypothesis that accessory factors can up- or down-regulate 
transcriptional activity by influencing the protein-protein interaction, which directly 
controls the transcriptional properties of a transcription factor (Chan et al., 2001). With 
similar mechanism, one can predict c-Jun’s ability to synergize with p73 to transactivate 
p53 responsive element containing promoters.  
 
5. The c-Jun potentiates p73 function to induce apoptosis in response to 
cisplatin treatment 
 
The resistance of p53-/-jun-/- and jun-/- fibroblasts to undergo apoptosis in the 
presence of anti-cancer drugs such as cisplatin highlights the importance of c-Jun and 
p53 related proteins such as p73 in inducing apoptosis. c-Jun potentiates p73 
transcriptional and proapoptotic activities that are markedly impaired in jun-/- and p53-/-
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jun-/- cells. These data are consistent with the ability of dominant negative c-Jun to 
prevent cisplatin mediated cell death (Sanchez-Perez et al., 1999).  It has been shown 
previously that mere transfection can “activate” p53 and p53-responsive downstream 
genes (Renzing et al., 1995).  c-Jun’s ability to potentiate p73 proapoptotic activites 
could be part of the stress response, as transfection itself activates a stress-signalling 
pathway.  Further, it has been shown that p63-/-p73-/- fibroblasts are resistant to undergo 
apoptosis in the presence of anti-cancer drugs such as doxorubicin and cisplatin. This 
highlights the importance of p73 and p63 in inducing apoptosis (Flores et al., 2002). 
Intriguingly, in response to doxorubicin treatment, p53 is induced in p73-/-p63-/- MEFs 
and it binds to p21 and MDM2 promoters but not to apoptotic promoters such as Bax, 
PERP, and NOXA. This data suggests that p63 and p73 are important elements in 
recruiting p53 to promoters at apoptosis-related genes. This proposal is supported by at 
least two facts. First, p63, possibly p73, has shown to be present at apoptotic-associated 
target gene promoters, even in the absence of p53. Second, p53 is not present at these 
promoters in the absence of p73 and p63(Flores et al., 2002). Similarly, in c-Jun null 
cells, though basal p53 and p21 levels are high and the levels of p53 protein is further 
induced in response to cisplatin treatment, these cells are relatively resistant to cisplatin 
mediated apoptosis. The reason for this could be that p73 is neither induced nor 
stabilized in c-jun null cells in response to cisplatin treatment. As described earlier, p73 
is required for p53’s ability to transactivate apoptotic target genes such as Bax, PERP 
etc. Intrestingly, the ability of c-Jun to synergize with p73 on p21 promoter is minimal. 
On the other hand, c-Jun synergized with p73 very effectively on Bax and p53AIP 
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promoters. Collectively, c-Jun, a known mediator of apoptosis(Bossy-Wetzel  et al.,  
1999) collaborates with p73 to induce apoptosis in response to cisplatin treatment.  
Finally, the ability of c-Jun to potentiate p73’s proapoptotic function can be used 
as a mode of treatment for cancer. Hence, identifying the modulators of pathways 
involving p73 and c-Jun is of great importance for the following reasons:  (1) At least 
50% of tumor cells harbor mutations in p53 gene, but its homologue p73 is infrequently 
mutated in human cancers. (2) p73 is an important player in chemotherapy-induced 
apoptosis. (3) p73 can induce apoptosis in the absence of p53.  
If p73’s proapoptotic activity is specifically activated using c-Jun derived peptides 
(derived from the common interacting regions of p73 and c-Jun) in cancer cells, then this 
can be used to increase the response of a variety of p53-defective cancer cells to 
therapeutic agents. 
 
6. Role of JNK in c-Jun-mediated p73 stability and transactivation 
 
The JNK kinases phosphorylate Jun and stimulate its transcriptional activity. 
JNKs are activated by stress inducing agents and their ability to induce apoptosis or 
proliferation will vary depending upon the cell type, cellular context and stimuli (Leppa 
et al., 1999). The data presented in this thesis suggests that c-Jun could promote p73 
function and stability independent of its phosphorylation (63/73; 91/93 a.a) status, as p73 
can be stabilized further by transfected c-Jun and p73’s function is not compromised in 
Jnk1-/-Jnk2-/- fibroblasts.  In addition, we have found that Jnk1-/-Jnk2-/- cells were more 
sensitive to cisplatin and induced c-Jun protein (data not shown). This data suggests that 
JNK1 and JNK2 are not essential for cisplatin mediated cell death.  In support of this 
finding, it has been shown that cisplatin treatment did not potentiate JNK activity 
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(Fokstuen et al., 1997; Liu et al., 1996), but clearly induced c-jun mRNA expression (Liu 
et al., 1996).  Thus, it appears that genotoxic stress-induced transcriptional induction of c-
Jun expression (nascent c-Jun) could co-operate with p73 effectively in transactivating 
apoptotic promoters carrying p53 responsive elements; and, JNK mediated increase in c-
Jun(Phosphorylated) protein levels may not co-operate with p73 effectively in 
transactivating p53-dependent apoptotic promoters. Accordingly, it has been shown that 
JNK-mediated c-Jun phosphorylation is not important for TNF-α or sorbitol mediated 
cell death, as Jnk1-/-Jnk2-/- fibroblasts were more sensitive to TNF-α and sorbitol-induced 
apoptosis in fibroblasts (Hochedlinger et al., 2002).  Further, this data suggests the 
following: 1. JNK1 and JNK2 negatively regulate apoptosis in response to certain stress 
stimuli.  2. The existence of JNK-independent apoptotic pathways in fibroblasts.  Further, 
JNK1 has been shown to degrade p53 by binding to the region near N-terminus (92-112) 
of p53 (Fuchs et al., 1988), however, this region is not conserved in p73. This may 
possibly eliminate a direct role for Jnks in p73 regulation. JNK-p53 complexes were 
found specifically in G0/G1 phases of the cell cycle (Ronai et al., 1999), while MDM2-
p53 complexes were preferentially found in S/G2-M phases of the cell cycle.  It appears 
that JNK is an Mdm2-independent regulator of p53 stability in nonstressed cells.  On the 
other hand, the same group has showed earlier that expression of a constitutively active 
form of JNKK upstream kinase, mitogen-activated protein kinase kinase kinase 
(DeltaMEKK1), increased the level of the exogenously transfected p53. Increased p53 
level by forced expression of DeltaMEKK1 coincided with a decrease in p53 
ubiquitination in vivo with prolonged p53 half-life. Correspondingly, JNK has been 
shown to phosphorylate p53 at T81 in response to DNA damage and stress-inducing 
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agents (Buschmann et al., 2001). Unlike wild-type p53, in response to JNK stimuli p53 
mutated on T81 (T81A) did not exhibit increased expression or concomitant activation of 
transcriptional activity, growth inhibition, and apoptosis. Similarly, transfection of 
antisense JNK 1- and -2 decreased T81 phosphorylation in response to UV irradiation. 
Together, the data accumulated from various laboratories in the recent past suggest that 
JNK augments p53 stability under stressfull conditions, while in non-stressful conditions, 
JNK appears to degrade p53.  How the same protein differentially regulates p53—
whether p73 is prone to similar regulation— under different conditions requires detailed 
investigation.  
Taken together, the results presented in this thesis suggest that phosphorylated c-
Jun (63/73) is neither essential for p73 stability nor for its transcriptional activity. 
 
7. The role of c-abl in c-Jun enhanced p73 stability and function 
 
The data presented in this thesis suggests that c-Jun can stabilize p73 in the 
absence of c-Abl at higher concentrations of cisplatin (Chapter 3.1 figure).  Thus, c-Jun 
mediated p73 stability is independent of c-Abl activity. In response to IR, c-Abl 
phosphorylates p73 and thereby stimulates its transcriptional function (Gong et al., 2000). 
On the other hand, co-transfection of c-Abl, c-Jun and p73 did not result in enhanced p73 
stability compared to the co-transfection of p73 and c-Jun (data not shown). This can be 
explained if one considers that transfecting eqimolar of c-Jun, c-Abl and p73 plasmids 
may not demonstrate their in vivo effect, as c-Abl protein level remains unchanged in 
response to IR, but its kinase activity is increased.  Although cisplatin induces c-Abl 
kinase activity, it does not phosphorylate p73 (White, 1999).  Moreover, it has been 
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shown that cisplatin does not activate JNK at concentrations that produce an increase in 
c-Abl activity in the HEC59 cell system suggesting that these kinases are not part of the 
same signaling pathway, and that JNK1 activation is not a universal feature of the 
cisplatin-induced cellular injury response (Nehme et al., 1999).  However, cisplatin can 
induce c-Jun expression at the transcriptional level and does not depend on JNK to 
increase the levels of c-Jun (Rabo, et al., 1996; Wang et al., 1996). In fact, c-Jun is 
increased in Jnk1-/-2-/- cells in response to cisplatin and the Jnk1-/-2-/- cells are more 
sensitive to cisplatin-mediated apoptosis, indicating that Jnks could function as a negative 
regulator of apoptosis (data not shown). Evidently, both Jnk1-/- and Jnk2-/- cells have also 
been shown to be more sensitive to TNF-α and sorbitol induced cell death (Hochedlinger 
et al., 2002).  These results support the idea that c-Jun expression is more important for 
cisplatin sensitivity but not JNKs. Consistently, it has been shown that activation of c-Abl 
and JNK represent distinct signaling responses to DNA damage (Liu et al., 1996). For 
example, UV irradiation induces JNK, but not Abl activity, while IR induces Abl but not 
JNK activity at lower doses. It is possible that c-Jun activation of Abl and JNK may form 
part of a phosphorylation circuit that integrates growth and stress-related stimuli for 
cellular fate decisions. Thus, these observations suggest that the fate of cells exposed to 
various stress signals does not always correlate with and is not always determined by 
JNK activity.  
Further, it has been shown that activation of c-Abl can contribute to apoptosis by 
phosphorylating, stabilizing and activating the p73 transcription factor.  However, it has 
been shown recently that c-Abl mediated p73 stability could be pro-apoptotic or anti-
apoptotic, as p73 gene can generate a number of splicing variants with pro-apoptotic and 
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anti-apoptotic functions(Wang., 2003). c-Abl appears to retain the ability to interact and 
phosphorylate all the isoforms of p73. If c-Abl could stabilize both the pro-apoptotic full-
length p73 and anti-apoptotic deltaN-p73, the effect of c-Abl on apoptosis would then be 
determined by the expression pattern of the p73 gene (Wang, 2003).   
    
Section II:  UV light mediated p73 induction/stability 
 
UV-radiation is one of the most biologically relevant inducers of DNA damage.  
UV-B radiation from the sunlight is the cause for most human skin cancers.  Exposure to 
UV-light causes DNA damage through formation of pyrimidine dimmers and 6-4 
photoproducts which effectively blocks RNA polymerase II from transcription (Cullinane 
et al., 1999; Mello et al., 1995; Selby et al., 1997). UV-induced DNA damage results in 
either transient cell cycle arrest or apoptosis (Lane, 1992; Lu and Lane, 1993).  Transient 
cell cycle arrest provides cells, an ample amount of time for the DNA repair before 
replicating damaged DNA (Elledge, 1996).  UV-induced DNA lesions are removed by 
nucleotide excision repair pathway (NER) (Friedberg et al., 1995).  
Although exposure to UV-radiation results in rapid p53 stabilization and its role 
in UV-radiation induced apoptosis is still questionable. Studies in the recent past suggest 
that primary and immortalized fibroblasts lacking functional p53 can be hypersensitive to 
apoptosis induced by moderate doses of UV-radiation (Lackinger et al., 2001; Sheikh et 
al., 1997; Bissonnette and Hunting, 1998).  In addition, UV light exposure rapidly 
stimulates c-Jun and in fact, c-Jun is one of the most UV-responsive genes identified so 
far (Devary et al., 1991). c-Jun appears to play a role in UV-radiation induced apoptosis, 
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as c-Jun null cells are resistant to UV-induced cell death and over-expression of c-Jun 
promotes the death of UV-irradiated cells (Shualin et al.,  2000). 
1. UV increases p73 levels 
Our data suggests for the first time that UV-irradiation can induce/stabilize p73 
levels. Endogenous p73 is induced in response to UV irradiation in many cell lines 
(NIH3T3, Cos7, MCF7, H1299) analyzed. After presenting this data in the 11th-p53 
international conference, Rome (2002), Melino et al., (2002) suggested that UV can 
stabilize p73. In support of these data, Zhang, et al., (2003) showed that UV-radiation can 
stabilize p73 in human keratinocytes.  
 Further, it appears that UV-induced p73 expression biphasic in nature and it 
could play a role both in DNA repair and apoptosis (data not shown). The induction of 
p73 in the earlier phase could lead the p73 to participate in DNA repair. Correspondingly, 
induction of p73 at the later phase could potentially involve p73 in p53-independent 
apoptosis. Further, transiently transfected p73 is stabilized much better in c-jun-/-+c-Jun 
cells, compared to jun-/- cells. However, endogenous p73 expression is induced to a 
comparable level in jun-/- and jun-/- + c-Jun cells. These differences noted highlight the 
fact that UV-mediated p73 induction could occur in the absence of c-Jun through 
alternative pathway mechanisms, possibly through p38 kinase pathway. Together, it 
appears that UV-mediated p73 expression is enhanced in the presence of c-Jun 
expression, but may not be entirely dependent on c-Jun, as UV-light is known to activate 
several stress related signaling pathways.  
p53 is stabilized at the post-translational level in response to DNA damaging 
agents. Similarly, our data suggests that UV-light mediated p73 induction and 
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stabilization can occur independent of transcription. However, considering the fact that 
p73 promoter encoades AP1 elements, one cannot exclude the transcriptional 
mechanisms contributing towards its upregulation in response to UV-radiation.  
The enhanced p53RE-carrying promoter activity observed in a panel of p53-
negative cell lines suggest that p53 family members could act as a compensatory 
mechanism to activate p53RE promoter activity in the absence of p53. However, it is 
important to note that UV-light induced p53-RE reporter and p73 transcriptional activity 
were less than 2 folds in the panel of p53 negative cell lines tested (data not shown). and. 
DeltaNp73, which does not contain the N-terminal activation domain in p73, has been 
thought to be transcriptionally inactive. It has been shown to form inactive complexes 
with TA-p73 and thereby hinder its function. However, it has been found recently that 
DeltaNp73beta is indeed active in inducing cell cycle arrest and apoptosis (Liu et al., 
2004). In addition, p53 has been shown to induce apoptosis by transcription dependent 
and independent mechanisms (Haput et al., 1995; 1997). The authors further suggested 
that the existence of two p53-dependent apoptotic pathways--one requiring activation of 
specific target genes, and the other independent of sequence-specific trans-activation. The 
latter pathway may actually be totally uncoupled from the binding of p53 to its consensus 
DNA sites. However, the relative contribution of trans-activation-independent apoptosis 
to tumor suppression by p53 is less clear. Similarly, p73 can contribute to UV-mediated 
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2. JNK 1, 2 and Abl do not influence UV-radiation induced p73 levels 
 
JNKs are stimulated upon UV irradiation of cells. Thus, the role of JNK1 and 2 in 
p73 induction in response to UV-radiation was checked. Our data suggests that UV-
mediated p73 induction does not depend on JNK1 and JNK2, as the Jnk1-/-2-/- fibroblasts 
exposed to UV irradiation still induce p73 expression. Further, it has been shown that IR-
induced activation of JNK is dependent on the c-Abl function in cell-type specific 
manner (Kharbanda et al., 1995). So, the role of c-Abl in UV-radiation mediated p73 
induction was analysed.  Intrestingly, p73 level was not significantly altered in response 
to UV irradiation of c-abl-/- fibroblasts, indicating that c-Abl is unlikely to participate 
directly in UV mediated p73 induction.  In support of this finding, it has been shown 
earlier that only IR is known to activate c-Abl tyrosine kinase (Liu et al., 1996), but not 
UV-radiation.  Hence, the role of c-Abl in JNK-dependent apoptosis is less apparent in 
our studies. 
 
3. Consecutive exposure of UV and IR induce apoptosis in p53-/- cells 
 
 
UV-radiation is a potent inducer of c-Jun but not IR. Increased levels of 
transfected p73 seen in response to UV-radiation, but not IR, indicate that UV-radiation 
can stabilize p73, but not IR. However, exposing cells to combination of IR and UV-
radiation at lower doses increased the stabilization of p73. Furthermore, exposing cells to 
the combined signals led to the absence of colony formation in p53-/- cells. Duration of 
p73 induction is the determining factor for cell cycle arrest versus apoptosis.  Transient 
p73 induction could lead to cell cycle arrest, whereas sustained p73 activation (leading to 
stabilization) causes apoptosis.  
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Ionising radiation induces cell cycle arrest but not apoptosis in most of the cell 
types except in thymosites (Nagasawa, 1993; Di Leonardo et al., 1994).  Zeng et al, 
(2000) have showed that UV-radiation induces apoptosis of teratocarcinoma cells, but IR 
induces growth arrest. Further, UV-radiation (10 or 20 J/m2), but not irradiation (7 or 10 
Gy), caused a massive apoptosis of human teratoma Tera-2 or murine testicular 
carcinoma F9 cells. This differential response (UV-radiation versus IR) can be explained 
by considering the fact that IR induced DNA damage results in double stranded breaks, 
which can be considered as part of the physiological mechanism in certain cells, as 
double stranded breaks often occurs during homologous recombination and meiosis. UV 
radiation mediated DNA damage produces pyrimidine dimers(PDs). The PDs are difficult 
to repair compared to double stranded breaks (DSB) and therefore induces apoptosis 
irrespective of the p53 status of the cell.  Thus, the observation that only UV radiation 
provides stabilization signal but not ionising radiation prompted us to propose that 
combined signals, that is, ionising radiation (induction signal provided by c-Abl) 
followed by UV irradiation (stabilization signal provided by c-Jun) could result in further 
stabilization of p73, which in turn, causes p53-independent apoptosis. IR mediated 
signalling results only in growth arrest in most of the cells. Therefore, it may not be 
necessary to stabilize p73, which would lead to apoptosis.  Transiently induced p73 in 
response to IR may play a role in DNA repair pathway, as MLH1 appears to be upstream 
of p73 (Gong et al., 1999).  
 
 
                               
 209 
 
Section III: The role of p73 in the regulation of AP-1 activity 
 
1. p73 augments AP-1  activity 
 
p53 binds in a squence specific manner to the p53RE containing genes and 
transactivates its target genes such as p21, MDM2, Bax, GADD45 etc. (Osada et al., 
1998; Yang et al., 1998). Similarly, TAp73 isoforms transactivate most of the p53 
responsive genes. However, further studies suggest that p73 plays a physiologically 
distinct role. Knocking out the p73 gene in mice led to inflammatory, neurological, 
secretory and phremonal defects (Yang et al., 2000), while p53 knockout mice developed 
normally with an early onset of tumorigenesis in different tissues (Donehowever et al., 
1992).  These differences between p73 and p53 suggest that they must be regulated 
through different mechanisms. Thus, the mechanism of regulating p73-dependent 
transcriptional activation is crucial for a better understanding of the biological role of 
p73.  
 p73 shows a degree of specificity for the promoters of target genes that are 
quantitatively distinct from the response mediated by p53 (Chen et al., 2001). For 
example, p73 activates the GADD45 gene more efficiently than p53, while the reverse 
situation was apparent for the p21 gene. These effects are, in part, due to the influence of 
a regulatory domain present in the extended C-termini of the p73 isoforms (Lee et al., 
1999). However, it is important to bear in mind that these differences are noted within the 
p53 responsive element containing promoters, for eg., p21, MDM2, Bax etc. and not 
other regulatory elements. 
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The results presented in this section demonstrate that p73 increases AP-1 
transcriptional activity.   When p73 was co-transfected with c-Jun, a significant increase 
in AP1-RE-luciferase activity, compared with construct alone, was noted. Moreover, 
when p73 was co-transfected with c-Jun at different ratios 1(p73): 1(c-Jun) and 1(p73): 
20(c-Jun), it stimulated AP-1 transcriptional activity.  Further, the study presented here 
shows that p73, but not p53 stimulates AP-1 activity. Intrestingly, there seems to be a 
strong symbiotic relationship between c-Jun (Leuzine zipper transcription factor, 
transactivates AP1 responsive elements) and p73 (transcription factor, transactivates p53 
responsive elements), considering the fact that c-Jun increases p73 levels and in turn, p73 
increases AP-1 activity in c-Jun dependent manner. Therefore, it is plausible that 
depending upon the cellular context and other accessory cellular factors, these 
transcription factors decide whether to potentiate AP-1 or p53 responsive elements 
containing promoters or both. However, the mechanism for this exciting observation is 
not obivious at present, hence several mechanistic possibilities are presented here: 
2. Mechanism of action: 
Mechanism 1: p73 enhances the affinity of Jun-Jun homodimers to enhance AP-1 
activity. 
Both fos and jun associate with binding site of activator protein-1 (AP-1) and 
increase its activity. However, fos did not bind to the AP-1 site on its own, but it acted 
synergistically with Jun to give enhanced DNA-binding activity. The increased affinity of 
the Fos-Jun complex for DNA is due to the stabilization of the protein-DNA complex 
(Rauscher et al., 1988). c-Jun can form homodimers and bind to the AP-1 site but not c-
fos. However, it has been shown that c-Jun homodimers are less stable and exhibit low 
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AP-1 activity (that is evident only at high concentrations of DNA) than Jun:Fos 
hetrodimers (Smeal et al., 1989).  The fact that p73 does not have LZ (leucine zipper) 
domain may suggest that it may not bind to AP-1 elements directly. Bearing these facts in 
mind, one could envisage a mechanism in which p73 could serve as a bridging factor to 
change the conformations of c-Jun homodimers (less stable/active). This conformational 
change could increase the stability and activity of c-Jun-c-Jun homodimers (Figure 4.2). 
In support of this mechanism, it has been shown that several cellular and viral modulators 
of transcription such as transcription factors and coactivators do not bind to DNA by 
themselves but operate through association with the DBDs of transcription factors 


















Figure 4.2 p73 stimulated AP-1 transcriptional activity: possible mechanisms  
The hypothetical model depicted above presents different scenarios by which p73 
could stimulate AP-1 responsive elements. A. p73 does not interact with AP-1 responsive 
elements directly but it just enhances the stability and DNA binding activity of AP-1 
complex.  B.  The interaction of c-Jun and p73 proteins could bring p300, a co-activator, 
to the closer proximity of AP-1 promoters, resulting in enhanced AP-1 transcriptional 
activity. C. p73 transactivates a coactivator of the AP-1 that potentiates the c-Jun 
homodimers abilty to increase transactivation of an AP-1-dependent promoter.   
 
Mechanism 2: Both c-Jun and p73 proteins could bring p300, a co-activator, closer 
to the proximity of AP-1 promoters, thereby enhancing AP-1 transcriptional 
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activity.  In support of this view, it has been shown that p300 interacts with p73 when 
this transcriptional activator binds to its responsive DNA element sequence (Zeng et al., 
2001).  Furthermore, p300 proteins might be the centre point for the assembly of diverse 
co-factor proteins into multicomponent co-activator complex by interacting with other 
HAT’s, including pCAF, SRC1, and P/CIP (Chan and Thangue, 2001).  By interacting 
with several transcription related proteins, p300, serves as a scaffold for the assembly of 
transcription co-factors and increases the relative concentration of these factors in the 
local transcription environment and thereby facilitate protein-protein and protein-DNA 
interactions (Chan and Thangue, 2001).   
Mechanism 3: p73 induces a target gene, which potentiates the ability of c-Jun to 
transactivate AP-1 responsive elements 
p73 has been shown to transactivate several p53RE containing gene promoters. 
However, accumulating evidence suggests that p73 will have its own set of target genes, 
other than transactivating p53RE containing gene promoters (Fummegallie et al., 2001).  
Thus, it is possible that specific expression profiles of p73-responsive genes could result 
from combinatorial interactions with other proximal transcription factors. p73 could 
transactivate a coactivator of the c-Jun transcription factor that potentiates the ability of 
c-Jun homodimers to increase transactivation of an AP-1-dependent promoters. All of 
these mechanistic possibilities may not exclude one another, although more studies are 
necessary for a better understanding of the regulation of the detailed mechanism for p73-
mediated regulation of AP-1 activity.  
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3. Domains required for p73-Jun stimulated AP-1 activity 
In an effort to identify the interacting domains required for p73.c-Jun enhanced 
AP-1 transcriptional activity, transactivation domain (TA) of p73 was found to be not 
essential for its ability to stimulate AP1 activity. However, it is required for the maximal 
activation, as ∆N-p73β was not as efficient as TA-p73β in stimulating AP-1 
transcriptional activity.  Then, how does delta-N-p73 stimulate AP-1 activity?  p73 has 
been proposed to have two transactivation domains, one near the N-terminus and other 
near the C-terminus(Takada et al., 1999). It is possible that second transactivation domain 
near the C-terminus of TAp73 could have interacted through c-Jun for its ability to 
stimulate AP-1 activity. Thus, in the absence of transactivation domain, p73 can stimulate 
AP-1 activity either through the second transactivation domain or the DNA binding 
domain (DBD) or both. However, ∆N-p73 failed to co-operate with c-Jun to increase AP-
1 activity. This data suggests that transactivation (TA) domain of p73 is required to 
synergize with c-Jun. This observation strongly suggests that transactivation property of 
p73 is required to synergize with c-Jun. Thus, p73 could transactivate a coactivator of c-
Jun that potentiates the ability of c-Jun to increase transactivation of an AP-1-dependent 
promoter.   
To co-operate with p73, c-Jun might require two regions of p73: One, N-terminus- 
transactivation domain and the other being the second transactivation domain near the C-
terminus.  Among the p73 family members (α,β,γ and δ) tested, only p73-β appeared to 
transactivate p73 efficiently, though, all of them stimulated AP-1 activity more than basal 
level.  On the c-Jun side, the reporter assays pointed that both DNA binding (DBD) and 
leucine zipper (LZ) domains are important for its ability to synergize with p73.   
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4. Phosphorylated c-Jun is required to synergize with p73 for maximal 
AP-1 activation. 
The data presented in this thesis suggests that phosphorylation of c-Jun is required 
for its ability to co-operate with p73 to increase AP-1 activity. As wild-type c-Jun co-
operated with p73-β much better than c-Jun63/73a/a (JNK phosphorylation site mutants) 
and Jun5XASP (serine is replaced with aspartate to mimic the phosphorlyation status) co-
operated much better than wild-type c-Jun (figure 4.3).  In support of these results, 
Sanchez Prieto et al., (2002) have suggested a possibility that JNK pathway can also 
promote p73 phosphorylation and stabilization. Further, jnk1-/-2-/- cells seem to be more 
sensitive to cisplatin mediated apoptosis (data not shown), indicating that JNKs are not 
required for cisplatin mediated apoptosis. Therefore, it appears that JNKs might as well 
decide between apoptosis versus survival, under a given cellular context. 
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Figure 4.3 Phosphorylated c-Jun is required to synergize with p73 for maximal AP-1  
activation 
 
5. Abl negatively regulates p73’s ability to potentiate AP-1 activity 
As described in chapter I, c-Abl has been shown to phosphorylate both p73 and c-
Jun (Agami et al., 1999; Barila et al., 2000) and it potentiates the ability of p73 to induce 
apoptosis by phosphorylating it (Yuan et al., 1999; Agami et al., 1999). On the other 
hand, the reporter assays presented in this thesis suggests that c-JunY170F (c-Abl 
phosphorylation site mutant) co-operated with p73 on AP-1 RE a few folds higher than 
wild-type c-Jun. This indicates that c-abl by phosphorylating c-Jun negatively regulates 
c-Jun’s ability to transactivate AP-1 responsive element containing promoter activity. 
Thus, c-abl mediated c-Jun phosphorylation may not be essential for its ability to co-
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operate with p73 in potentiating AP-1 activity.  
 
6. Dominant negative p73 (p73DD) inhibits AP-1 transcriptional activity 
p73 is essential for increased AP-1 activity is revealed from the fact that dominant 
negative p73 inhibits both basal AP-1 and c-Jun mediated AP-1 transcriptional activity. 
This exciting data could mean the following: 1.p73 is required for increased AP-1 
activity. 2. p73 contributes to the basal AP-1 transcriptional activity either directly or 
indirectly by turning on AP-1 coactivator. 3. p73 dominant negative proteins could 
sequester AP-1 family members and prevent them from binding to AP-1 family members.  
 
 
7. Identification of AP-1 like responsive elements in both TA and DN-
p73 promoters 
 
 The ability of c-Jun to regulate p73 levels led us to make an in silico search for 
promoter regions of the TP73 gene. This analysis suggests that several AP-1 like 
elements are present in both TA-and DN-p73 promoters. In agreement with this data, it 
has been shown that promoter region present in the intron 1 of TA-p73 gene and DNp73-
promoter encodes AP-1 like responsive elements (Sayan, et al., 2004; Costanzo et al., 
2002).  Although it is not clear whether AP-1 responsive elements present in the TA-p73 
gene and DN-promoters will be used in tissues, it is possible that AP-1 like elements will 
be actively used in tissues, where AP-1 transcription factors are highly expressed.  The 
ability of c-Jun to stabilize TA-p73 at the protein level in response to cisplatin treatment, 
and transactivate TA/DN-p73 at the promoter level under basal conditions might add to a 
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complex regulatory network that would activate/inactivate the function of TA-p73 under 
different cellular contexts. Further, c-Jun, TA-p73 and deltaNp73 promoters encode AP-
1-like responsive elements, indicating a possibility that these proteins can share a positive 
feed back loop to regulate proliferation and death depending upon the cellular context. 
This may be an essential mechanism adapted by the cells to exit from the stress response 
when damaged DNA is repaired. However, how these complex regulatory networks are 
controlled in response to stress and growth will require a further investigation. In 
addition, the differential ability of c-Jun to regulate seemingly opposing function could 
decide the cellular outcome and function of p73 protein. 
8. Identification of p73-c-Jun target genes 
 
1. Collagenase-1: p73 increases the Collagenase-1 (AP-1 responsive 
elements) promoter activity 
 
To check the effect of p73 on other AP-1 responsive element containing 
promoters, collagenase-1 promoter was used. Indeed, p73-β is able to increase 
collagenase promoter activity as well. This finding opens up new vistas. Firstly, those 
promoters, which encode AP-1-like responsive elements, will be stimulated by p73. 
Secondly, collagenase-1, Matrix metalloproteinase’s (MMPs) are proteolytic enzymes 
capable of degrading extra cellular matrix. The MMPs have been shown to play a 
significant role in tumor invasion, metastasis and tumor-induced angiogenesis. 
Intriguingly, p73 is over expressed in tumors, however its role in tumorigenisis is not 
clear yet. The ability of TA-p73-β to increase collagenase-1 (MMP-1) gene promoter 
activity indicates that it can support metastasis and thereby it could behave like an 
oncogene in human tumors. In support of p73’s role in metastasis, it has been shown 
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recently that p73 augments the expression of VEGF (Vikanskya et al., 2001), which is 
known to play a major role in tumor angiogesis and metastasis.  Hence, it is plausible that 
p73 might play an important role in controlling the proteolytic phenotype of fibroblasts, 
e.g. in tumor invasion by augmenting the expression of   collagenease-1.  
 
2. hMSH1:  p73 increases the hMSH1 (p53 and AP-1 responsive 
elements) promoter activity 
 
The data presented in this thesis further suggests that MSH-1 promoter, which 
encodes classic AP-1 and p53 elements adjacent to each other, is stimulated by p73 and 
c-Jun.  In support of this finding, it has been shown recently that treatment of the cells 
with tetradecanoylphorbol- 13-acetate (TPA), an activator of p73, c-Jun expressions and 
AP-1 activity, specifically increases the amount of hMSH2 mRNA (Humbert et al., 2003; 
Fontemagi et al., 2001) in p53 negative cell lines. Further, it was shown that AP-1 
binding sites present in the hMSH2 promoter were potentially functional, since these sites 
were involved in the p53 regulation of hMSH2 associated with UV exposure (Scherer, et 
al., 2000).  The synergism between p53 and c-Jun in response to UV irradiation was 
explained based on the presence of binding sites for both p53 and AP-1 in the hMSH2 
promoter sequence.  However, the type of positive up regulation that we describe here for 
the hMSH2 transcription is clearly independent of p53, since the H1299 cell line used in 
the study is p53 negative.  This opened the possibility that targets for both c-Jun and p73 
could exist in cells.  For example, when DNA damage is not lethal to the cells then DNA 
repair mechanism is activated and that could lead to the activation of both p73 and c-Jun 
to effectively transactivate MSH-1 in repairing the damaged DNA. Thus, it is possible 
that increased p73 and c-Jun expression could augment Mismatch repair (MMR) 
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function. Interestingly, AP-1 has been suggested to play a critical role in the cellular 
response to genotoxic agents. Indeed AP-1 target genes exist among known repair genes, 
ERCC1 and MGMT (alkyl guanine DNA methyl-transferase) (Humbert et al., 2003). For 
both the ERCC1 and MGMT genes, AP-1 induced transcription arises in response to 
genotoxic stress mediated by cisplatin (Li et al., 1998). Therefore given the ability of p73 
to stimulate AP-1 target genes, one can undertake studies aimed at examining whether 
other MMR genes are p73/AP-1 responsive genes.  
 
 
Section IV:  p73 and c-Jun co-operate in transformation 
 
 
The results presented in section IV suggests that wild type TA-p73 and c-Jun co-
operate in transformation. Both p73α and β transform immortalized NIH 3T3 mouse 
fibroblasts in conjunction with c-Jun. On the other hand, c-Jun rescues the p73-mediated 
inhibition of colony formation in MCF-7 cells (data not shown), indicating more 
oncogenes are required to transform human cells. The ability of c-Jun to function as a 
transcriptional activator varies in different cell types and this partly explains the 
differences in the ability of c-Jun to transform cells (Imler et al., 1988; Vogt 2001).  In 
addition, mouse primary cells are more easily transformed than primary human cells (in 
some cases, at least four oncogenes are needed). These results open up many avenues 
relating to the ability of p73 to transform immortalized fibroblasts in conjunction with 
established oncogenes. 
Both full length TA-p73 and delta-N-p73 have independently over expessed in a 
variety of tumours.  The overexpression of p73 can be co-related with the over expression 
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of other established oncogenes such as c-Myc, Ras etc. in human cancer (Zaika et al., 
2000; Sun et al., 2002). The inability of overexpresed TA-wild-type p73 to prevent 
neoplastic process can be explained by considering the ability of deltaNp73 to inhibit 
TA-p73 function.   
At least, 30% of human tumors over express c-Myc and in turn induce 
tumorigenesis, however, conditions favorable for it to induce tumorigenesis or apoptosis 
is not yet clear. Interestingly, c-Myc over expressing clones seems to over express p73-
α/β constitutively. Similarly, ras over expression has been co-related with increased p73 
expression in colorectal tumors and there seems to be a positive correlation with 
increased p73 expression and poor survival of the patients (Sun et al., 2002). The 
correlations between over expression of p73 and established oncogenes in tumours 
indicate that p73 function could be modified and tuned in tumours to augment/favour 
proliferation. Evidently, as stated earlier, c-Myc over expressing clones do over express 
p73, but its ability to transactivate p53RE containing promoters is reduced (Zakia et al., 
2000). The activation of p53RE promoters in cells could result in apoptosis. Further, it 
has been shown that p73 activity is highly cell-context and promoter-specific. TA--Full-
length--p73 expressed in the transformed leukemia cell line Jurkat behaves as a specific 
dominant negative transcriptional repressor of the cell cycle inhibitor gene p21 and 
blocks p53-mediated apoptosis (Freebern et al., 2003). These findings provide evidence 
for a new mechanism in oncogenesis through which the functional properties of p73 can 
be altered in cell-specific fashion. The p73’s p53-related function—ability to 
transactivate p53RE promoters—needs to be compromised in order to transform 
fibroblasts.  In cell lines or tissues (keratinocytes) that overexpress c-Jun there is an 
                               
 222 
increase in DN-p73 levels (Costanzo et al., 2002).  Similarly, immortalized cell lines that 
constitutvely express both p73 and c-Jun, TA-p73 would loose its ability to transactivate 
p53 responsive elements containing promoters.  It seems that if a cell line manages to 
compromise p73’s, p53 related function then it can express TA-p73 constitutively. This is 
evident from the fact that we managed to generate TA-p73β overexpressing NIH 3T3 and 
MCF cell lines. Similarly, Vikhanskaya (2001) has generated stable p73alpha 
overexpressing clones from the human ovarian cancer cell line A2780. Further, 
Vikhanskaya et al., (2001) had shown that the clones overexpressing p73 increases VEGF 
expression and reduces thrombospondin-1 production.  Production of the other 
angiogenic factors FGF-2, PIGF and PDGF-B was also increased in p73 overexpressing 
clones. Furthermore, the p73 overexpressing clones were more angiogenic than parental 
cells, as shown in vitro by their increased chemotactic activity for endothelial cells, and 
invivo by the generation of more vascularized tumors (Vikhanskaya et al., 2001).  In 
support of these findings, our data suggests that p73 augments collagenase-1 or MMP-1 
expression in conjuction with c-Jun. Among the multiple MMPs expressed in a wide 
range of tumors, MMP-1, which is expressed especially in tumor cells with significant 
invasive properties, is thought to be particularly important for proteolysis (Seiki, 2003).  
Thus, p73 by increasing the expression of collagenase-1, it could support tumorigenesis.  











Figure 4.4   Co-existence of p73 and the established oncogenes in cancers 
 A schematic diagram depicted indicates a seemingly positive co-relation between the 
over expression of p73 and established oncogenes. 
 
The data presented in section IV is in conjunction with results obtained from various 
laboratories support the notion that p73 function is modulated in cancer cell 
microenvironment to support tumorigenesis. Furthermore, the ability of p73 to co-operate 
and co-exist with established oncogenes explains how TA-p73α/ β failed to prevent 
cancer cells from aberrant proliferation. Together, these findings indicate a possibility 
that p73 in conjuction with established oncogenes can promote transformation and tumor 
angiogenesis.  
Further, our data suggests that c-Jun mutants can cooperate with p73 in 
transformation. Although the discussion regarding how N- and C-terminus of c-Jun co-
operate with p73 to transform fibroblasts may not be physiologically relevant, it would 
indicate the domains (of c-Jun) required for p73 to transform fibroblasts.  Both N and C-
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termini of c-Jun did not increase the colony number on its own compared to vector 
control. However, in the presence of p73, both N and C-termini of c-Jun increased the 
colony numbers. Comparison between the ability of N- and C-termini of c-Jun to co-
operate with p73 revealed that C-terminus (194-331) of c-Jun seems to produce more 
colonies than N-terminus of c-Jun. This difference could be attributed to the fact that C-
terminus of c-Jun contains both DNA binding and leucine zipper domain, which is vital 
for intermolecular interactions.   
 
Although both p73 and c-Jun appear to co-operate with each other in transformation, it is 
not clear how they bring about transformation. In order to explain this, several 













Figure 4.5 A potential mechanism: how the co-operative effect of p73, c-Jun and 
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A model proposed here (figure 4.5) explains how p73, c-Jun and MDM2 co-operate with 
each other in the degradation of p53.  c-Jun increases p73 levels, which in turn augment 
the expression of MDM2. Increased expression of MDM2 degrades p53 on one hand and 
stabilizes p73 on the other. The degradation of p53 and increased expressions of p73 and 
c-Jun, would favour transformation.  
Mechanism 1: The co-operative effect of p73, c-Jun and MDM2 could promote 
transformation 
Our data suggests that p73, Jun and MDM2 synergistically increase the MDM2 promoter 
activity.  A model depicted above explains how p73, c-Jun and MDM2 co-operate with 
each other to promote transformation. c-Jun could increase p73 stability.  In turn, p73.c-
Jun could co-operatively augment the expression of MDM2.  Increased MDM2 
expression would augment p73 stability, as MDM2 has been shown to stabilize p73 
protein (Ongkeko et al., 2000). Sequentially, increased p73 stability can further augment 
the expression of MDM2, which in turn degrades p53, an important step that promotes 
transformation.  
Mechanism 2: how p73 increases colony number in the presence of c-Jun 
 
The data presented in section III suggests that p73 enhances AP-1 activity. Furthermore, 
p73 has been shown to increase the transcriptional activity of AP-1 target genes such as 
MMP-1 and Msh-1 in conjuction with c-Jun.  c-Jun has been shown to transactivate 
Cyclin D1 promoter ( Shualin et al., 2001 ), which encoades AP1 responsive elements in 
it.  Thus, in principle, p73, in concert with c-Jun, can enhance the expression of Cyclin 
D1 —an AP-1 target gene. The following molecular reaction could occur in cells 
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sequentially: First, increased cyclin D1 levels would increase Cyclin dependent kinase 
(CDK4/CDK6) activity. Second, increased CDK4/CDK6 activity would phosphorylate 
Rb heavily, which results in the release of E2F1. Third, increased E2F1 activity would 
increase p73 levels, a transcriptional target of E2F1 (Irwin et al., 2001). In turn, p73 
would augment the expression of cyclin D1. Thus, increased expression of cell cycle 
regulatory proteins such as E2F1, p73 and cyclin D1 could decrease the cell cycle time of 
immortalized cells and increase the colony number. In support of this proposed 
mechanism, it has been shown recently that various Cyclins (A,B,D and E) and cyclin 
dependent kinases such as CyclinA-CDK1/2, CyclinB-CDK1/2 and Cyclin E/CDK2 
complexes interact with p73 and phosphorylate it at T-79 and thereby inactivate its ability 
to transactivate p53 responsive element containing promoters such as p21 (Gaiddon  et 
al., 2003). These concurrent events would favor the increased colony numbers seen in the 
presence of c-Jun and p73.  Together, these mechanisms proposed support the idea that 
p73 and c-Jun indeed co-operate with each other in transformation.  




Figure 4.6 How p73 increase the colony number in the presence of c-Jun 
c-Jun enhances p73 level.  Both p73 and c-Jun synergistically increase cdk4/cyclin D 
activity. In turn, Rb is heavily phosphorylated, which results in the release of E2F-1.  
Increased E2F1 activity could agument the transcription of p73.  Also, both c-Jun and 
p73 cooperate with each other to augment the expression of MDM2. In turn, MDM2 
enhances p73 level.  Hence, co-existence of p73 and c-Jun can increase cyclin D1 levels 
and suppress p53 function in tumors, thereby increasing colony numbers.  
Further, c-Jun has been shown to be over expressed in some human cancers 
(Mathas et al., 2002).  And, the full oncogenic properties of some cancer cells might 
require elevated c-Jun function (Vogt et al., 2001). Moreover, it is important to realize 
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that c-Jun does not have the capacity to increase the colony numbers on its own. This 
notion is also supported by the fact that transgenic over expression of c-Jun in the 
absence of additional oncogenic stimulation does not increase tumor incidence. However, 
c-Jun supports the proliferation in conjunction with other oncogenes such as ras.  
Intrestingly, Ras causes senescence in primary mouse fibroblasts, but supports 
tumorigenisis and even serves as a causative factor in colorectal tumors. Similar to 
oncogenic Ras and c-Myc, p73 induces apoptosis or transformation depending on the 
absence or presence of survival signals respectively. Intrestingly, it has been shown 
recently that ras-induced immortalized fibroblasts focus formation without cell cycle 
regulation (Jacobsen et al., 2002). That is, the growth rate of numerous independent Ras-
transformed NIH3T3 cell clones in several NIH3T3 sublines indicated no alteration in 
doubling times at low cell densities of the  transformed cells. It appears that Ras-induced 
changes do not result in growth advantage at low cell densities. Also, the transforming 
activity of oncogenic ras is sufficient to relieve cells from contact inhibition, but does not 
confer a proliferative advantage to cells in low serum (Jacobsen et al., 2002). Moreover, 
ras appears to regulate p73 levels (Melino, 2003; Sun, 2002).   c-Jun has been shown to 
be downstream of ras.  Therefore, p73 mediated c-Jun dependent transformation could 
result in focus formation, but may not result in increased proliferation rates at low 
densities.   
Furthermore, Pelengaris et al., (2001) showed that switchable c-Myc protein can 
induce apoptosis and proliferation-- in specific tissues, pancreatic islets cells and 
keratinocytes-- depending upon the cellular context. Activation of c-Myc in pancreatic 
beta cells, promotes entry of cells into the cell cycle. However, this is followed by 
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apoptosis that overcomes proliferation. By contrast, activation of c-Myc in skin cells, 
triggers proliferation, but no apoptosis is evident.  This is attributed to the excess of anti-
apoptotic survival factors present in skin that acts to suppress the otherwise apoptotic 
action of c-Myc. Similarly, in tissue culture models, p73 induces apoptosis when it is 
over expressed in the absence of anti-apoptotic survival factors, while in the presence of 
excessive oncogenic signals it increases the colony numbers. Hence, these studies suggest 
that the co-operativity of p73 and c-Jun can promote transformation in continuously 
growing cell lines.  
p73 could be a growth regulatory protein, endowed with the ability to induce 
apoptosis. The ability of p73 to induce apoptosis and transformation should not be 
surprising considering the fact that a number of proteins perform two opposing functions:  
First, TNF-alpha, which elicits two opposing effects, the induction of apoptosis and the 
transcription of antiapoptotic genes. Second, TGF-beta can switch from a tumor 
suppressor in the premalignant stages to an ongogenic agent at later stages to result in 
metastasis (Wakefield et al.,.2003). Third, E2F1, a potent transcriptional activator of p73: 
mouse model suggests that it is a tumor suppressor, however, in tissue culture it promotes 
proliferation, Fourth, c-fos has been shown to induce both proliferation and apoptosis in 
several cell lines etc.  Regulatory systems that control proliferation and apoptosis appear 
to overlap extensively, and indeed, a number of genes identified as oncogene products 
have been found to mediate apoptosis under certain circumstances. Thus, proteins that 
regulate both cell cycle and apoptotic machinery are closely connected. This strategy may 
have been adapted as a ‘fail-safe mechanism’ to prevent aberrant cellular proliferation 
which could lead to cancer. Finally, it is worth investigating the mechanisms underlying 
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this phenomenon in order to establish optimum molecular targets whose modulation 

























Figure/Table 4.7 Both c-Jun and p73 regulate cellular proliferation.  (Ref. 1a. 
Schreiber et al, 1999; 1b. Wisdom et al., ; 2. Shualin , 2002; 3. Maeda , 2003 ;4. Costanzo 
















Figure/Table 4.8 Both c-Jun and p73 regulate apoptosis (Ref. 1a.Sanchez-Perez , 
1999; 1b. Kolbus , 2000 ; 2. Ginsberg , 1991; 3. Bossy-Wetzel , 1997; 4. Flores , 2003; 5. 
Jost, 1997) 
• G Melino, V De Laurenzi, KH Vousden. p73: Friend or foe in tumorigenesis.  
Nat Rev Cancer. 2002 Aug; 2(8): 605-15. Review. 
• E Shaulian, M Karin.AP-1 as a regulator of cell life and death. 
Nat Cell Biol. 2002 May; 4(5): E131-6. Review. 
 
 




“Science may set limits to knowledge, but should not set limits to imagination”.    























This study suggests that both c-Jun and p73 reciprocally regulate each other’s stability 
and function in response to stress and growth stimuli. This fact is strengthened by the 
following observations: 
1. jun-/- cells are resistant to cisplatin mediated apoptosis.  
2. Transduction of c-Jun in jun-/- cells restores sensitivity to cisplatin mediated apoptosis 
and augments p73 expression. This suggests that p73 and c-Jun may collaborate with 
each other to induce apoptosis in response to cisplatin mediated apoptosis.  
3. UV increases both endogenous and exogenous p73 levels. 
4. p73 acts as  a positive regulator of AP-1 activity.  
5.p73 synergizes with c-Jun to potentiate AP1 target genes such as collagenase-1 and 
MSH-1.  Transactivation domain(TA) of p73 is essential for its ability to synergize with 
c-Jun.  
6. Identification of AP-1 like elements in both TA-and ∆Np73 promoters suggests that 
both p73 and c-Jun regulate each other in the cell.  
7. The PPxY domain is conserved in both p73 and c-Jun. 
8. c-Jun synergies with p73 to potentiate p53RE activity.  Consecutively, p73 synergizes 
with c-Jun to increase AP1 activity. 
9. The inter-dependence of p73 and c-Jun is evident from the observations that jun null 
cells exhibit weak p73 transcriptional activity (on p53RE promoters) on one hand, and on 
the other hand, dominant negative p73 inhibits c-Jun’s ability to transactivate AP-1 RE 
promoters.  
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 10. In the colony formation (long term) assay, wild-type p73α/β and c-Jun co-operate 
with each other in transformation, indicating that p73 could behave like an oncogene in 
the presence of excessive oncogenic signals.  
 
1. c-Jun mediated p73 stabilization and activation 
 This study has identified for the first time, p73 and c-Jun, two key players in the p53 
independent apoptotic pathway that collaborate with each other in causing cisplatin 
sensitivity.  p73 has been shown to be induced in response to DNA damage (Agami, et 
al., 1999; Yuan et al.,1999 and Gong et al., 1999). However, only cisplatin stabilizes p73 
but not IR (White et al., 1999). This study explains why cisplatin stabilizes p73 and 
identifies c-Jun as a component that is responsible for this differential response.  Cisplatin 
is most effective in the treatment of metastatic testicular tumors and is indicated in 
various combinations of chemotherapeutical regimes for ovarian, head and neck, bladder, 
cervical and other neoplasms.  In addition to its toxic side effects, a major drawback of 
cisplatin chemotherapy is drug resistance. Hence, understanding the molecular basis of 
cisplatin mediated apoptosis and drug resistance could significantly improve clinical 
protocols. Toward this goal, the present study suggests that the absence of c-Jun, could 
lead to the decreased stability of p73, resulting in cisplaitn resistance in tumor cell lines. 
Moreover, p73 appears to augment AP1 activity. Several enzymes known to be involved 
in repair of DNA-cisplatin adducts and implicated in cisplaitn resistance contain AP-1 
related sites in their promoters including DNA polymerase β and proliferating cell 
nuclear antigen (PCNA) (Patopova et al., 1997).  It is likely that transcription of these 
genes can be activated by p73-c-Jun upon stimulation by cisplatin treatment.  This 
                               
 236 
finding opens up new vistas to look for c-Jun and p73 expression in cisplatin resistant 
human tumours. The following cell lines have been identified to lack p73 expression and 
are known to be resistant to cisplatin treatment: 
1. p53 expression is induced to the similar level in cisplatin resistant human bladder 
carcinoma cell line such as TCC (transitional carcinoma) cell line and its isogenic 
cell line. On the other hand, p73 expression is not induced in cisplatin resistant 
TCC, emphasizing the importance of p73 in cisplatin mediated apoptosis.  In 
addition, these results suggest that loss of p73 induction may lead to CDDP 
resistance of TCC carcinoma (Ono et al., 2001).   
2. p73 expression is not induced in Hereditary cancer syndrome human non-
polyposis colon carcinoma (defective in mismatch repair) cells that  are resistant 
to cisplatin (Gong et al., 1999). 
3.  p73-negative SK-N-AS, a human neuroblastoma cell line, is more resistant to 
cisplatin than p73 positive-SK-N-SH cells (Gong et al., 1999).  
4. p73-/- cell lines are more resistant to cisplatin compared to wild type (Flores et al., 
2002). 
5. The study presented here shows that jun-/- and p53-/-jun-/- cell lines are more 
resistant to cisplatin compared to wild type; and p73 transcriptional activity (p53 
RE promoters) is reduced in the absence of c-Jun (p53-/- Vs p53-/-Jun-/-). 
These data generated from various laboratories support the idea that p73 expression plays 
a major role in cisplatin resistance, which is commonly found in various human cancers. 
p73 could be an attractive therapeutic target in oncology because its tumor-suppressor 
mimicking (apoptotic inducing) activity can be activated to eradicate tumor cells. 
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Promoting the p73–c-Jun interaction could be a promising approach for activating p73, 
because this association could lead to further stabilization and increased transcriptional 
activity of p73.  It is important to note that a similar strategy has been used to activate 
p53 by peptides that inhibit the p53–MDM2 interaction (Chene et al., 2001). These 
peptide inhibitors exhibit an antiproliferative effect in tumor cells over expressing 
MDM2. 
2. UV radiation enhances p73 levels 
The results in this study show for the first time that UV radiation enhances p73 levels. 
Next, it would be worthwhile to find out the kinases responsible for the phosphorylation 
of p73 in response to UV irradiation. p38, a serine-threonine kinase, could be one of 
those candidates that need to be verified in detail. p38 kinase has been shown to play a 
critical role in the initiation of a G2 delay after ultraviolet radiation and inhibition of p38 
blocks the rapid initiation of this checkpoint in both human and murine cells after 
ultraviolet radiation (Boulavin et al., 2001).  Although our results suggest that UV 
radiation increased p73 levels could lead to p53-independent apoptosis, it is worthwhile 
to understand the molecular mechanisms involved. Given the ability of p73 to respond to 
UV irradiation, it is possible that p53-independent UV-mediated cell cycle arrest and 
apoptosis can occur through p73. Studies need to be carried out further to address these 
issues in detail.  
3. p73 synergies with c-Jun to induce  AP-1 activity 
  The results in this study show for the first time that p73 functions as a positive 
regulator of AP-1 activity. The AP-1 activity is stimulated in response to an incredible 
array of stimuli, including mitogenic growth factors, growth factors of the TGF-beta 
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family, UV, cellular stress, antigen binding, and neoplastic transformation, which 
indicates that p73 could, in principle, participate in regulatory network of all these 
processes.  For example, many of the growth and stress regulatory genes encode AP-1 
elements in their promoter, so in principle p73 can play a part in the growth, DNA repair 
and stress response.  The ability of p73 to regulate AP-1 encoding genes can be exploited 
for pharmacological benefits.  Hence, our findings open up new vistas in p73 mediated 
gene regulatory pathways that differ from its counter part, p53.  This study has identified 
MSH-1, a mis-match repair enzyme and Collagenase-1, Matrix metalloprotease enzyme 
as targets of the c-Jun-p73. Also, it is possible that p73 could potentiate c-Jun dependent 
expression of other AP1 target genes. However, it is not clear how exactly p73 stimulates 
AP-1 activity and how does p73 co-operate with c-Jun to stimulate its activity.  
Moreover, p73-c-Jun appears to regulate both p53REs and AP-1REs, possibly in a 
context dependent manner.  Thus, studies need to be carried out further to address these 
questions in detail. 






Figure 5.1 Schematic representation of the ability of p73 and c-Jun to choose 
promoters containing different response elements in a context dependent manner 
In a context dependent manner, both p73 and c-Jun synergistically enhance the 
transcription of either p53 RE (stress) or AP1 RE (growth) containing promoters.  
 
The schematic diagram depicted here (5.1) exemplifies preferential selectivity of 
transcription factors to particular DNA responsive elements based on the imposed 
conditions i.e. under growth promoting conditions AP-1 promoter activity is 
predominantly chosen and under stressful conditions p53RE activity is chosen. In 
addition, promoter selectivity could rely on the composition of partner proteins 
responding to a given stimuli. This would play a major role in determining whether to 
potentiate either p53RE or AP-1 activity, consequently, to favor apoptosis or 
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proliferation. Furthermore, this partner dependent promoter regulation is applicable to 
both AP-1 responsive promoters and p53RE containing promoters.  The dynamic balance 
between p73 and c-Jun may play a decisive role in whether the cell survives or undergoes 
apoptosis.  However, it is important to note that AP-1 activity is also induced by various 
chemotherapeutic agents and stress stimuli and seems to play a role in the induction of 
apoptosis. Evidently, it has been shown that AP-1 binds directly to the promoter region of 
the p21WAF1 gene in a p53-deficient human lung carcinoma cell line, H1299 and 
regulates its expression in response to H2O2 (Chung, 2002). This data suggests that p73 
could regulate p21 expression in p53 deficient cells in cooperation with c-Jun/AP1. 
Similarly, the p73-c-Jun complexes could effectively transactivate genes that encode AP-
1 responsive elements in their promoters and thereby participate in cellular proliferation, 
DNA repair and apoptosis, depending upon the cellular context. Therefore, p73, possibly 
assisted by c-Jun, could control the expression of an even broader set of growth 
regulatory genes such as cyclin D1, apoptotic and DNA repair genes.  In the future, it will 
be interesting to analyse other candidate genes for p73-c-Jun dependence. Dominant 
negative p73 (DD) does not only lower the ability of c-Jun or p73 to increase AP-1 
activity but it lowers the basal AP-1 activity in cells.  
The ability of dominant negative p73 to inhibit AP-1 activity certainly highlights 
p73’s importance in influencing AP-1 activity other than through c-Jun in cells. 
Moreover, one would also be interested to find out how different JNK members influence 
the p73 function, as phosphorylated c-Jun is more efficiently synergized with p73 in 
increasing AP-1 activity.   
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4. p73 and c-Jun co-operate with each other in Transformation 
 
 
 The results presented here suggest that p73 could support transformation in the 
presence of excessive oncogenic signals provided by c-Jun. The data from various 
laboratories indicate that p73 co-operates with several established oncogenes (Zakia et 
al., 2001; Melino, 2002). These observations support the view that p73 could be a 
proliferative response gene, which has the capacity to induce proliferation or apoptosis in 
a context dependent manner.   
The p73 (full-length) is overexpressed in a variety of tumour cells (Zakia et al., 
2002; Melino, 2002). The results in this study shed new insight on p73 and provide a 
likely explanation as to why p73 failed to prevent tumorigenesis and in turn how p73 can 
support transformation in the presence of excessive oncogenic signals provided by c-Jun.   
Evidently, p73 co-operates with oncogenes such as E2F-1, E1A, c-Jun, c-Myc etc. The 
ability of p73 to co-operate with several oncogenes would certainly make it a less 
susceptible candidate for acquired loss of functional mutations during oncogenesis, as 
there is no selection pressure to mutate p73, unlike tumour suppressor p53. This 
prediction is strongly supported by the following facts: First, hepatocytes express only 
delta N-p73, where as the activation of TA-p73 expression in hepatocellular carcinoma 
(HCC). Second, monoallelic expression of p73 has been noted in normal lung, while the 
activation of ‘p73 silent allele’ in lung cancer. Third, monoallelic expression of p73 has 
been found in gastric mucosa, while the activation of ‘p73 silent allele’ in gastric cancer.  
Thus, the acquired expression of TA- p73 in HCC, lung cancer and gastric cancer looks 
like transformation related rather than a tumour suppressor related function. Together, 
our results provide a framework for understanding why wild-type TA-p73 (full length) 
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failed to prevent tumorigenesis in spite of it’s over expression seen in several tumors. 
Cell proliferation and apoptosis might appear like opposing functions, but proto-
oncogene c-Jun and putative tumor suppressor homologue, p73 might be able to initiate 
or regulate both.  The mechanism of oncogenes initiated cell death and its targets are just 
beginning to emerge. Furthermore, how oncogenes regulate both proliferation and cell 
death machinery is far from being understood.  However, it makes lots of sense now as to 
why these processes need to be linked.  Apoptosis is not only induced by stress stimuli, 
but also induced by excessive oncogenic signals, and therefore to prevent cancer.  In 
addition, when oncogenes like c-Jun, c-Myc, E1A, E2F, c-fos etc. are ectopically over 
expressed under conditions not appropriate for cell proliferation, for example, under 
serum starved conditions (Colotta et al., 1992; Clark et al., 1997) or DNA damaged cells, 
then they have been shown to be capable of initiating apoptotic cascades.  Evidently, it 
has been shown recently that apoptotic target genes such as Fas L (Kolbus et al., 2000) 
and caspases (Nahle et al., 2002) are direct targets of proliferation associated genes such 
as c-Jun and E2F1 respectively. 
This study shows for the first time that p73 functions as a co-factor for c-Jun mediated 
biological responses, in turn, it appears that c-Jun influences p73’s stress related activity.  
In line with our results, Massimo’s group showed that deltaN-p73 promoter, which 
encodes AP-1 responsive elements, is regulated by c-Jun (Costanzo et al, ESDR meeting, 
2002).  Furthermore, the TA/DN p73 promoter analysis presented in this thesis and data 
presented by Costanzo et al., suggested that deltaN p73 promoter, which encodes both 
AP-1 and p53 responsive elements, can be regulated both by c-Jun and p53/p73.  It is 
possible that p73 and c-Jun regulate the deltaN-p73 promoter and inactivate p53/p73 by 
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complexing with it directly, which would be analogous to p53 mediated MDM2 
regulation.  It is also important to emphasize here that MDM2 promoter contains both 
AP1 and p53RE in its promoter and it is subjected to the regulation of both by c-Jun and 
p73 (Ries et al., 2000).  These interesting findings could well suggest that the co-
operation between p73 and c-Jun on AP-1 promoters will be very effective in switching 
off stress related activities especially in tumor cells. While in normal cells the relative 
regulatory networks could be stringent and it could effectively induce apoptosis in 
response to stress.  Collectively, it appears that both c-Jun/AP-1 and TA/DN-p73 can 
regulate each other in cells.  However, further studies should be extended to understand 
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Figure 5.2 Schematic representation of the existence of a regulatory loop between the 
TA-p73/∆N-p73 and c-Jun. 
In response to cisplatin treatment, both c-Jun and p73 are activated, and p73 is stabilized 
by c-Jun dependent mechanism and they collaborate with each other to induce apoptosis.  
The ability of c-Jun-p73 to transactivate deltaN-p73 could be switched off transiently by 
post-translational modifications in response to stress.  In response to growth stimuli or in 
tumor cells, c-Jun-p73 could increase deltaN-p73 transcripts level and the increased 
deltaN p73 could compete with p73/p53 protein to form inactive complexes. Increasing 
the deltaNp73/TA-p73 ratio will favour growth, transformation and tumorigenesis. In 
addition, deltaN-p73 is proposed to function as growth promoting gene, independent of 
its ability to inactivate p73/p53.   
 
Together, this study shows for the first time that both p73 and c-Jun regulate each other 
in regulating life and death of a cell.  In addition, this study points out a future direction 
in which how other AP-1 family members regulate p73 in response to various extra and 
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